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SUMMARY 
In vulvar neoplasia, substantial improvements in therapy and care have been attained during the last 
decades.1 Nevertheless even minor surgical interventions cause multiple symptoms and side effects 
that impact women’s quality of life.2 The term ‘vulvar neoplasia’ includes vulvar intraepithelial 
neoplasia (VIN) and vulvar cancer.3, 4 Vulvar neoplasia is a rare condition with increasing incidence 
rates in the last 3 decades in Europe and the US.5, 6 The incidence of vulvar neoplasia in Germany and 
Switzerland is about 2 to 7 per 100’000 women per year.7, 8  Surgical treatment is the standard therapy 
for women with vulvar neoplasia.9, 10 The prevalence of surgery related complications, such as wound 
infections, is estimated to be between 5% to 45%.2, 11 Surgery-related complications are one type of 
adverse event and a substantial number of these complications are preventable.12, 13 Surgery-related 
complications in women with vulvar neoplasia result in a variety of physical and psychosocial 
problems,2, 14 and contribute to high health care costs.15, 16 Modified surgical procedures such as the 
replacement of radical vulvectomy by less wide local excision often mean shorter hospitalizations.17 
Furthermore oncology care in general is shifting to the outpatient setting.17 Thus, after discharge 
women with vulvar neoplasia and surgical treatment are confronted with the need to assess, evaluate 
and manage surgery-related symptoms without the support of the inpatient care team. 
Symptoms are defined as patient’s perceived changes in biopsychosocial functioning, sensations, or 
cognition,18, 19 e.g. bleeding, shame, and fear. A patient’s symptom experience includes 2 common 
dimensions with symptom occurrence, frequency and severity as the cognitive dimension, and 
symptom distress as the emotional dimension.20 Dodd et al.18 developed a generic symptom 
management model to understand how patients experience and manage symptoms, to provide health 
care professionals with direction for selecting clinical interventions, and to inform research. The 
model provides a framework for understanding the relationship between aspects of symptom 
experience, symptom management strategies and patient outcomes. In a patient-centred health care 
approach, this model provides appropriate guidance for treatment and care of patients with vulvar 
neoplasia. It is crucial to understand symptom experience in order to specify symptom assessment 
strategies and identify the focus for symptom management.18  
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Symptom assessment should be part of the general screening for adverse symptom events. This can be 
undertaken by collecting Patient-Reported Outcome (PRO) data.21 A PRO is any report of the patient’s 
health status that comes directly from the patient, such as his/her symptom experience.22 The 
assessment of both objective and subjective data allows for better supportive care.23  
In clinical practice complications and symptoms after vulvar surgical treatment are an immense 
challenge for affected women because they are often discharged before their surgical wound has 
healed. Despite this, for this patient population there is limited research about the prevalence and risk 
factors for different types of short-term wound complications and about women’s experiences during 
the first 6 months following surgical treatment. Furthermore, no structured symptom assessment 
instrument is available and there is little guidance for the assessment of symptom experience in 
women with vulvar neoplasia and surgical treatment. To date, nursing care and research are hampered 
by effective symptom assessment following vulvar surgical treatment. An effective assessment will 
allow nurses to better assign management strategies and to be able to evaluate the improvement in 
assessed symptoms. With the goal of improving care of women with vulvar neoplasia and surgical 
treatment, this international, multicenter research project aimed to develop a symptom assessment 
instrument for patients with vulvar neoplasia who have undergone surgical treatment.  
To address this aim we used a mixed-methods research approach and pragmatism guided this project.24 
This project consisted of a series of quantitative and qualitative studies with equal weighting of both 
methods using data of more than 180 women recruited from four Swiss (Zurich, Basel, Berne, St. 
Gallen) and four German University Hospitals (Berlin, Dusseldorf, Freiburg, Munich) from the years 
1997 to 2011. The first study of the research project was a cross-sectional investigation focusing the 
clinical perspective. With a sequential exploratory two-phase strategy, in studies 2 to 5 we intended to 
give voice to the patients’ experiences by the means of a qualitative approach in the first phase. Their 
experiences were then systematically analyzed in the quantitative component of the project (the 
second phase).  
First, we conducted a cross-sectional study on the period prevalence and risk factors for postoperative 
short-term wound complications in vulvar cancer patients in Switzerland. Data were collected 
retrospectively from medical records from 2007 to 1997 using an investigator-developed data 
collection instrument to assess risk factors preoperatively and perioperatively, and wound 
complications that occurred within the first 30 postoperative hospital days. The period prevalence of 
wound complications was 45.4% (49/108), showing at least 1 of 8 assessed wound complications per 
patient within the median hospital duration of 11 days. The period prevalences for the wound 
complication were: 31.5% for dehiscence, 12% for hematoma, 6.5% for necrosis, 5.6% for infections, 
4.6% for seroma, 1.9% for lymph cysts, 1.9% for malignant wounds, and 0% for disturbed tissue 
formation. Two of the 14 risk factors examined, the type surgical therapy (OR, 2.6; 95% confidence 
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interval [CI], 1.34-5.14) and inguinofemoral lymphadenectomy (OR, 3.0; 95% CI, 1.03-8.76) were 
significantly associated with short-term wound complications. The results of this retrospective study 
showed, that the high prevalence of short-term wound complications indicates a need for systematic 
wound assessment and early risk management, especially after hemivulvectomy, radical vulvectomy, 
and inguinal lymphadenectomy.25  
Second, in order to understand the women’s perspective, we conducted a qualitative study exploring 
the symptom experience in 20 women with vulvar precancer or cancer and surgical treatment in one 
Swiss and two German University Hospitals. Narratives showed eight key themes composing the 
essence of women’s symptom experience: delayed diagnosis, disclosed disease, disturbed woman’s 
self-image, changed vulva care, experienced wound-related symptoms, evoked emotions, affected 
interpersonal interactions and feared illness progression. The identified themes were consistent across 
different surgical procedures. The pattern present in all narratives was that women experienced a lack 
of information with regard to the above interrelated themes and that all of them used strategies to 
handle their situation, which affected their distress level. The communication, assessment and 
treatment of symptoms were hampered by the society’s and the health system’s tendency to overlook 
these symptoms and leave them in the realm of the unspeakable. We recommend that health care 
professionals need new strategies to support these women to recognize, assess and evaluate the 
seriousness of symptoms, and to communicate their symptom experience in order to minimize 
potentially preventable symptom-related distress.26 
Third, we focused on the perspective of women with VIN during their illness trajectory by conducting 
a secondary data analysis of the qualitative study. Eight narratives showed women’s experiences 
during their course of illness occurred in five phases: (1) There is something unknown; (2) One 
knows, what it is; (3) It is treated and should heal; (4) It has effects on daily life; (5) Meanwhile it 
works. These phases showed many women (1) had a late or incorrect diagnosis; (2) despite having a 
diagnosis women did not know what they suffered; (3) experienced a high uncertainty in decision-
making during treatment, (4) VIN had an impact on the physical and psychosocial level; and (5) that 
the women learned over time to deal with their illness. Central for these women during their course of 
illness was a sense of ‘Hope and Fear’. It reflects the fear of recurrence but also the trust in healing. 
Women’s experiences were particularly influenced by the feeling of ‘embarrassment’ and by ‘dealing 
with professionals’. Current care seems to lack adequate support for women with VIN to manage these 
phases. We recommend that new models of counseling and providing information need to be 
developed and evaluated.  
Fourth, a new Patient-Reported Outcome instrument for WOMen with vulvAr Neoplasia (WOMAN-
PRO) was developed according to the PRO guidelines and based on literature searches, expert 
feedback (n=9) and patient interviews (n=20). Thirty-seven items were first pilot-tested by patients 
SUMMARY 
- 8 - 
(n=6) and experts (n=6). The revised 36 items were pilot-tested by patients (n=4). Participants were 
recruited from one Swiss and two German University Hospitals. To our knowledge, this is the first 
PRO measure designed specifically to assess post-vulvar-surgery symptoms, informational needs and 
related distress after hospital discharge. The revised WOMAN-PRO showed an excellent item and 
scale Content Validity Index (CVI=1.0) and has the potential to support women in recognizing, 
assessing, and evaluating the seriousness of post-surgical symptoms and in communicating their 
symptom experience to health care providers. This can decrease women’s uncertainty about symptoms 
and reassure their decision-making about when to seek health care provider evaluation. It can provide 
clinical experts with systematic information about key symptoms from a patient perspective, and 
women’s unmet informational needs. 
In the fifth part of this research project, we identified the occurrence and distress associated with post-
surgery symptoms of women with vulvar neoplasia measured with a Patient-Reported Outcome 
instrument (WOMAN-PRO). The study was a prospective cross-sectional survey conducted in 8 
Hospitals in Switzerland and Germany. Outpatients (n=54) rated the occurrence of each of 31 
symptoms, and the degree to which the symptoms distressed them. The average number of symptoms 
reported per patient was 20 (SD 5.02) with a range of 10 to 31 symptoms on a 0 to 3 scale. The 3 most 
prevalent wound-related symptoms were ‘swelling’ (n=46), ‘drainage’ (n=46) and ‘pain’ (n=43). The 
3 most prevalent difficulties in daily life were ‘sitting’ (n=52), ‘wearing clothes’ (n=48) and ‘carrying 
out my daily activities’ (n=43). ‘Tiredness’ (n=51), ‘insecurity’ (n=44) and ‘feeling that my body has 
changed’ (n=42) were the 3 most prevalent psychosocial symptoms. The most distress symptoms were 
‘sitting’ (Mean 1.98, SD 0.90), ‘carrying out my daily activities’ (Mean 1.79, SD 0.89), and ‘open spot 
(e.g. opening of skin or suture)’ (Mean 1.79, SD 0.92), which were on average reported to be ‘quite a 
bit’ distressing.  In this study we also examined the reliability of the instrument using a Cronbach’s 
alpha coefficient. For the items representing wound-related symptoms and difficulties in daily life 
alpha was 0.70, and it was 0.87 for items representing psychosocial symptoms. An alpha of 0.70 or 
above reflects adequate reliability.27 The WOMAN-PRO data (1) show high symptom prevalence and 
distress, (2) call for a comprehensive symptom assessment, (3) may allow identification of areas for 
symptom management. If the results of further psychometric testing are promising, the WOMAN-PRO 
will provide an outcome measure for clinical trials. 
The results of the research project contributed to the evidence on women with vulvar neoplasia and 
surgical treatment. First, it added knowledge to support nurses and physicians ability to identify 
patients at risk for post-surgical wound complications. Second, it provided, for the first time, a 
conceptual model of symptom experience in affected women. Third, it established, for the first time, 
evidence to help understand the VIN patient’s experiences during her illness trajectory. Fourth, the 
development of the WOMAN-PRO instrument with a good content validity has the potential to 
contribute to a valid assessment of symptoms, informational needs and related distress in women 
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diagnosed with vulvar neoplasia and treated surgically. Fifth, WOMAN-PRO data showed a high 
symptom prevalence and distress, and provided preliminary evidence that the WOMAN-PRO 
instrument offers a feasible, targeted screening instrument to support systematic symptom assessment.  
We conclude that our research project added to the existing knowledge on complications, symptoms 
and associated distress of women with vulvar neoplasia and surgical treatment, confirmed the given 
need for further research on (a) implementation strategies for comprehensive symptom assessment and 
(b) the identification of areas in symptom management to support early recognition of symptoms and 
decrease symptom related distress in women with vulvar neoplasia and surgical treatment.  
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INTRODUCTION 
The following sections of this first chapter introduce the evidence concerning vulvar neoplasia (1.1), 
vulvar neoplasia treatment (1.2), post-surgical complications (1.3.), women’s experiences following 
the diagnosis and treatment of vulvar neoplasia (1.4.), the concept of symptom experience (1.5), 
Patient-Reported Outcome instruments (1.6), challenges related to the care of patients with vulvar 
neoplasia (1.7), and the subsequent content of this research project (1.8). 
1.1 Vulvar neoplasia  
Vulvar intraepithelial neoplasia (VIN) and vulvar cancer are rare diseases, but show increasing 
incidence rates especially in young women1, 2 and high recurrent rates.3, 4 VIN refers to precancerous 
changes that occur in the skin that covers the female external genital organs (the vulva).5 In the past, 
VIN was categorized as VIN 1, 2 and 3 according to the degree of abnormality. This classification was 
adapted by the International Society for the Study of Vulvar Disease in 2004. According to the new 
classification, VIN 1 is excluded from the classification and VIN includes lesions formally classified 
as VIN 2 or 3 or high grade VIN lesions. VIN is classified in two clinicopathologic subtypes. The 
usual VIN type is normally Human Papilloma Virus (HPV) related, while the differentiated type VIN 
is not associated with HPV in most cases.6 Most people who are sexually active will have HPV at 
some time during their life. The vast majority of genital HPV infections are asymptomatic and clear 
within 1 to 2 years.7 In Germany, the incidence rate of VIN in 2010 was estimated to be 7 per 100’000 
women per year.8 VIN incidence rate has increased in the last three decades in Europe and in the 
United States.1, 9 The number of women with VIN tripled during 1985 and 1997 in a Central European 
sample.2 VIN can affect women at any age, but it is more common under the age of 50.10, 11 Reported 
risk factors are infection with HPV, smoking, and poor immunological status.5, 11 VIN may be 
asymptomatic or may present with symptoms such as itching, discomfort, burning, and/or painful 
intercourse. The vulvar lesions may be red, brown, or white. A concern with VIN is the known 
progression to invasive cancer of the vulva.11, 12  
Vulvar cancer usually develops slowly over several years.13 Most vulvar cancers are squamous cell 
carcinoma (85% to 90%), although other histologic types such as adenocarcinoma, melanoma and 
Bartholin’s gland cancers do occur.14 The Federation Internationale de Gynecologie et Obstetrique 
(FIGO) and the American Joint Committee on Cancer (AJCC) classify the stages of vulvar cancer as 0 
to 4.15 Vulvar cancer incidence in Germany and Switzerland is between 1 and 7 cases per 100,000 
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women per year.16, 17 The mean age of women with vulvar cancer is 72 years.16 Reported risk factors 
for vulvar cancer are VIN, HPV infection, another anogenital intraepithelial neoplasia or carcinoma, 
syphilis, herpes genitalis, Acquired Immunodeficiency Syndrome (AIDS), smoking, lichen sclerosis, 
and squamous cell hyperplasia.8, 18 VIN-related cancer recurs in 30% to 40% of patients.3, 8 
1.2 Vulvar neoplasia treatment 
VIN lesions are managed by surgical excision or laser treatment.5, 19, 20 Surgery involves a wide local 
excision for focal lesions or a simple vulvectomy if the lesions are multifocal. It is estimated that after 
treatment of VIN by excision and/or laser vaporization 50% of women with positive surgical margins 
will required at least one additional treatment within 5 years.10 Due to the high recurrence rate, the 
disfiguring nature of these procedures and the negative psychosexual impact on patients,21 less 
invasive medical interventions have been developed and are still being evaluated. For example topical 
imiquimod cream appears to be effective in women with VIN, but its safety in view of the known 
progression of VIN to invasive disease needs further examination and more data on its adverse effects 
are required.11  
Standard therapy for vulvar cancer is surgery.22 In line with the FIGO guidelines, it consists of 
different surgical methods such as wide local excision, partial or radical vulvectomy and an 
inguinofemoral lymph node dissection depending on disease stage and lymph node involvement.13 
Based on tumor staging and patient factors, (neo-) adjuvant chemotherapy and radiation therapy may 
also be indicated.23 Surgical reconstruction of the vulva may improve morbidity and quality of life 
after treatment.24, 25 Generally, after minor surgical procedures an acute wound exists with good 
circulation and slight tissue damage and primary healing (per primam intentionem) generally occurs 
within three weeks.26 However, even relatively small excisions are susceptible to post-surgical 
complications.27 After major vulvar cancer surgery or in case of complications, delayed wound healing 
(per secundam intentionem) occurs.28 Although surgical modifications have been made to reduce 
postoperative morbidity in women with vulvar neoplasia,29 care for these patients is challenging with 
respect to post-surgical complications. 
1.3 Post-surgical complications  
Complications are defined as a medical problem that occurs during a disease or after a procedure or 
treatment.13 Clinicians diagnose complications with clinical parameters. The main diagnostic criteria 
of a wound infection, for example, are fever, leukocytosis, positive blood cultures and serous or 
purulent discharge from the wound.30 Most research published on complications following vulvar 
surgical treatment reflects the clinician perspective.31 Reports of post-vulvar-surgery complications 
focus most often on physical and psychosexual effects.  
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Physical complications include wound dehiscence, wound infections, venous thrombosis, pulmonary 
embolism, pressure ulcers, introitale stenosis, urine incontinence/dysuria, rectocele, fecal 
incontinence, inguinal seroma, lymphedema, hernia, pain, scars, adhesions, and development of 
eschar.5, 32-34 A recent randomized clinical trial included 30 women with VIN and reported no 
statistically significant differences in disease recurrence and adverse events in women treated with 
carbon dioxide laser (CO2 laser) versus ultrasonic surgical aspiration (selective removal of diseased 
tissue) after one year follow-up. Several adverse events were reported: (1) pain (n = 30, 100%), (2) 
scars (n = 5, 16.6%), (3) dysuria or burning (n = 7, 23.3%), (4) adhesions (n = 1, 3.3%), (5) infection 
(n = 4, 13.3%), and (6) development of eschar (n = 4, 13.3%).5 Three complications, lower extremity 
lymphedema (30% to 70%), wound dehiscence and infection (20% to 40%) were reported most 
frequently after surgical treatment in women with vulvar cancer.35, 36 In a cross-sectional US study of 
53 women whose vulvar cancer was treated surgically, lower-limb lymphedema was the most common 
complication and was experienced by 36% of the women.36 Wound dehiscence and wound infection 
were reported in up to 85% of patients after radical vulvectomy and lymphadenectomy, depending on 
the definition of these wound complications, sampling strategies, measurement methods and wound 
complication assessment periods (ranged from 1 to 35 months).17, 35, 37, 38 In a retrospective 
observational study of 101 patients after a modified radical vulvectomy and bilateral 
lymphadenectomy, Gaarenstrom et al.39 reported that 9% to 17% of women had a wound dehiscence, 
1% to 4% developed a hematoma, 9% to 39% had infections and there was a 40% lymph cyst rate. 
After less radical treatment, which disfigured the genitals to a lesser degree, post-surgical wound 
complications occurred less frequently.35, 40, 41 For example, in a retrospective observational study 
examining complications after different types of vulvectomies in 149 patients, Leminen et al.40 found  
that modified surgical techniques decreased dehiscence rates by 27% and infections by 28%. 
Psychosocial complications have been addressed by most of the studies investigating sexual 
functioning.5, 19, 21, 31, 42-45 Few studies focused on other psychosocial outcomes such as body image, 
partner relationships, and quality of life.19, 43 A literature review of Graziottin & Serafini46 reported 
that the psychosexual consequences in women with intraepithelial HPV-related neoplasia increases 
with the number of recurrences of HPV infection. The most frequently reported emotions in women 
with intraepithelial HPV-related neoplasia were depression, anxiety, and anger.46 For example, Mc 
Fadden et al.19 included seven women with VIN who had undergone surgical treatment in a two-year 
prospective study in Scotland. This study assessed depression and anxiety, quality of life, sexual 
functioning, and partner relationships every six-month with questionnaires. VIN had an adverse 
impact on quality of life and sexual functioning.19 Another retrospective study in the US compared 
preoperative with postoperative sexual dysfunction and body image scores. The findings from this 
questionnaire telephone survey of 41 vulvar cancer patients showed significant sexual dysfunction (P 
= 0.01) and disturbed body image (P = 0.004) three months after surgical treatment.43 
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Overall, studies show evidence for high complication rates in women with vulvar neoplasia who 
undergo surgical treatment. Affected women have to assess and manage surgery-related problems and 
deal with emotional concerns after discharge. But how do women experience surgery-related 
complications and how do these complications impact their emotional and social lives?  
1.4 Women’s experiences following the diagnosis and treatment  
of vulvar neoplasia 
This section includes qualitative research reporting on women’s experiences concerning physical, 
emotional and social effects after vulvar surgical treatment from a patient perspective. Our literature 
search in 2009 identified three studies examining women’s experiences following surgical treatment 
for vulvar neoplasia. One study focused on quality of life47, one on women’s experiences with VIN48 
and one on women’s experiences with cancer of the vulva.49 Based on their results, several symptoms 
and concerns were identified by women with vulvar neoplasia and surgical treatment.  
Janda et al.50 developed a vulvar cancer specific subscale to assess quality of life within the Functional 
Assessment of Cancer-General questionnaire (FACT-G). Instrument development was based on open-
ended interviews with 15 patients 2 weeks to 39 months after surgery.47 Results revealed reductions in 
several aspects of quality of life including physical, emotional and social functioning plus sexuality 
and body image. The vulvar cancer specific subscale included symptoms such as bleeding, odor, 
itching and burning in the vulva and a short vagina, as well as problems with swelling in the legs, 
sexual function, body appearance, urine control, and constipation. Likes et al.48 utilized a qualitative 
focus group with six US women with VIN to explore patients’ experiences with diagnosis and therapy. 
Participants reported symptoms of itching and pain. Shame, embarrassment and loss of control were 
reported as their most distressing experiences.48 Jefferies and Clifford49 described the experiences of 
13 women in the UK with cancer of the vulva who were interviewed between 6 months and 5 years 
after surgery. Women’s experiences were described as ‘searching’ to control their symptoms and 
emotions and emphasized their personal informational needs.49  
Likes et al.48 also explored emotional and social experiences in a group of women with VIN. The 
women feared infecting others with HPV. She found that for patients, sexually transmitted diseases 
had connotations of stigma, shame and impurity and caused problems in relationships with respect to 
loyalty and honesty. During the course of the illness, families and friends were perceived as either 
supportive or as a burden. Younger patients, in particular, felt that their peers often lacked the maturity 
to understand their experience.48  
In summary, three qualitative studies showed that affected women reported several symptoms such as 
vulvar bleeding, odor and embarrassment. These studies rarely took the socio-cultural context 
influencing women’s experiences into consideration. In conclusion, there is limited research on 
physical and emotional symptoms of affected women. No study could be identified that embedded 
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symptoms in a conceptual model of symptom experience in this patient population. It is crucial to 
understand women’s symptom experiences in order to identify the symptom assessment strategies 
which are necessary to support symptom management.51  
1.5 The concept of symptom experience  
Symptoms are defined as a patient’s perceived changes in biopsychosocial functioning, sensations, or 
cognition.51, 52 Examples of common symptoms are pain and fatigue.52 According to Dodd et al.,51 the 
experience of symptoms may prompt patients to visit their health care providers. Symptoms also 
create distress and may disrupt social functioning. The management of symptoms generally becomes 
the responsibility of the patient. Health care providers often have difficulty proposing symptom 
management strategies that can be applied in acute and home care settings. To better understand how 
patients experience and manage symptoms, a generic symptom management model was developed by 
Dodd et al.51 This model provides a framework for understanding the interrelatedness of three 
dimensions of symptom management, namely (1) symptom experience, (2) symptom management 
strategies and (3) outcomes. The model is designed to provide direction for health care professionals in 
selecting clinical interventions and informing research. Symptoms can help to bring problems to the 
attention of patients and clinicians. Dodd’s model is based on the assumption that the gold standard for 
the study of symptoms is the perception of the individual experiencing the symptom and his/her self-
report.  
One dimension of the model is symptom experience, which contains the following three elements:  
(1) An individual’s perception of a symptom, i.e., perceived changes from the way the 
individual usually feels or behaves.  
(2) The evaluation of the meaning of a symptom which entails the cause, frequency, temporal 
nature, severity, treatability of a symptom; the effect of the symptom on the individual’s 
life and the threat posed by the symptom, for example, whether or not it is dangerous.  
(3) The individual’s response to a symptom which contains physiological, psychological, 
socio-cultural and behavioral components.51 
Personal, environmental and health / illness components affect patient’s symptom experience. For 
instance, a woman’s  symptom experience will vary by age, reproductive status, her current stage of 
disease, whether she is assessed in the clinic or at home, and her cultural beliefs about the meaning of 
a symptom.52 Cultural components may cause distress especially in women with symptoms at the 
vulva, because in our socio-cultural context the vulva is known as a key element of eroticism,46 and is 
strongly affected by taboo in Western society.53 A patient’s symptom experience includes two 
common dimensions with symptom distress as the emotional dimension, and symptom occurrence, 
frequency and severity as the cognitive dimension.54 It is crucial to understand symptom experience 
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and the cultural aspects of a patient population in order to develop effective symptom assessment 
strategies. Symptom assessment, in turn, provide the basis for developing symptom management 
strategies to avert negative patient outcomes.51, 55 Further supporting the importance of symptom 
assessment in women with vulvar neoplasia are studies that have shown that a significant proportion 
of cancer patients report severe symptoms that are not detected by clinicians during routine 
consultations.56-58  
In literature searches in the Medline and CINAHL databases, Cochrane library and the Web of Science 
from 2000 to 2009, no studies focusing on symptom experience or symptom assessment in women 
with vulvar neoplasia and surgical treatment were found. Only one validated instrument measuring 
aspects of quality of life in vulvar cancer patients was identified, the Functional Assessment of Cancer 
Therapy-Vulvar (FACT-V).50 
Summarizing the literature on complications, symptoms, and symptom experience of women with 
vulvar neoplasia, to date, most research on VIN and vulvar cancer patients has been restricted to 
retrospective observational studies, a few prospective studies and several randomized controlled trials 
examining specific treatment options for vulvar neoplasia. Many studies had small samples and data 
were primarily collected from the health care provider not the patient. Qualitative studies addressing 
symptoms, psychological and social problems related to a surgical treatment in these women are 
sparse. To date, little is known about how women experience symptoms after surgical treatment for 
vulvar neoplasia. Self-report instruments for assessing symptom experience are not available in this 
patient population. While current guidelines emphasize improving symptom assessment by providing 
written material for patients,59, 60 such as Patient-Reported Outcome (PRO) instruments, nothing exists 
for women with vulvar neoplasia. 
1.6 Patient-Reported Outcome instruments  
PROs evolved from health-related quality of life tools that were becoming more disease-specific and 
symptom oriented.61, 62 A PRO is any report of the status of a patient‘s health condition that comes 
directly from the patient, e.g. symptoms.63 Systematic under-reporting and bias resulting for the use of 
standard summary methods have been described, potentially leading to treatment regimens appearing 
less toxic than they actually are.62 Patient reporting is invaluable in detecting the severity of adverse 
symptoms and in allowing timely treatment. There are limitations to both clinically-reported outcomes 
and patient-reported outcomes. Therefore, assessment of both is the most accurate way to describe a 
patient’s status, rather than using traditional objective measurements alone. A combination of 
assessments allows for better supportive care.64 A patient’s self-report captures important information 
that can only be assessed through a patient’s perception.65, 66 Basch67 emphasized the necessity of 
regularly including the patient’s voice by collecting PRO data as part of general screening for adverse 
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symptom events. As clinicians often underestimate the severity of a patient’s symptoms, patient self-
report can help to detect and prevent adverse events. When patient self-report of symptoms is standard 
practice, symptoms tend to be reported earlier in relation to their occurrence.67 Thus, a PRO 
instrument can add important information about the patient’s health status, the consequences of 
treatment, and the effectiveness of interventions.65 The first three steps that the US Food and Drug 
Administration recommend in developing a PRO instrument are to: (1) identify concepts or domains 
that are important to patients and develop a conceptual model; (2) create and pilot test the instrument; 
and (3) assess its measurement properties.68, 69  
1.7 Challenges for the care of patients with vulvar neoplasia 
The decreasing length of post-surgery hospital stay has increased the responsibility for the patient to 
assess and manage symptoms.60 Women with vulvar neoplasia are usually discharged before their 
surgical wound has healed. Follow-up visits are usually scheduled every three months for the first 
three years to detect recurrent cancer and to prevent predictable complications.70 However, for this 
patient population there is limited research about the prevalence and risk factors for different types of 
short-term wound complications. Furthermore, evidence has shown that clinicians may underestimate 
the severity of a patient’s symptoms that can, in turn, result in the occurrence of preventable adverse 
events.71 Therefore research needs to focus on the patient perspective. Women need to assess and 
manage symptoms at home until they see their health care providers again.48 Following surgery, 
women with vulvar neoplasia may not be able to identify complications such as wound infections. It is 
important to empower these women to recognize, assess and communicate symptoms, for example 
redness, that may indicate a complication. As symptoms vary over time, changes in the strategy to 
manage symptoms are required. Health care and especially nursing care should differ along an illness 
trajectory to meet patient and family needs.72, 73  
In summary, published studies on this patient group are limited and showed weaknesses in design, 
sample size and analytical methods. No published studies based on a conceptual model and addressing 
the socio-cultural aspects of symptom experience of women with surgically treated vulvar neoplasia in 
Germany and Switzerland could be identified. Based on guidelines for the development of PRO 
measures, the wound complications and symptom experiences in women with surgically treated vulvar 
neoplasia need to be explored prior to developing a symptom assessment instrument.  
Although an effective instrument collecting PRO data could support appropriate patient, nurse and 
physician decisions on symptom management following surgery, no instrument was found that 
assessed and quantified experienced symptoms and related distress in this patient population. A PRO 
instrument can support women with vulvar neoplasia in recognizing and evaluating the seriousness of 
symptoms so that appropriate treatment is sought in a timely fashion. In addition, such an instrument 
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can facilitate a woman’s ability to communicate effectively with health care professionals by 
providing structured information on symptom occurrence and distress. This should facilitate targeted 
optimization of interventions to prevent and manage symptoms and their related distress, addressing 
patient needs as well as improving vulvar neoplasia treatment.  
1.8 Subsequent content of this research project 
Given the gaps in the evidence base on women with vulvar neoplasia and surgical treatment, this 
research project includes the following chapters. In chapter 2 the aims and methods of this research 
project are described. Chapter 3 is the publication “Period prevalence and risk factors for 
postoperative short-term wound complications in vulvar cancer – A cross-sectional study”.74 This 
chapter also synthesizes the limited evidence concerning risk factors and prevalence of post-surgery 
complications from a clinical perspective. In chapter 4 the findings of the article “The unspoken 
disease: Symptom experience in women with vulvar neoplasia and surgical treatment - A qualitative 
study” are reported.75 In this chapter, we suggest a conceptual model that may be useful in 
understanding the symptom experience of affected women from a patient perspective. In chapter 5, 
we focused on the patient perspective of women with vulvar intraepithelial neoplasia during their 
illness trajectory by conducting a secondary data analysis of the foregoing qualitative study. In 
chapter 6 the development and content validity of a PRO instrument designed to self-monitor the 
post-surgery symptom experience and informational needs of WOMen with vulvAr Neoplasia 
(WOMAN-PRO) is reported. In chapter 7 the initial findings of a cross-sectional survey using the 
WOMAN-PRO instrument to identify the occurrence and distress of post-surgery symptoms are 
presented. In chapter 8 the key findings and research methods of the research project’s studies are 
discussed. Furthermore suggestions for further research and clinical practice and conclusions are 
presented. 
INTRODUCTION 
- 22 - 
1.9 References 
1. Lanneau GS, Argenta PA, Lanneau MS, et al. Vulvar cancer in young women: demographic 
features and outcome evaluation. Am J Obstet Gynecol 2009;200:645.e1-e5. 
2. Joura EA, Losch A, Haider-Angeler MG, Breitenecker G, Leodolter S. Trends in vulvar 
neoplasia. Increasing incidence of vulvar intraepithelial neoplasia and squamous cell carcinoma 
of the vulva in young women. J Reprod Med 2000;45:613-5. 
3. Nugent EK, Brooks RA, Barr CD, Case AS, Mutch DG, Massad LS. Clinical and pathologic 
features of vulvar intraepithelial neoplasia in premenopausal and postmenopausal women. J 
Low Genit Tract Dis 2010;15:15-9. 
4. Frega A, Sopracordevole F, Scirpa P, et al. The re-infection rate of high-risk HPV and the 
recurrence rate of vulvar intraepithelial neoplasia (VIN) usual type after surgical treatment. Med 
Sci Monit 2011;17:CR532-5. 
5. Kaushik S, Pepas L, Nordin A, Bryant A, Dickinson HO. Surgical interventions for high grade 
vulval intraepithelial neoplasia. Cochrane Database Syst Rev 2011;1:CD007928. 
6. Sideri M, Jones RW, Wilkinson EJ, et al. Squamous vulvar intraepithelial neoplasia: 2004 
modified terminology, ISSVD Vulvar Oncology Subcommittee. J Reprod Med 2005;50:807-10. 
7. Trottier H, Ferreira S, Thomann P, et al. Human papillomavirus infection and reinfection in 
adult women: the role of sexual activity and natural immunity. Cancer Res 2010;70:8569-77. 
8. Interdisziplinäre S2K-Leitlinie für die Diagnostik und Therapie des Vulvakarzinoms und seiner 
Vorstufen. Deutsche Gesellschaft für Gynäkologie und Geburtshilfe, 2009. (Accessed 
December 2011, at http://www.krebsgesellschaft.de/download/leitlinie_vulva_2010.pdf.) 
9. Hampl M, Wentzensen N, Vinokurova S, et al. Comprehensive analysis of 130 multicentric 
intraepithelial female lower genital tract lesions by HPV typing and p16 expression profile. J 
Cancer Res Clin Oncol 2007;133:235-45. 
10. Jones RW, Rowan DM, Stewart AW. Vulvar intraepithelial neoplasia: aspects of the natural 
history and outcome in 405 women. Obstet Gynecol 2005;106:1319-26. 
11. Pepas L, Kaushik S, Bryant A, Nordin A, Dickinson HO. Medical interventions for high grade 
vulval intraepithelial neoplasia. Cochrane Database Syst Rev 2011;4:CD007924. 
12. Eva LJ, Ganesan R, Chan KK, Honest H, Luesley DM. Differentiated-type vulval intraepithelial 
neoplasia has a high-risk association with vulval squamous cell carcinoma. Int J Gynecol 
Cancer 2009;19:741-4. 
13. Vulvar Cancer Treatment. U.S. National Institutes of Health, 2011. (Accessed December 2011, 
at http://www.cancer.gov/cancertopics/pdq/treatment/vulvar/HealthProfessional/page4.) 
14. Vulvar Cancer Treatment. Cellular Classification of Vulvar Cancer. U.S. National Institutes of 
Health, 2011. (Accessed December 2011, at http://www.cancer.gov/cancertopics/ 
pdq/treatment/vulvar/HealthProfessional/page6.) 
INTRODUCTION 
- 23 - 
15. Stage Information for Vulvar Cancer. TNM Category - AJCC Stage Groupings. National Cancer 
Institute, 2010. (Accessed December 2011, at http://www.cancer.gov/cancertopics/ 
pdq/treatment/vulvar/HealthProfessional/page3.) 
16. Dittmer C, Katalinic A, Mundhenke C, Thill M, Fischer D. Epidemiology of vulvar and vaginal 
cancer in Germany. Arch Gynecol Obstet 2011;10.1007/s00404-011-1850-9 [doi]. 
17. Johann S, Klaeser B, Krause T, Mueller MD. Comparison of outcome and recurrence-free 
survival after sentinel lymph node biopsy and lymphadenectomy in vulvar cancer. Gynecol 
Oncol 2008;110:324-8  
18. Van de Nieuwenhof HP, Massuger LF, Van der Avoort IA, et al. Vulvar squamous cell 
carcinoma development after diagnosis of VIN increases with age. Eur J Cancer 2009;45:851-6. 
19. McFadden KM, Sharp L, Cruickshank ME. The prospective management of women with newly 
diagnosed vulval intraepithelial neoplasia: clinical outcome and quality of life. J Obstet 
Gynaecol 2009;29:749-53. 
20. Rodolakis A, Diakomanolis E, Vlachos G, et al. Vulvar intraepithelial neoplasia (VIN)-
diagnostic and therapeutic challenges. Eur J Gynaecol Oncol 2003;24:317-22. 
21. Andreasson B, Moth I, Jensen SB, Bock JE. Sexual function and somatopsychic reactions in 
vulvectomy-operated women and their partners. Acta Obstet Gynecol Scand 1986;65:7-10. 
22. Lai KW, Mercurio MG. Medical and surgical approaches to vulvar intraepithelial neoplasia. 
Dermatol Ther 2010;23:477-84. 
23. Shylasree TS, Bryant A, Howells RE. Chemoradiation for advanced primary vulval cancer. 
Cochrane Database Syst Rev 2011;4:CD003752. 
24. Hockel M, Dornhofer N. Vulvovaginal reconstruction for neoplastic disease. Lancet Oncol 
2008;9:559-68. 
25. Zeng A, Qiao Q, Zhao R, Song K, Long X. Anterolateral thigh flap-based reconstruction for 
oncologic vulvar defects. Plast Reconstr Surg 2011;127:1939-45. 
26. Bostelaar R, Schaperdoth E, Lunau L, Eming S, Beckurts T. Wundmanagement in der Klinik. 
Ein Ratgeber zum Umgang mit chronischen Wunden. In. Hannover: Schlütersche 
Verlagsgesellschaft; 2006:31-6. 
27. Simcock B. Invasive vulval cancer. In: Obstetrics, Gynaecology and Reproductive Medicine; 
2008:64-8. 
28. Salgarello M, Farallo E, Barone-Adesi L, et al. Flap algorithm in vulvar reconstruction after 
radical, extensive vulvectomy. Ann Plast Surg 2005;54:184-90. 
29. Gray HJ. Advances in vulvar and vaginal cancer treatment. Gynecol Oncol 2010;118:3-5. 
30. Maier S, Korner P, Diedrich S, Kramer A, Heidecke CD. Definition and management of wound 
infections. Chirurg 2011;82:235-41. 
31. Jefferies H, Clifford C. A literature review of the impact of a diagnosis of cancer of the vulva 
and surgical treatment. J Clin Nurs 2011;10.1111/j.1365-2702.2011.03728.x [doi]. 
INTRODUCTION 
- 24 - 
32. Han LY, Schimp V, Oh JC, Ramirez PT. A gelatin matrix-thrombin tissue sealant (FloSeal) 
application in the management of groin breakdown after inguinal lymphadenectomy for vulvar 
cancer. Int J Gynecol Cancer 2004;14:621-4. 
33. Management of vulval cancer. Royal College of Obstetricians and Gynaecologists, 2006. 
(Accessed December 2011, at http://www.rcog.org.uk/files/rcog-corp/uploaded-
files/WPRVulvalCancerFull2006.pdf.) 
34. Uyl-De Groot CA, Hartog JG, Derksen JG, et al. Cost-effectiveness and quality of life of 
granulocyte-colony stimulating factor (filgrastim) after radical vulvectomy and bilateral 
inguino-femoral lymphadenectomy: results of a randomized clinical trial. Eur J Obstet Gynecol 
Reprod Biol 2004;114:77-82. 
35. De Hullu JA, Van der Avoort IA, Oonk MH, Van der Zee AG. Management of vulvar cancers. 
Eur J Surg Oncol 2006;32:825-31. 
36. Beesley V, Janda M, Eakin E, Obermair A, Battistutta D. Lymphedema after gynecological 
cancer treatment : prevalence, correlates, and supportive care needs. Cancer 2007;109:2607-14. 
37. Van der Zee AG, Oonk MH, De Hullu JA, et al. Sentinel node dissection is safe in the treatment 
of early-stage vulvar cancer. J Clin Oncol 2008;26:884-9. 
38. Dardarian TS, Gray HJ, Morgan MA, Rubin SC, Randall TC. Saphenous vein sparing during 
inguinal lymphadenectomy to reduce morbidity in patients with vulvar carcinoma. Gynecol 
Oncol 2006;101:140-2. 
39. Gaarenstroom KN, Kenter GG, Trimbos JB, et al. Postoperative complications after vulvectomy 
and inguinofemoral lymphadenectomy using separate groin incisions. Int J Gynecol Cancer 
2003;13:522-7. 
40. Leminen A, Forss M, Paavonen J. Wound complications in patients with carcinoma of the 
vulva. Comparison between radical and modified vulvectomies. Eur J Obstet Gynecol Reprod 
Biol 2000;93:193-7. 
41. Rouzier R, Haddad B, Dubernard G, Dubois P, Paniel BJ. Inguinofemoral dissection for 
carcinoma of the vulva: effect of modifications of extent and technique on morbidity and 
survival. J Am Coll Surg 2003;196:442-50. 
42. Weijmar Schultz WC, van de Wiel HB, Bouma J, Janssens J, Littlewood J. Psychosexual 
functioning after the treatment of cancer of the vulva. A longitudinal study. Cancer 
1990;66:402-7. 
43. Green MS, Naumann RW, Elliot M, Hall JB, Higgins RV, Grigsby JH. Sexual dysfunction 
following vulvectomy. Gynecol Oncol 2000;77:73-7. 
44. Andersen BL, Hacker NF. Psychosexual adjustment after vulvar surgery. Obstet Gynecol 
1983;62:457-62. 
45. Thuesen B, Andreasson B, Bock JE. Sexual function and somatopsychic reactions after local 
excision of vulvar intraepithelial neoplasia. Acta Obstet Gynecol Scand 1992;71:126-8. 
INTRODUCTION 
- 25 - 
46. Graziottin A, Serafini A. HPV infection in women: psychosexual impact of genital warts and 
intraepithelial lesions. J Sex Med 2009;6:633-45. 
47. Janda M, Obermair A, Cella D, Crandon AJ, Trimmel M. Vulvar cancer patients' quality of life: 
a qualitative assessment. Int J Gynecol Cancer 2004;14:875-81. 
48. Likes WM, Russell C, Tillmanns T. Women's experiences with vulvar intraepithelial neoplasia. 
J Obstet Gynecol Neonatal Nurs 2008;37:640-6. 
49. Jefferies H, Clifford C. Searching: the lived experience of women with cancer of the vulva. 
Cancer Nurs 2009;32:E30-6. 
50. Janda M, Obermair A, Cella D, et al. The functional assessment of cancer-vulvar: reliability and 
validity. Gynecol Oncol 2005;97:568-75. 
51. Dodd M, Janson S, Facione N, et al. Advancing the science of symptom management. J Adv 
Nurs 2001;33:668-76. 
52. Humphreys J, Lee KA, Carrieri-Kohlman V, et al. Theory of Symptom Management. In: Smith 
MJ, Liehr PR, eds. Middle Range Theory for Nursing. 2 ed. New York: Springer Publishing 
Company; 2008:145-58. 
53. Scholz G. Das Tor ins Leben. In. 1 ed. Belzig: LebensGut-Verlag; 2007:5-8. 
54. Leventhal H, Diefenbach M, Leventhal EA. Illness Cognition: Using Common Sense to 
Understand Treatment Adherence and Affect Cognition Interactions. Cognitive Therapy and 
Research 1992;16:143-63. 
55. Agarwal S, Bodurka DC. Symptom research in gynecologic oncology: a review of available 
measurement tools. Gynecol Oncol 2010;119:384-9. 
56. Del Priore G, Taylor SY, Esdaile BA, Masch R, Martas Y, Wirth J. Urinary incontinence in 
gynecological oncology patients. Int J Gynecol Cancer 2005;15:911-4. 
57. Velikova G, Booth L, Smith AB, et al. Measuring quality of life in routine oncology practice 
improves communication and patient well-being: a randomized controlled trial. J Clin Oncol 
2004;22:714-24. 
58. Snyder CF, Blackford AL, Aaronson NK, et al. Can patient-reported outcome measures identify 
cancer patients' most bothersome issues? J Clin Oncol 2011;29:1216-20. 
59. Innovative care for chronic conditions: building blocks for action: global report. World Health 
Organization, 2002. (Accessed December 2011, at http://www.who.int/chp/knowledge/ 
publications/icccreport/en/.) 
60. Nationales Krebsprogramm für die Schweiz 2011-2015. Pflege. Oncosuisse, 2011. (Accessed 
December 2011, at http://www2.oncosuisse.ch/pdf/NKP_2011-2015_Vollversion_dt.pdf.) 
61. Patrick DL, Ferketich SL, Frame PS, et al. National Institutes of Health State-of-the-Science 
Conference Statement: Symptom Management in Cancer: Pain, Depression, and Fatigue, July 
15-17, 2002. J Natl Cancer Inst 2003;95:1110-7. 
INTRODUCTION 
- 26 - 
62. Trotti A, Colevas AD, Setser A, Basch E. Patient-reported outcomes and the evolution of 
adverse event reporting in oncology. J Clin Oncol 2007;25:5121-7. 
63. Guidance for Industry. Patient-Reported Outcome Measures: Use in Medical Product 
Development to Support Labeling Claims. U.S. Department of Health and Human Services, 
2009. (Accessed December 2011, at http://www.fda.gov/downloads/Drugs/Guidance 
ComplianceRegulatoryInformation/Guidances/UCM193282.pdf.) 
64. Bateman E, Keefe D. Patient-reported outcomes in supportive care. Semin Oncol 2011;38: 
358-61. 
65. Lipscomb J, Gotay CC, Snyder CF. Patient-reported outcomes in cancer: a review of recent 
research and policy initiatives. CA Cancer J Clin 2007;57:278-300. 
66. Basch E, Goldfarb S. Electronic patient-reported outcomes for collecting sensitive information 
from patients. J Support Oncol 2009;7:98-9. 
67. Basch E. The missing voice of patients in drug-safety reporting. N Engl J Med 2010;362:865-9. 
68. Burke L, Stifano T, Dawisha S. Guidance for industry: patient-reported outcome measures: use 
in medical product development to support labeling claims: draft guidance. Health Qual Life 
Outcomes 2006;4:79. 
69. Revicki DA, Gnanasakthy A, Weinfurt K. Documenting the rationale and psychometric 
characteristics of patient reported outcomes for labeling and promotional claims: the PRO 
Evidence Dossier. Qual Life Res 2007;16:717-23. 
70. Kreienberg R, Digel S. Neubildungen von Vulva und Vagina In: Reuter P, ed. Springer Lexikon 
Diagnose & Therapie. Berlin, Heidelberg: Springer 2006. 
71. Basch E, Jia X, Heller G, et al. Adverse symptom event reporting by patients vs clinicians: 
relationships with clinical outcomes. J Natl Cancer Inst 2009;101:1624-32. 
72. Corbin JM, Strauss A. A nursing model for chronic illness management based upon the 
Trajectory Framework. Sch Inq Nurs Pract 1991;5:155-74. 
73. Corbin JM. The Corbin and Strauss Chronic Illness Trajectory model: an update. Sch Inq Nurs 
Pract 1998;12:33-41. 
74. Senn B, Mueller MD, Cignacco EL, Eicher M. Period prevalence and risk factors for 
postoperative short-term wound complications in vulvar cancer: a cross-sectional study. Int J 
Gynecol Cancer 2010;20:646-54. 
75. Senn B, Gafner D, Happ MB, et al. The unspoken disease: symptom experience in women with 
vulval neoplasia and surgical treatment: a qualitative study. Eur J Cancer Care (Engl) 
2011;10.1111/j.1365-2354.2011.01267.x [doi]. 
 
 - 27 - 
 
CHAPTER 2:  
AIMS AND METHODS 
 
 
 
 
 
 
 
 
 
 
  
AIMS AND METHODS 
- 28 - 
 
AIMS AND METHODS 
Despite fundamental efforts to improve standard diagnostic, medical and surgical therapy for women 
with vulvar neoplasia,1-3 adverse events such as surgery-related complications are common.4-6 Given 
the gaps in the evidence regarding women with vulvar neoplasia and surgical treatment as discussed in 
the introduction section, health care professionals need new strategies to decrease adverse symptom 
events and symptom-related distress by focusing more intensively on patients’ perspectives.  
2.1 Aims 
Therefore the aims of this research project were: 
(1) To examine period prevalence and risk factors for postoperative short-term wound 
complications following surgical treatment of vulvar cancer in a cross-sectional study. 
(2) To explore symptom experience, more specifically symptom occurrence and symptom 
distress in women with surgically treated vulvar neoplasia in a qualitative study. 
(3) To explore women’s experiences during their course of illness for vulvar intraepithelial 
neoplasia and its surgical treatment by carrying out a secondary data analysis of the 
forgoing qualitative study.  
(4) To develop and pilot-test the self-administered WOMAN-PRO instrument for monitoring 
the post-vulvar-surgery symptom experience and informational needs of women with 
vulvar neoplasia.  
(5) To examine the occurrence and distress related to post-surgery symptoms of women with 
vulvar neoplasia during the first week following hospital discharge following vulvar 
surgery in a cross-sectional study.  
2.2 Methods 
2.2.1 Design 
To address these aims we used a mixed-methods research approach, which combined quantitative and 
qualitative methods with equal weighting of both methods. Mixed-methods research is a design with 
philosophical underpinnings and methods of inquiry.7   
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2.2.2 Methodology and methods of inquiry 
As a methodology, mixed-methods research involves philosophical worldviews that guide the 
direction of the collection and analysis of data and the mixture of quantitative and qualitative 
approaches in several phases of the research process.7 In the worldview of pragmatism, the actions 
taken are purposeful and aim at creating desired outcomes.8 Pragmatism guided this mixed-methods 
research focusing on the primary importance of the research aims stated rather than the methods. 
Therefore this research project was oriented toward ‘what works in clinical practice’. Both objective 
and subjective knowledge and combined deductive and inductive thinking were valued while 
analyzing data. 
As a method of inquiry, mixed-methods research focuses on collecting and analyzing quantitative and 
qualitative data in a single study or series of studies.7 The central premise of  mixed-methods research 
is that the use of qualitative and quantitative approaches in combination provides a better 
understanding of research problems than either approach alone.7 As the understanding of post-surgical 
complications and related symptom experience in women with vulvar neoplasia has received 
negligible research attention, a pluralistic approach was chosen. With such an approach we intended to 
give voice to the patients’ experiences by the means of a qualitative approach. Their experiences were 
then systematically analyzed in the quantitative component of the project.  
To address aim 1, the first study of the research project was a cross-sectional investigation exploring 
the prevalence and risk factors for postoperative short-term wound complications in women diagnosed 
with vulvar cancer at University Hospital Berne. Addressing the research problem from a patient 
perspective required adding a secondary form of data (qualitative data) to the first study. 
To address aims 2 to 5, a sequential exploratory two-phase mixed-methods study (WOMAN-PRO) 
was conducted to explore symptom experience and illness trajectory in women with vulvar neoplasia 
and surgical treatment. The first phase of the WOMAN-PRO study included two qualitative studies 
with affected women recruited from the University Hospital Berne in Switzerland and two German 
University Hospitals in Freiburg and Munich. The use of interviews to explore important issues 
allowed us to discover the concerns of women diagnosed with vulvar neoplasia and treated with 
surgery. Heideggerian hermeneutics,9 an approach to interpret and understand the meaning of people’s 
lived experiences, provided the philosophical underpinning for the qualitative studies. According to 
Diekelmann et al.,10 we used a critical hermeneutic approach to embed women’s experiences in a 
wider socio-cultural context by relating the interpretation to additional literature, for example 
historical literature about the vulva in a German-speaking society.11 Data analysis focused on the 
understanding of people, the language and the study of texts.12 This process aims at uncovering 
meanings that may be hidden from social actors themselves,13 and at generating knowledge, which 
contribute to empowerment and change.14 This qualitative research enabled us to deconstruct initial 
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assumptions about patient experiences and showed us alternative ways in which they might be 
interpreted.15 Findings from this qualitative study phase allowed us to formulate relevant instrument 
items and were used to develop the WOMAN-PRO instrument. 
In the second phase of the WOMAN-PRO study, the pilot-tested instrument was administered to 
affected women from four Swiss Hospitals in the German speaking part of Switzerland and four 
University Hospitals in Germany. The data collected were used to examine the psychometric 
properties of the WOMAN-PRO and the prevalence of symptoms and their associated distress in 
women with vulvar neoplasia and surgical treatment during the first 7 days after discharge. 
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Abstract 
Background 
Although clinicians recognize that postoperative wound management in patients with vulvar cancer 
(VC) is challenging, the prevalence and risk factors for different types of short-term wound 
complications (WC) remain unclear. The aims of this study were: (1) to determine the period 
prevalence of postoperative short-term WC and (2) to identify risk factors associated with short-term 
WCs in patients with VC.  
Methods 
In a cross-sectional study in a Swiss University Hospital, a sample of 108 patients with VC treated 
surgically (and free of WCs at the time of admission) was included. Data were collected 
retrospectively from 2007 to 1997 from medical records using an investigator-developed data 
collection instrument to assess risk factors preoperatively and perioperatively and WCs that occurred 
within the first 30 postoperative hospital days. The period prevalence of WCs was calculated, and 
logistic regression was used to identify risk factors for WCs. 
Results  
The median age was 69 years (interquartile range [IQR], 21 years). The period prevalence of WCs was 
45.4% (49/108), showing at least 1 of 8 assessed WCs per patient within the median hospital duration 
of 11 days (IQR, 12 days). The period prevalence for each type of WC was 31.5% for dehiscence, 
12% for hematoma, 6.5% for necrosis, 5.6% for infections, 4.6% for seroma, 1.9% for lymph cysts, 
1.9% for malignant wounds, and 0% for disturbed tissue formation.  
Two significant predictors of WCs were identified out of 14 risk factors examined (P < 0.05). The 
odds ratio (OR) for WC increased with the extent of surgical therapy, i.e. from excision to hemi-
vulvectomy and to radical vulvectomy, by a factor of 2.6 (OR, 2.6; 95% confidence interval [CI], 
1.34-5.14), and, in the case of inguinofemoral lymphadenectomy, by a factor of 3 (OR 3.0; 95% CI 
1.03-8.76).  
Conclusions 
The high prevalence of short-term WCs (45.4%) indicates a need for systematic wound assessment 
and early risk-management - especially after hemivulvectomy, radical vulvectomy and inguinal 
lymphadenectomy. 
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3.1 Introduction 
Although patients with vulvar cancer (VC) have different treatment options, care of these patients 
remains a challenge with respect to postoperative wound care. The incidence of VC in North America 
and Europe is about 1.6 per 100,000 women per year and is currently increasing in young women.1 In 
line with the International Federation of Gynecology and Obstetrics (FIGO) and subject to the tumor 
stage, VC surgical treatment consists of wide excision, laser therapy, skinning vulvectomy, modified 
or radical vulvectomy.2 Based on tumor staging, (neo-) adjuvant chemotherapy and/or radiation 
therapy may also be indicated. In the past 2 decades, several surgical modifications have been made to 
reduce postoperative morbidity, for example: (1) separate incision approach instead of en bloc radical 
vulvectomy and groin lymph node dissection, (2) radical local excision for the T1 lesion of the vulva 
instead of radical vulvectomy, and (3) modification of femoral lymphadenectomy, avoiding deep groin 
dissection and preservation of great saphenous vein.  
Wound complications (WCs) after the surgical treatment of VC can be classified as dehiscence, 
hematoma, necrosis, infection, seroma, lymph cyst, disturbed tissue formation and malignant wounds.3 
Although WC in VC cause enormous physical and psychosocial problems and prolonged hospital stay 
as well as high health care costs,4 information on prevalence and risk factors for wound complications 
is sparse. To identify previous studies on WCs in VC, we performed a literature search in MEDLINE, 
CINAHL and the Cochrane database, including all studies on patients with VC in the period between 
1998 and 2008. The 11 studies identified examined WCs after a variety of surgical procedures and did 
not provide a definition of each WC.4-14 Existing literature so far has focused on 2 types of WC, 
namely, wound infection and dehiscence in the region of the groin and genitalia.4-14 Studies focusing 
on wound dehiscence and wound infections described rates from 5% to 85%, depending on the 
definition of the WC, the studied VC sample, and the assessment period of the WC.5, 13 Only 5 of 9 
observational studies and 2 randomized experimental studies described a VC sample with more than 
100 patients.6, 9, 11, 13, 14 Of these, only 1 study focused directly on different postoperative WCs after 
vulvectomy.6 Gaarenstrom et al.,6 in a retrospective observational study with a sample of 101 patients 
after a modified radical vulvectomy and bilateral lymphadenectomy, reported that 9% had vulvar 
wound dehiscence and 17% had groin wound dehiscence, 1% (vulvar) to 4% (groin) had hematomas, 
9% (vulvar) to 39% (groin) had infected wounds, and 40% developed lymph cysts in their groin.  
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Gottrup et al.15 reviewed risk factors associated with surgical site infections (SSIs) across surgical 
patients. The patient-related risk factors included diabetes, jaundice, chronic renal failure, poor 
physical condition, advanced age, alcoholism, smoking, obesity, poor nutrition, previous radiotherapy 
or chemotherapy, as well as medications. Assmussen et al.16 and Lippert17 reported that the risk of 
WCs was higher in patients on anticoagulants, immunosuppressants, cytostatics, antiphlogistics, and 
psychotropics as well as those with arterial and venous blood disorders. 
In 149 patients with VC, Leminen et al.9 identified bilateral tumor localization, a nonradical 
vulvectomy and a body mass index (BMI) over 25 as significant risk factors for wound infections in a 
retrospective observational study examining complications after different vulvectomies. In a recent 
prospective observational multicenter study examining the safety of sentinel node procedures, Van der 
Zee et al.13 reported a decrease in the number of wound dehiscence inguinal from 34.0% to 11.7% and 
the number of wound infections from 21.3% to 4.5% after exclusive sentinel node dissection without 
inguinofemoral lymphadenectomy. Rouzier et al.11 reported in a retrospective observational study with 
194 patients that a BMI over 24 increased the risk of wound infection. They stated that age older than 
70 years, BMI of more than 24, and the extent of lymphadenectomy increased the risk of wound 
dehiscence. Contrary to these results, Gaarenstrom et al.6 and Carlson et al.14 reported no increased 
risk in women older than 65 years. In a randomized clinical trial designed to compare the impact of 
vapor-heated fibrin sealant and sutured wound closure on lower extremity lymphedema after inguinal 
lymphadenectomies in 137 patients with vulvar malignancies, Carlson et al.14 reported a significantly 
higher rate of vulvar infections in the vapor-heated fibrin sealent group. The use of a Blake drain was 
associated with an increase in vulvar and inguinal wound breakdown. There was no significant 
increased risk for WCs associated with a BMI of more than 30. 
Other medical and patient-related risk factors for postoperative WCs that are crucial for identifying 
those at risk of possible WC and for initiating effective interventions in the future so far remain 
unmapped. Thus, prevalence and risk factors influencing the occurrence of WCs in patients with VC 
remains as two central, yet unresolved issues for health care professionals involved in post-surgical 
care of patients with VC. 
The aims of the present study were to: (1) determine the period prevalence of WCs from the first to the 
30th postoperative hospitalization day (short-term WC) in patients with VC and (2) identify medical 
and patient-related risk factors that were associated with short-term WCs.  
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3.2 Methods 
3.2.1 Design, sample and setting 
Using a retrospective cross-sectional design, the period prevalence of documented WCs and the 
associations between risk factors and short-term WCs were examined. Data were collected from the 
medical records of patients with VC in one Swiss University Hospital treated surgically between 
January 01, 1997 and December 31, 2007. On average, 14 patients with VC per year were operated on 
over the last 11 years in the designated hospital. The sample was comprised of all patients with VC 
meeting the inclusion criteria (Table 1).  
Table 1. Inclusion and Exclusion Criteria 
Inclusion criteria Exclusion criteria 
• Older than 18 years at the beginning of treatment • Patients with VC treated exclusively with 
radiotherapy, chemotherapy, other gynecologic 
surgery 
• Patients independent of  FIGO stage or lymph node 
status treated surgicallya in the time period of 1997-
2007 
• Patients with VC with pre-existing WCs at 
admission  
• Stationary hospitalization and vulvar surgery on one 
of two gynecologic wards of the designated hospital 
 
FIGO, International Federation of Gynecology and Obstetrics; VC, vulvar cancer; WCs, wound complications 
a
  Vulvar surgeries from 1997-2007 were performed by standardized methods according to the guidelines of German Society 
for Gynecology and Obstetrics.18 Since 1997, VC surgeries have been carried out with sentinel lymph node dissection. 
Between 1997 and 2002, the surgery included the usual inguinofemoral lymphadenectomy with triple incision. Since 
2003, a unilateral inguinofemoral lymphadenectomy was accomplished exclusively, depending on the lymph node status. 
During the survey period patients got routinely Redon drains after complete inguinofemoral lymphadenectomy (drain 
removal, if liquid flow rate <20mL). 
3.2.2. Instrument, Variables and Measurement 
A standardized data collection instrument was developed because no instrument for assessing short-
term WCs based on medical record review was available.15 For infections, the US Centers for Disease 
Control and Prevention suggests the use of the term ‘surgical site infection’ (SSI), which must meet 
specific criteria and occur within 30 days.15 Because to date there is no standard definition of short-
term WC, the definitions used in this study were based on the SSI criteria. 
Documented demographic data, medical and patient-related risk factors and specific WCs were 
captured by this instrument. Development of this instrument was based on a literature review focusing 
on criteria, instruments, definitions of the risk factors, WCs and VC. Three wound healing experts, a 
professor of gynecology and 2 clinical nurse specialists, validated the criteria for each item according 
to the definitions (content validity). The first author (B.S.) conducted a pretest with the revised 
instrument with the first 10 medical records to determine if complete and accurate data could be 
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retrieved. If there were questions about information documented in the medical record, they were 
discussed with experts in the field. Intercoder reliability was tested by two authors (B.S. and M.E.) 
independently coding 5 medical records. Their coding resulted in a high intercoder agreement 
(Krippendorff’s alpha = 1).  
3.2.3 Demographic characteristics 
In addition to the medical and patient-related risk factors, the following socio-demographic data were 
retrieved from medical records: civil status (married [1], single [2], widowed [3], divorced [4]), 
language (German [1], French [2], Italian [3], Spain [4], Others [5]), occupation (working [1], retired 
[2], housewife [3]), insurance (general [1], semiprivate [2], private [3]) and length of hospitalization 
(number of days [1-]). 
3.2.4 Medical and patient-related risk factors 
Six VC- and surgery-related characteristics were recorded: Diagnosis (primary tumor [1], recurrent 
tumor [2]), FIGO stage (I-IV [1-4]), surgical therapy (excision-including any kind of excision 
technique, skinning vulvectomy or laser therapy [1]; hemivulvectomy-including resection of one left, 
right, anterior, or posterior part of the vulva [2]; radical vulvectomy-radical resection or exenteration 
with or without flap reconstruction [3]), sentinel lymph node dissection (no [0]/ yes [1]), 
inguinofemoral lymphadenectomy (no [0]/ yes [1]/ others [2]) and number of eliminated lymph nodes 
(number of lymph nodes [1-]).  
The following 16 patient-related characteristics were recorded: age (years), BMI (kg/m²), diabetes 
mellitus (type I, type II, no [0]/ yes [1],), liver disease (chronic hepatitis, cirrhosis or jaundice, no [0]/ 
yes [1]), kidney disease (kidney failure, hem dialysis or patients after kidney transplant; no [0]/ yes 
[1]), arterial disorders (atherosclerosis, peripheral arterial disease or arterial hypertension, no [0]/ yes 
[1]), venous disorders (venous insufficiency, varicose veins or heart failure with leg edema; no [0]/ yes 
[1]), general condition (good [0]/ reduced [1]), alcohol consumption (no [0]/ yes or sometimes [1]), 
smoking (no [0]/ yes or sometimes [1]), malnutrition risk (instrument ‘Nutrition risk score’; no = <3 
points [0]/ yes ≥3 points [1]), previous radiotherapy (up to 6 months before surgery, no [0]/ yes [1]), 
previous chemotherapy (up to 6 months before surgery, no [0]/ yes [1]), immunosuppressant 
medication (no [0]/ yes [1]), cytostatic medication (no [0]/ yes [1]) and psychotropic medication (no 
[0]/ yes [1]). During the survey period, all patients with VC underwent surgery routinely got 
antibiotics, anticoagulants and anti-inflammatory medication, so that these medications were not 
examined as potential risk factors. 
Measurement of all 22 possible risk factors was based on information documented in the preoperative 
and perioperative records by physicians or nurses. Given that the influence of select medications on 
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WCs was also of interest with respect to the postoperative phase, data on medications were collected 
both preoperatively and postoperatively.  
3.2.5 Short-term wound complications 
Short-term WCs in the operative area were recorded as dichotomous dependent variables based on 
physician or nurse diagnosis. The WCs were operationalized as follows: wound dehiscence (presence 
[1] or absence [0] for each location of a level I, II, or III vulvar, inguinal and combined vulvar and 
inguinal dehiscence), hematoma (superficial or deep: no [0]/ yes [1]), necrosis (demarcated or wet 
border-necrosis or necrosis: no [0]/ yes [1]), infections (presence [1] or absence [0] for each location 
of superficial, deep or organ related vulvar, inguinal and combined vulvar and inguinal infection), 
seroma (serous exudates, ie, serum or lymph in cavities of the wound area: no [0]/ yes [1]), lymph 
cysts (well-defined amount of lymph in a cyst: no [0]/ yes [1]), malignant wounds (exulcerate or 
cicatricial malignant wound: no [0]/ yes [1]) and disturbed tissue formations (keloid, hypertrophic 
cicatricial tissue or cicatrice contracture: no [0]/ yes [1]). 
Each short-term WC was classified as present or absent during the data collection period (first to 30th 
post-operative day). To indicate the association between risk factors and short-term WCs, the 8 WCs 
were combined in 1 variable ‘at least 1 of 8 WCs’.  
3.2.6 Data collection  
Data were selected from the medical and nursing records by the first author in the designated hospital 
and were directly coded into an electronic data file. 
3.2.7 Data analysis 
Descriptive data analyses were performed using SPSS 15.0 (SPSS, Inc., Chicago, IL) including 
measures of central tendencies, frequencies, distributions, medians and interquartile ranges (IQRs) 
depending on the measurement level of the variables. First the period prevalence was calculated to 
describe the proportion of patients with VC with at least 1 WC. Second period prevalences were 
calculated for each type of WC, considering the location of wound dehiscences and infections.  
Inferential analysis was calculated using SAS 9.1.3., (SAS Institute, Inc., Cary, NC). Logistic 
regression was used to explore possible associations between risk factors and the dichotomy outcome 
variable ‘at least 1 of 8 WCs’, using generalized estimation equations to account for the fact that some 
patients had multiple hospitalizations during the data collection period of 11 years. The following risk 
factors were omitted from the model because of strong associations with other predictors in the model 
(based on a variance inflation factor of >2): general condition, liver disease, immunosuppressant 
medication, cytostatic medication, and the number of resected lymph nodes. The risk factors kidney 
disease, previous chemotherapy and malnutrition risk were excluded because of missing values. To 
avoid bias by misinterpreting the interrelationship between malignant wounds and tumor stage, 
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malignant wounds were excluded from the regression analysis. All remaining risk factors (n = 14) 
were tested separately in simple regression models. Because we expected FIGO to be confounded by a 
primary versus a recurrent tumor, we entered the interaction term of FIGO (I-IV) and diagnosis 
(primary and recurrent tumor) in the regression analysis, which allowed the effect of FIGO stage on 
WCs to be different for diagnosis (primary tumor / recurrent tumor). In a second step, all 14 risk 
factors were entered in a multiple regression model, which was purged by manual backward deletion.  
The study was approved by the ethics committee of the canton Berne. The master list linking the study 
ID-number to VC patients was stored in a secure place separate from the study instruments in order to 
guarantee confidentiality. 
3.3 Results 
3.3.1 Sample characteristics 
In total, 152 medical records of patients with VC were screened for eligibility. Seven medical records 
were missing and 37 patients did not meet eligibility criteria. A total of 108 patients with VC who 
were treated surgically were included in the calculation of WC period prevalence. In this sample, 74 
patients were operated on once, 23 twice, 6 three times, 4 four times, and 1 five times. One patient 
with a missing BMI value and 2 patients with malignant wounds were excluded from the regression 
analysis. The sample for the regression was 105 patients (Figure 1). 
 
 
 
 
 
 
 
 
 
 
 
VC, vulvar cancer; BMI, body mass index 
152 patients with VC were screened 
Excluded:  
7 missed medical records  
Excluded: 
29 VC patients with solely radiotherapy/ chemotherapy 
or gynecologic surgery, without VC surgery 
145 patients were screened for eligibility  
Excluded:  
8 patients with existing wound complications at 
admission 
108 patients included in prevalence analysis 
116 patients 
Excluded:  
2 patients with malignant wounds  
105 patients included in regression analysis  
106 patients 
Drop-out:  
1 patient with missed BMI value  
Figure 1. Flowchart: Numbers of Included and Excluded Patients with Vulvar Cancer. 
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The mainly German-speaking sample of 108 patients with VC had a median age of 69 years (IQR, 21). 
The median length of hospitalization was 11 days (IQR, 12). Approximately half of the cases had 
FIGO stage I tumors (44.5%) and half of them were FIGO stage II to IV (53.6%). The tumor was 
removed in 45.4% of the cases through excision and in 54.6% through hemivulvectomy or radical 
surgery. A similar proportion of cases received a sentinel lymph node dissection (47.2%) and 
inguinofemoral lymph node dissection (58.3%; Table 2). 
Table 2. Demographics, Risk Factors and Medical Characteristics of the Sample (n = 108).  
Variables Frequency,  Median 
%, 
IQR 
Civil state 
  
 Married 45 41.7% 
 Single 12 11.1% 
 Widowed 32 29.6% 
 Divorced 3 2.8% 
 Not documented 16 14.8% 
Language 
  
 German 102 94.4% 
 French 2 1.9% 
 Italian 3 2.8% 
 Spain 1 0.9% 
Occupation 
  
 Working 12 11.1% 
 Retired 52 48.1% 
 Housewife 30 27.8% 
 Not documented 14 13.0% 
Insurance 
  
 General 60 55.6% 
 Semiprivate 19 17.6% 
 Private 10 9.3% 
 Not documented 19 17.6% 
Length of hospitalization  
  
 In days 11 (median) 12 (IQR) 
Diagnosis 
  
 Primary tumor 58 53.7% 
 Recurrent tumor 48 44.4% 
 Not documented 2 1.9% 
FIGO stage  
  
 Ia and Ib (primary tumor) 22 20.4% 
 II (primary tumor) 17 15.7% 
 III (primary tumor) 12 11.1% 
 IV (primary tumor) 7 6.5% 
 Ia and Ib (recurrent tumor) 26 24.1% 
 II (recurrent tumor) 12 11.1% 
 III (recurrent tumor) 9 8.3% 
 IV (recurrent tumor) 1 0.9% 
 not documented 2 1.9% 
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Table 2. (continued) Frequency, Median %, IQR 
Surgical therapy 
  
 Excision 49 45.4% 
 Hemivulvectomy 38 35.2% 
 Radical vulvectomy 21 19.4% 
Lymph node dissection 
  
 Sentinel 51 47.2% 
 Inguinofemoral 63 58.3% 
 Others 1 0.9% 
Eliminated lymph nodes 
  
 Number of lymph nodes 2 (median) 15 (IQR) 
Age 
  
 In years 69 (median) 21 (IQR) 
BMI 
  
 In kg/m² 27.9 (median) 7.3 (IQR) 
Diabetes mellitus  
  
 Type I 0 0% 
 Type II 16 14.8% 
Arterial disorders 
  
 Atherosclerosis, peripheral arterial disease or arterial hypertension 46 42.6% 
Venous disorders 
  
 Venous insufficiency, varicose or heart failure with leg edema 29 26.9% 
Alcohol consumption 
  
 Yes or sometimes 59 54.6% 
Smoking 
  
 Yes or sometimes 28 25.9% 
Previous radiotherapy 
  
 Up to 6 months before surgery  5 4.6% 
Psychotropic medication 
  
 Yes  32 29.6% 
IQR, interquartile ranges; FIGO, International Federation of Gynecology and Obstetrics; BMI, body mass index 
3.3.2 Period prevalence of short-term wound complications 
The period prevalence for any short-term WC was 45.4% (49/108). These patients developed at least 1 
of 8 WCs within a median hospital stay of 11 days (IQR, 12). The period prevalence for each type of 
WC was 31.5% for dehiscence (34/108), 12% for hematoma (13/108), 6.5% for necrosis (7/108), 5.6% 
for infection (6/108), 4.6% for seroma (5/108), 1.9% for lymph cyst (2/108), and 1.9% for malignant 
wounds (2/108). No patient had disturbed tissue formation. Dehiscences occurred twice as often in the 
vulva (n=20) as in the inguinal (n=10) region, and infections were more commonly located in the 
vulvar region (n=4) than in the inguinal region (n=1; Table 3).  
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Table 3. Period Prevalence of Short-term Wound Complications in Vulvar Cancer Patients (n = 108). 
Variables n % 
At least 1 WCa per patient    
 Vulvar and/or inguinal  49 45.4% 
Dehiscence    
 Vulvar and/or inguinal 34 31.5% 
 Vulvar 20 18.5% 
 Inguinal 10 9.3% 
 Vulvar and inguinal 2 1.9% 
 Location not documented 2 1.9% 
Hematoma    
 Vulvar and/or inguinal 13 12.0% 
Necrosis    
 Vulvar and/or inguinal  7 6.5% 
Infection    
 Vulvar and/or inguinal 6 5.6% 
 Vulvar 4 3.7% 
 Inguinal 1 0.9% 
 Vulvar and inguinal 1 0.9% 
Seroma  
  
 Vulvar and/or inguinal 5 4.6% 
Lymph cyst  
  
 Vulvar and/or inguinal 2 1.9% 
Malignant wound  
  
 Vulvar and/or inguinal 2 1.9% 
Disturbed tissue formation  
  
 Vulvar and/or inguinal  0 0% 
WC, wound complication 
a
  Each short-term WC was documented as present or absent during the data collection period (1st to 30th post-operative day). 
The period prevalence was calculated to describe the proportion of vulvar cancer patients with at least one WC within a 
median hospitalization period. 
3.3.3 Risk factors for short-term wound complications 
In the uncontrolled simple regression analysis (Table 4), diagnosis, surgical therapy, sentinel lymph 
node dissection, and inguinofemoral lymphadenectomy were significant predictors of WCs. Two of 
them remained significant in the multiple model (Table 5): surgical therapy (P = 0.005) and 
inguinofemoral lymph node dissection (P = 0.044). Compared with patients who had an excision, 
those who had hemivulvectomy were 2.6 times more likely to have a WC. Compared further with 
patients who had a hemivulvectomy, those who had a radical vulvectomy were 2.6 times more likely 
to have a WCs (odds ration [OR], 2.6; 95% confidence interval [CI] 1.34-5.14). Patients receiving an 
inguinofemoral lymphadenectomy were 3 times more likely to have a WC compared with patients 
without an inguinofemoral lymphadenectomy (OR, 3.0; 95% CI 1.03-8.76). In simple logistic 
regressions, the interaction term of diagnosis and FIGO stage was significant (P = 0.004), suggesting 
that the association of FIGO and WC differ depending on the diagnosis. Indeed, a further exploratory 
analysis (Table 4) showed that the evidence of an association between WC and FIGO stage could exist 
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for patients who have a recurrent tumor, and not a primary tumor. This could not be corroborated on 
the multiple model.  
Table 4. Risk Factors associated with Short Term Wound Complications after Vulvar Cancer 
Surgery: Simple Logistic Regressions (n = 105). 
Variables   df Odds ratios (95%CI) 
Chi-
Square p value 
Diagnosis     
Primary tumor, recurrent (1,2) 1 0.34 (0.16-0.72) 8.00 0.0047 
FIGO stage     
Primary tumor (I-IV) (n = 58) 1 0.76 (0.45-1.30) 0.99 0.3209 
Recurrent tumor (I-IV) (n = 47) 1 1.86 (0.96-3.61) 3.36 0.0667 
Surgical therapy      
Excision, hemi-vulvectomy, radical vulvectomy (1-3) 1 3.62 (1.98-6.62) 17.51 <0.0001 
Sentinel lymph node dissection     
No = 0, yes = 1 1 3.35 (1.59-7.06 10.14 0.0015 
Inguinofemoral lymphadenectomy      
No = 0, yes = 1 1 5.98 (2.13-16.80) 11.54 0.0007 
Diabetes mellitus      
Type II (no = 0, yes = 1) 1 1.31 (0.83-2.08) 1.36 0.2443 
Arterial blood disorders     
Atherosclerosis, peripheral, arterial disease or  
arterial hypertension (no = 0, yes = 1) 
1 1.25 (0.59-2.64) 0.33 0.5643 
Venous disorders     
Venous insufficiency, varicose or heart failure 
with leg edema (no = 0, yes = 1) 
1 0.90 (0.35-2.29) 0.05 0.8249 
Age     
Years (1-) 1 1.02 (0.99-1.05) 1.07 0.3002 
Alcohol consumption     
No = 0, yes or sometimes = 1 1 1.47 (0.68-3.21) 0.95 0.3298 
Smoking     
 No = 0, yes or sometimes = 1 1 0.71 (0.28-1.82) 0.51 0.4751 
Previous radiotherapy     
Up to six months before surgery (no = 0, yes = 1) 1 0.82 (0.12-5.65) 0.04 0.8358 
Body Mass Index      
In kg/m² 1 1.02 (0.96-1.09) 0.38 0.5397 
Psychotropic medication     
No = 0, yes = 1 1 1.62 (0.72-3.63) 1.38 0.2396 
CI, confidence interval; df = degree of freedom; FIGO, International Federation of Gynecology and Obstetrics 
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Table 5.  Risk Factors associated with Short-term Wound Complications after Vulvar Cancer Surgery: 
Multiple Logistic Regression (n = 105). 
Variables a  df Adjusted odds 
ratios (95%CI) 
Chi-
Square p value 
Surgical therapy     
           Excision, hemivulvectomy, radical vulvectomy (1-3) 1 2.62 (1.34 - 5.14) 7.89 0.005 
Inguinofemoral lymphadenectomy     
           No = 0, yes = 1 1 3.00 (1.03 - 8.76) 4.06 0.044 
CI, confidence interval; df=degree of freedom; FIGO, International Federation of Gynecology and Obstetrics 
a
  Model consisted of 14 risk factors: diagnosis, FIGO stage, surgical therapy, sentinel lymph node dissection, inguinofemoral 
lymphadenectomy, diabetes mellitus, arterial blood disorders, venous disorders, age, alcohol consumption, smoking, 
previous radiotherapy, Body Mass Index, psychotropic medication. 
3.4 Discussion 
This study is the first to report period prevalences for 8 short-term WC and risk factors for WCs in a 
Swiss sample. Owing to the definition of WCs used in this study and the consideration of 8 specific 
types of WCs the reported period prevalence (45.4%) is not directly comparable with reported WCs of 
about 40% in other western countries.6, 9, 11, 13, 14 Furthermore, the relatively high prevalence of WCs 
may be related to the sample characteristics. Approximately 30% of the tumors in this study were 
stages III to IV. This explains the high proportion of women (58%) who had inguinofemoral lymph 
node dissection, which, in comparison with exclusive sentinel lymph node dissection, is accompanied 
with higher prevalence of WCs.11, 13 Differences in the type of surgical intervention may explain 
differences in the prevalence rates of wound dehiscence and infection in different studies. For 
example, Van der Zee et al.13 examined the prevalence of wound dehiscence and infection after 
sentinel node biopsy (SLN) dissection alone (n = 264) or SLN dissection with subsequent 
inguinofemoral lymphadenectomy (n = 47). The prevalence rates of wound infections and dehiscence 
in the total sample were 7% and 15%, respectively (infections, 4.5% and 21.3%, respectively, and 
dehiscence, 11.7% and 34.0%, respectively, in the SLN dissection alone group and in the SLN 
dissection with lymphadenectomy group). In comparison, the sample in this study showed more 
extensive surgeries. Thus, compared to Van der Zee et al.,13 a higher WC prevalence could be 
expected.  
In particular, this study demonstrates that the 3 most frequently observed short-term WCs were wound 
dehiscence, hematoma, and necrosis. With a prevalence of 31.5%, wound dehiscence was the most 
frequent WC in this study. This relatively high period prevalence falls within the range reported in 
other studies, which reported 9% to 47% wound dehiscence rates in patients with comparable 
surgeries.6, 9, 13, 14 Yet, the definition used in this study covers each wound rupture (level I, II and III), 
irrespective of size.17 Such definition is more encompassing than that used in the study by 
Gaarenstrom et al.6 in which 17% of patients had a wound disruption over more than one third of the 
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length of the incision. Therefore, compared with that in Gaarenstrom et al., a higher prevalence could 
be anticipated in the current study. 
In contrast to similar studies, the rate of documented wound infection (5.6%) was lower. Leminen et 
al.9 reported that 47% of the patients in their study had wound infections, Gaarenstrom et al.6 reported 
a 9% rate in vulvar region and 39% in the inguinal region, Van der Zee et al.13 reported a rate of 4.5% 
after sentinel node procedure and 21,3% after lymphadenectomy, and Carlson et al.14 a rate of 14% in 
vulvar region (33% in the fibrin sealant arm) and 35% in the inguinal region (36% in the fibrin sealant 
arm).6, 9, 13 The low rate of infection in the current study may be related to the strict Centers for Disease 
Control and Prevention definition used. In contrast to the findings of Gaarenstrom et al.,6 in the present 
study, both wound dehiscence and infection were more common in the vulvar than the inguinal region. 
Wound dehiscence and infection rates may have been related to the surgical techniques, the Redon 
drains and sutured closure after inguinal lymphadenectomy used in the participating hospital, or due to 
the differences in the prevalence of risk factors such as tumor localization, urine and fecal 
incontinence. These risk factors should be systematically recorded and examined in the future.  
In this study, hematoma (12%) and necrosis (6.5%) were the second and third most frequent WCs. The 
prevalence of seroma was 4.6% in the current study. Lymph cysts (1.9%) were a relatively rare WC in 
the current study, in comparison with a 7% prevalence rate reported by Leminen et al.9 and a 40% rate 
reported by Gaarenstrom et al.6 Malignant wounds (1.9%) were rare in the current study which is 
consistent with the previously reported low prevalence (3%) of malignant wounds in the groin and 
genital region.19 Interestingly, no other VC studies examining the prevalence of seroma and necrosis 
were found. Hematomas, malignant wounds, and lymph cysts have seldom been mentioned in other 
VC studies despite that they are well-known postoperative WCs and that they require additional 
therapies. Another WC, disturbed tissue formation, was not observed in this study sample. The 
absence of this wound complication was assuredly affected by the relatively short duration of 
hospitalization (median = 11 days) and the 30-day measurement period. 
Two of the risk factors examined, the type surgical therapy and inguinofemoral lymphadenectomy, 
were significantly associated with short-term WCs in the current study. These findings are consistent 
with findings of other studies that reported a significant association between radical vulvectomy and 
inguinofemoral lymphadenectomy and WCs.9, 11 Leminen et al.9 reported that modified surgical 
techniques decreased wound dehiscence rates by 27% and infections by 28%. Recent studies suggest 
that sentinel node dissection in vulvar cancer is a safe alternative to inguinofemoral lymph node 
dissection and reduces the morbidity associated with surgical treatment.13  
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3.4.1 Limitations 
Despite reviewing medical records of women who had been treated surgically for VC over an 11-year 
period, the low incidence of VC resulted in small sample of 108 women. The small sample limited the 
power to detect relationships that may have been evident with a larger sample.  
Given that the data collection was limited to only 1 hospital, the results might not be representative of 
other hospitals. Owing to the retrospective data collection from medical records, mainly nominal 
variables were obtained with low information content (information bias). Nevertheless, a complete and 
accurate data collection was performed. An accurate recording of wound location was only possible in 
case of infection and dehiscence. The limited sample size allowed no regression analysis per WC type. 
Moreover, the study design did not allow for a description of causal relationships.  
3.5 Conclusions 
Acknowledging these limitations, the high prevalence of 45.4% short-term WC and 2 identified risk 
factors supported by findings in previous studies indicates that focused systematic wound assessments 
and early risk management are important components of the care for women with VC, especially 
patients with an increased risk after hemivulvectomy, radical vulvectomy, and inguinofemoral 
lymphadenectomy. The study results should enable clinicians to better identify patients with an 
increased risk for WCs and to provide appropriate interventions. In our hospital, we implemented a 
process guideline for regular postoperative multidisciplinary wound assessments performed by a 
physician, a nurse and a wound specialist in patients at risk. Further studies are being developed to 
enhance postoperative wound assessment for patients with vulvar cancer.20  
Although other studies described several risk factors as predictors for WCs,6, 9, 11, 14 this study found 
only 2 significant predictors, an aspect that requires further investigation. Given the rarity of VC, 
international, prospective multicenter studies are necessary21 to clarify influencing factors on short-
term and long-term WCs. Studies should examine additional risk factors and use uniform definitions 
and standardized survey instruments to provide the evidence base for systematic wound management. 
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Abstract 
Background 
Women with vulvar neoplasia often experience severe post-surgical complications. This study focuses 
on symptom experience of women during the first 6 months following surgical treatment for vulvar 
neoplasia considering their socio-cultural context. 
Methods 
In this qualitative study using a critical hermeneutic approach, narrative interviews were conducted. A 
purposeful sample of 20 patients was recruited from 1 Swiss and 2 German University Hospitals. 
Content analysis was employed to analyze the transcribed interviews considering women’s 
experiences and social perceptions.  
Results 
Narratives showed eight interrelated themes: delayed diagnosis, disclosed disease, disturbed self-
image, changed vulva care, experienced wound-related symptoms, evoked emotions, affected 
interpersonal interactions, and feared illness progression. The women experienced a general lack of 
information pertaining to above themes and all described strategies used to handle their situation, 
which affected their distress. The communication, assessment, and treatment of symptoms were 
hampered by the society’s and the health system’s tendency to overlook these symptoms and leave 
them in the realm of the unspeakable. 
Conclusions 
Health care professionals need new strategies to support these women to recognize, assess, and 
evaluate the seriousness of symptoms, and to communicate their symptom experience so that timely 
medical treatment is sought. This support may minimize potentially preventable complications and 
symptom-related distress. 
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4.1 Introduction 
Women with vulvar neoplasia often experience severe post-surgical complications,1 but there is 
limited research on their symptom experience. The term ‘vulvar neoplasia’ comprises the diagnosis of 
vulvar intraepithelial neoplasia (VIN)2 and the diagnosis vulvar cancer.3 VIN is the presence of 
abnormal keratinocytes in a woman's external genital that have the potential to develop into invasive 
carcinoma.4 Human papilloma virus infection and older age can affect the risk of developing vulvar 
cancer.5 About 30–50% of women with VIN or squamous cell carcinoma of the vulva will develop 
recurrent disease within 2 years of primary treatment.4, 6 Surgery is the standard therapy for women 
with VIN and vulvar cancer.4, 7 It consists of different surgical treatment methods such as local 
excision, laser vaporization, partial or radical vulvectomy and an inguinofemoral lymph node 
dissection depending on disease stage and the lymph node involvement. VIN is a premalignant skin 
condition and the majority of women with VIN require surgical treatment such as a local excision or a 
laser therapy.8-10 Surgical interventions for VIN cause psychosexual morbidity and impact womens’ 
quality of life.8, 9 Even relatively small excisions are susceptible to post-surgical complications.11 
Although surgical modifications have been made to reduce postoperative morbidity in women with 
vulvar cancer,12 the prevalence of complications, such as 30-70% rates of lower extremity 
lymphedema,13-15 20-40% wound complications16-18 and psychosexual effects19, 20 remain high.  
Despite these reported complication rates, to date, little is known about the complication-related 
symptom experience of women and how socio-cultural aspects like stigma influence these 
experiences. Symptom experience is defined as patients’ perceived indications of disease or changes in 
their biopsychosocial functioning and cognition.21 Studies have shown that a significant proportion of 
cancer patients reported severe symptoms that were not detected by clinicians during routine 
consultations.22, 23 Therefore the assessment of symptom experience is crucial in identifying immediate 
health care needs and in providing high-quality care.24, 25 Three previous qualitative studies, showed 
that affected women reported symptoms such as vulvar bleeding, odor, pain, itching, burning, 
irritation, as well as problems with vulvar self-examination, leg swelling, sex, body appearance, loss 
of control, lack of information, shame, embarrassment, trouble controlling urine and constipation.26-28 
These studies rarely took the socio-cultural context influencing women’s experiences into 
consideration. In summary, there is very limited research on the symptoms of affected patients. We 
found no published study that offered a conceptual framework and addressed the socio-cultural aspects 
of the symptom experience in these women in Germany and Switzerland. Therefore, this study will 
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contribute to a comprehensive understanding of the symptoms and symptom-related experiences by 
women during the first 6 months following surgical treatment within their socio-cultural context. The 
goal is to identify the main themes, and understand the meaning of symptoms from a patient 
perspective. This knowledge is crucial to improve communication about symptom experience, to 
assess symptom experience, to develop interventions to improve self-management of symptoms and to 
prevent symptom-related complications (e.g. wound infections) in the future.  
4.2 Methods 
This qualitative study is part of a larger mixed-methods research project (Clinical Trial ID: 
NCT01300663). We used a critical hermeneutic approach to identify the relevant individual themes of 
women with vulvar neoplasia embedded in a wider socio-cultural context.29 Heideggerian 
hermeneutics, an approach to interpret and understand the meaning of people’s lived experiences,30 
provided the philosophical underpinning. Diekelmann, Allen and Tanner29 described the used critical 
hermeneutic process of data analysis, focusing on language and understanding of people as well as on 
the study of texts, in relation to wider socio-cultural aspects.31 This process aims at uncovering 
meanings that may be hidden from social actors themselves,32 and at generating knowledge, which 
contribute to empowerment and change.33 
The study was approved by the ethical committees of Berne, Switzerland; Freiburg (No. 385-09) and 
Munich (No.412-09), Germany. A sample of affected women was recruited from gynecological wards 
or ambulatory clinics/facilities at 1 Swiss (Berne) and 2 German University Hospital’s (Munich, 
Freiburg) based on the inclusion and exclusion criteria (Table 1).  
Table 1. Inclusion and Exclusion Criteria. 
Inclusion criteria Exclusion criteria  
• Older than 18 years • Cognitive impairments which hinder to make an 
interview 
• Able to read and write German  • Concurrently psychiatric treatment 
• Diagnosis vulvar neoplasia (condyloma 
accuminatum, vulvar intraepithelial neoplasia 
pagetoid type, vulvar intraepithelial neoplasia, 
melanoma, squamous cell carcinoma) 
• Terminal illness 
• Vulvar surgical treatment in the last 6 monthsa   
a
 Surgeries were performed with standardized methods according the guidelines of German Society for Gynecology and 
Obstetrics.  
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To include a broad range of experiences, women were chosen purposefully considering variation in the 
following factors: diagnosis, age groups, time points after surgery, and surgical techniques.1 They 
were contacted during hospitalization or after discharge and invited to participate in the study by a 
physician or a nurse. The first 2 authors contacted the women who agreed to participate and conducted 
10 interviews each between September 2009 and March 2010. The 2 nurses, 1 with a Bachelor and 1 
with a Master Degree, had experience in gynecological nursing care but neither was involved in direct 
clinical care when conducting the interviews. Both were educated in qualitative research and received 
extensive interview training and supervision by the senior researchers. All interviews were conducted 
in a private room, according to women’s’ preferences, in their homes or in the clinic. Interviews lasted 
40-80 minutes (Table 2).  
Table 2. Examples of interview questions. 
Narrative interviews with open-ended and focused questions a 
The interviews began by inviting women to tell their story: 
 ‘How are you at the moment?’  
 ‘How did you experience the time since your surgery?’ 
The Subsequent questions were guided by patients’ answers, such as: 
 ‘Could you tell me more about your bleeding in the vulvar area?’ 
Finally the interviewer clarified any unresolved issues using focused questions, e.g.: 
 ‘How did you handle the vulvar bleeding?’ or 
 ‘Which emotions did you experience during vulvar bleeding?’ or 
 ‘You mentioned, not having spoken with others about your diagnosis, what type of  
  communication was hampered?’  
a  Written informed consents were obtained prior to each interview. 
Data collection and analysis occurred in parallel. This allowed revision of the interview guide as new 
themes emerged. For example, after the first 6 interviews, new questions were added about caring for 
the vulva. All women completed a socio-demographic data form. The interviewer contacted a 
physician or a nurse after the interview to gather medical information from medical records.  
The data analysis was started after the first 2 interviews and it influenced further analysis. As some 
pre-surgical and post-surgical symptoms of participants were similar and pre-surgical symptoms 
affected women’s symptom experience after surgery, this timeframe was included in further data 
analysis. All interviews were audio-recorded, transcribed verbatim, and organized in ATLAS.ti 5.6.3 
(ATLAS.ti GmbH, Berlin, Germany). Pseudonyms have been used for participants. Data analysis was 
performed using a seven-stage process to identify categories, themes and constitutive patterns.29 
Critical hermeneutics allowed reflection and interpretation of the text and its language. By taking 
notes after each interview and by relating text interpretation to additional literature, socio-cultural 
aspects during conversation were considered (Table 3).  
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Table 3. Content analysis conducted in this study. 
The seven stage process according to Diekelmann et al. (1989) 
1. The first 2 authors read all the interview texts for an overall understanding 
2. The first 2 authors summarized each interview and inductively identified categories. The first 2 authors and the 
fourth author with scientific and clinical expertise in gynecological oncology and experience in qualitative research 
analyzed selected transcribed interviews. Dialogue among team members clarified the analyses with group 
consensus as the goal.  
3. The research teama (consisting of 4 members) with experience in qualitative research compared the interpretations of 
identified categories for similarities and differences. Discrepancies were clarified by referring to the text. The socio-
cultural context was considered by relating interpretation to additional literature (historical, cultural literature, e.g. 
concerning the vulva in a German-speaking society within Europe). 
4. The research team discussed similar and contradictory meanings of the categories, identified and documented 
relational themes (a theme cuts across all texts). Any disagreements in interpretation were resolved by going back 
to the text. 
5. The research team discussed common meanings by comparing and contrasting the text as well as the relationships of 
the relational themes and identified constitutive patterns (present in all the documents). 
6. An external expert in qualitative research reviewed the entire analysis. 
7. Suggestions of the research team members regarding the draft of the final report using sufficient excerpts were 
incorporated into the final report. 
a
 Five peer group meetings with four qualitative research members (B. Senn, D. Gafner, M. Eicher, R. Spirig) took place 
during data collection, to establish some degree of intersubjectivity.31 Feedback on the research findings were obtained 
from six participants to ensure that participants’ own meaning were represented. 
As the translation of the interviews from oral into written text and the translation of quotes from 
German into English language were subject to interpretation, we tried to enhance trustworthiness of 
this analytical process. The first 2 authors conducted all interviews, read all transcripts, and 
individually analyzed the transcribed text to then identify and discuss categories. This process of data 
analysis was supervised by the fourth and last authors who are experienced qualitative researchers. 
The first author translated the entire analysis and specific excerpts illuminating the practices and 
concerns relevant to each woman and prepared a draft of the final report in English. Quotes were back 
translated. The first and third author, the latter is a native English-speaker, discussed the entire 
analysis word by word and the draft report during 3 personal meetings and online to enhance the 
representation of participants’ own meaning in the translated text.  
4.3 Results 
4.3.1 Participants 
Fifty-five women were screened for eligibility. Thirty-six were approached for study inclusion and 20 
agreed to participate and were interviewed (11 in Berne, 6 in Freiburg, 3 in Munich). Primary reasons 
for not participating in the study were being too busy or too ill. Pattern recognition occurred after the 
17th interview and no new themes were identified during the last 3 interviews; thus, sampling ceased. 
Characteristics of participants are listed (Table 4).   
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Table 4. Socio-demographic and Medical Characteristics (n = 20).  
Variables Frequency, Median 
%,  
IQR 
Age 
  
 In years 55.5 (ME) 44.5-72.5 (IQR) 
Marital status 
  
 Single 4 20% 
 Married 7 35% 
 Widowed 6 30% 
 Divorced  3 15% 
Nationality 
  
 German 9 45% 
 Swiss 10 50% 
 Thai 1 5% 
Educational level 
  
 10 or less school years 5 25% 
 More than 10 years 15 75% 
Employment status 
  
 Working 12 60% 
 Not working 8 40% 
Living arrangement 
  
 Alone 8 40% 
 With the partner and / or children 12 60% 
Help with wound management 
  
 Without help 15 75% 
 Help of a health care professionals 3 15% 
 Help by a non-health care professionals 2 10% 
Type of vulvar disease  
  
 Condyloma accuminatum 3 15% 
 Vulvar intraepithelial neoplasia, pagetoid type 1 5% 
 Melanoma 2 10% 
 Vulvar intraepithelial neoplasia (II & III) 5 25% 
 Vulvar squamous cell carcinoma 9 45% 
Stage of disease (International Federation of Gynecology and Obstetrics) 
  
 0 9 45% 
 Ia and Ib 6 30% 
 II 1 5% 
 III 4 20% 
Recurrent diagnosis 8 40% 
Surgical therapy 
  
 Local excision 2 10% 
 Laser-vaporization 9 45% 
 Partial vulvectomy (ant-, posterior or unilateral)  4 20% 
 Radical wide excision / vulvectomy (bilateral) 5 25% 
Lymph node dissection 
  
 Sentinel 9 45% 
 Inguinofemoral 4 20% 
 Removed lymph nodes 0 (ME) 0-3.5 (IQR) 
Radiotherapy 
  
 Adjuvant postoperative radiotherapy 1 5% 
Length of hospitalization (in days)  6.5 (ME) 2-10.25 (IQR) 
IQR, inter quartile range; ME, median 
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4.3.2 Symptom experience 
Narratives showed key themes composing the essence of women’s symptom experience focusing the 
postoperative phase: delayed diagnosis, disclosed disease, disturbed woman’s self-image, changed 
vulva care, experienced wound-related symptoms, evoked emotions, affected interpersonal 
interactions, and feared illness progression. The identified themes were consistent across different 
surgical procedures. The pattern present in all narratives was that women experienced a lack of 
information with regard to the above interrelated themes and that all of them used strategies to handle 
their situation, which affected their distress level. Women’s symptom experience was affected by the 
socio-cultural context and the health care system (Figure 1).  
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Figure 1. Symptom Experience in Women with Vulvar Neoplasia and Surgical Treatment: A Conceptual Model.a 
a
 The conceptual model presents also 
the coding scheme, including the 
eight interrelated themes (headings 
in the white circles) with their 
subordinate categories (listing in 
the white circles). Women 
experienced a lack of information 
about the interrelated themes and 
all used strategies to handle their 
situation, which affected their 
distress. Women’s symptom 
experience was affected by the 
socio-cultural context and the 
health care system. 
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4.3.3 Delayed diagnosis 
Eleven of 20 women experienced a delayed diagnosis. The diagnostic delays formed the context for 
their experience of symptoms before surgical intervention. Some delayed visiting the doctor and others 
felt that they were misdiagnosed and treated inappropriately. Different reasons for a delayed diagnosis 
were mentioned. Most women were surprised that cancer can occur in the genital area. One mentioned 
that if she had known this fact she would have gone to the gynecologist earlier when symptoms such 
as swelling, pain, itching, pressure, open skin first occurred. Older participants often felt embarrassed 
and delayed visiting the doctor. Linda, an 80-year-old woman, with a vulvar intraepithelial neoplasia 
grade III stated:  
The others are probably thinking I am crazy. What does she have down there? It is a 
stupid place, so that you sometimes have inhibitions. …I thought, now it’s enough, I 
can’t stand it any longer, I now have to look, if I can see anything… It looked strange, 
bumpy. Then I thought, now I have to go…, ashamed, but no choice.  
Younger women more often felt that they were treated inappropriately, e.g. for herpes for months, 
although they regularly went to their check-ups. They believed that clinicians ignored their symptoms. 
Two women changed doctors on their own initiative to obtain the correct diagnosis, because their 
clinicians had a lack of familiarity with the signs and symptoms of this rare disease. 
4.3.4 Disclosed disease 
The symptoms experienced by women with vulvar neoplasia and the location of neoplasia often 
remained unspoken. Nearly all women avoided and paraphrased the location of their disease with 
terms such as, ‘down there’, ‘it’ or ’thing’. Friends, colleagues and neighbors were only told it is a 
diagnosis in the ‘lower body area’. Most women only revealed their diagnosis with information about 
the location to 1 close relative, usually a partner, a daughter or a sister. Linda said:  
I have not told [my daughters] directly. I showed the medical report only to Sarah 
[one daughter] who said: ‘This is something I have never heard of’.  
Vulvar neoplasia, an unknown and hidden disease in our society, has been attributed to stigmatized 
behaviors such as promiscuity. Women were concerned that others would attribute their disease to 
inadequate hygiene, promiscuity or deformities and they felt uncertain or ashamed. Kathrin, 58 years 
old reported:  
I think it's somehow so hurtful. They [others] did not have an understanding at all... 
[They thought:] Does one get such a thing, if one has too much sex or does not wash 
oneself?  
Participants feared being stigmatized and were, therefore, reluctant to disclose the exact nature of their 
disease. 
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4.3.5 Disturbed self-image 
The surgical intervention influenced participants’ self-perception of being a woman in mainly 4 
dimensions: the appearance of changed female genital, sexuality, attractiveness and self-confidence. 
Depending on the extent of surgery, the women’s descriptions of surgery ranged from an embarrassing 
procedure to a disfiguring and mutilating surgery. Elisabeth, a 46-year-old woman, described her 
female genital after a vulvectomy using the words ‘it looked totally disfigured… ugly’ and mentioned 
feeling embarrassed when anticipating the situation of a partner who would see her vulva. Pamela, 80 
years old, even used the strong metaphor of a ‘bloody pig’ to describe her feelings about the bleeding 
wound after vulvar cancer surgery: 
I thought, now you're open, like when they kill a pig, but it later closed a little.  
Sandra, a 25-year-old woman, described her impression when she looked at her vulva after a laser 
vaporization with words as ‘dirty’ or ‘unclean’. This impression affected her feelings of attractiveness 
and self-confidence:  
[It] is not beautiful. It eats away a little bit at the self- esteem.  
Harriet, 55 years old even reported that her whole female self-image was changed: 
When I walk through the city …. I have the feeling that I am surely the only woman 
running around here now with half a vulva. … I feel incomplete. 
4.3.6 Changed vulva care 
Almost all women reported searching actively for information in order to perform adequate vulva care, 
even if they had not reported having a delayed or problematic wound healing process. Their personal 
hygiene took more time than before surgery. Caring for the female genitalia was done in a variety of 
ways and the choice of treatment was trial and error: Women washed their genitals with a washcloth, 
used only the shower, a Bidet or sits baths with various additives. Emilie, 67 years old, went through 
trial and error experiences related to recurrent vulvar cancer surgeries during the last 30 years, until 
she found out which kind of vulva care best supported the wound healing process after surgery. She 
got the additives from her daughter, who obtained them from her midwife. Even after her long illness 
trajectory, Emilie is not sure if she needs both additives (Tanolat and Calendula) in her sits bath: 
I first made this with chamomile but chamomile tears it [the wound] open. 
[Afterwards] the Tanolat…, I put it into the sits bath, in warm water.... I put also a 
couple of drops [Calendula] into it. I do not know if I need both, in any case … it is 
very good. 
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4.3.7 Experienced wound-related symptoms  
The theme, wound-related symptoms, included symptoms in the wound area, the inter-relationships 
between emotions and other wound-related symptoms, symptom distress, activities affecting wound 
healing, and handling wound-related symptoms. 
Women experienced and managed different symptoms in the wound area: bleeding, drainage (clear, 
cloudy, and purulent), warmth, swelling, redness, pain, itching, unusual odor, burning, altered 
sensation, pressure, hardness, open spot (skin or suture), scaring, and/or unusual skin color. These 
symptoms were affected by activities such as urination, bowel movements, sitting, wearing clothes, 
daily activities in the household and the workplace (Table 5). Pamela described her pain during 
urination after surgery, her symptom-related distress, the unexpected time frame of the symptom and 
how she handled this symptom:  
You’re passing water and you think that you are burning. It hurts so much! That is 
sheer madness, because one doesn’t expect it. You think now that surgery is over, it 
will burn a little bit for a few days, but that was a pain. And now, the black tea helped 
[relieve the burning pain].  
Most women with vulvar intraepithelial neoplasia and vulvar cancer reported that symptoms occurred 
and were most distressing during the early post-discharge period. Some women had experienced 
symptoms and related difficulties in daily life over several months, especially women with progression 
of the disease, a recurrence of the neoplasia or a complication. 
Table 5. Wound-related Symptoms in Women with Vulvar Neoplasia and Surgical Treatment. 
Symptoms a in the wound area and affected activities  
Symptoms in the wound area Affected activities 
• bleeding  
• drainage (e.g. clear, cloudy, purulent) 
• warmth 
• swelling  
• redness 
• pain 
• itching 
• unusual odor 
• burning 
• altered sensation (e.g. numbness) 
• pressure 
• hardness open spot (skin or suture) 
• scaring 
• unusual skin color 
• urination 
• bowel movement 
• sitting for a period of time 
• wearing clothes (e.g. underwear, trousers) 
• daily activities (e.g. walking) 
• activities in the household (e.g. cooking) 
• activities in the workplace 
a
 Symptoms occurred and were most distressing during the early post-discharge period. Some women had experienced 
symptoms and related difficulties in daily life over several months, especially women with progression of the disease, a 
recurrence of the neoplasia or a complication. 
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4.3.8 Evoked emotions 
The unknown diagnosis, the surgery, the location, the changed female genital and the experienced 
symptoms evoked feelings of embarrassment, uncertainty, fear, sadness, and tiredness bringing some 
women to the limit of their endurance. Seeing the vulva the first time after the surgical treatment 
evoked strong feelings. Amanda was ‘shocked’ the first time she saw the vulva during a follow-up 
visit. Most women did not know how to care for the vulva and the common postoperative symptoms to 
expect which resulted in fear. Susan diagnosed with vulvar intraepithelial neoplasia grade III stated:  
The fact that passing urine can burn, or it is uncomfortable to sit, or wear pants or 
something... that you just want to know, if I have this, is it normal? Otherwise ... one 
may have fear and think that, I am not within the norm.  
4.3.9 Affected interpersonal interactions 
For some women, the diagnosis, the surgical treatment and the postoperative symptoms affected their 
intimate and social contacts as well as interactions with health care professionals. Some women 
changed their perceptions about intimate contacts and their behavior in a partnership. Marianne, a 
single woman with a vulvar intraepithelial neoplasia grade II, reported:  
There are some days where I would like to have a partner again, but I think I can’t 
expect this of someone. With this mindset, I will withdraw completely.  
Mary, 37 years old with a vulvar intraepithelial neoplasia grade III treated with laser vaporization was 
living in a partnership. She asked herself why she was affected by the human papilloma virus and 
reported:  
It is not easy to speak with the partner … I felt guilty …and somewhere you are 
always open [in the female genital] ... and the first times after surgery sexuality was 
not the same as before ... perhaps you were cramped and had not enjoyed [the sexual 
intercourse]… it is important to speak with the partner and he should be informed … 
yes one relationship [with another partner] was broken therefore [because of the 
disease]. 
Some women minimized the frequency of their contacts with friends due to their symptoms 
experienced following the surgical treatment. Many women described the importance of social 
contacts such as with family members or colleagues at their working place. They described helpful and 
difficult situations. Most women felt uncertain about how to behave and how to speak about their 
disease and their symptom experience. Sandra went back to work 1 week after laser vaporization as 
her doctor had told her to and said:  
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I went to work after 1 week, that was really stupid. Working was sometimes difficult, 
because you don’t want to do less than before. And nobody knew about it [the vulvar 
intraepithelial neoplasia]. Perhaps I should have said something [to my colleagues]. 
... I have scars from this first surgery, they will never disappear... If you would have 
cared for it [the wound] better, rested, perhaps I would have no [scars]. … At that 
time I felt mentally not well … I think it is important that you explain it [the vulvar 
disease and surgical treatment] ... so that you would have been protected.  
Trying to behave as normally as possible and hiding the disease possibly influenced the development 
of complications and psychological well-being. 
In relations with health care professionals such as nurses, clinical nurse specialists, physicians, and 
doctors women reported that some of them helped with clear advice about looking at the vulva for the 
first time. Not every woman was told to look at the vulva during her hospitalization and this discovery 
took place at different time points after surgery, sometimes after hospital discharge or at a follow-up 
visit. Sophia saw her vulva ‘…not until at home, then [I] just took a mirror and looked at the wound.’ 
Some health care professionals gave helpful recommendations concerning the wound management 
(e.g. wound sprays); however, other health care professionals did not even assess the wound healing 
process during the hospital stay. Elisabeth reported, irritated:  
The day, before I was discharged, I said I would really like to see what it looks like 
down there. No one has looked at me, other than where the drainage tube was lying, 
but no one ever looked at my vagina, after surgery.  
4.3.10 Feared illness progression 
Many women reported fears about progression of the disease and recurrence of a precancer or cancer. 
Sandra, with vulvar intraepithelial neoplasia grade I diagnosis, said:  
This may come back anytime. This is the silly thing. But, yes, so far I've hoped or 
feared a little that there is nothing bad.  
Other women associated the neoplasia with a disease progression, even if it was not yet a cancer 
diagnosis. Hannah with vulvar intraepithelial neoplasia grade III stated:  
Yes, well, cancer, first comes radiation, then chemo, then death. So, these are the first 
3 things that come to mind.  
When women first obtained their diagnosis vulvar surgical interventions helped to save their life, but 
many of them experienced the above mentioned symptoms and problems nobody told them before. 
Women with recurrent vulvar diseases usually treated with repeated surgical interventions described a 
illness journey over years. During this journey women took several efforts to deal with their problems. 
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4.3.11 A lack of information & strategies to handle situations to decrease distress 
Every participant described information needs concerning diagnosis, prevention strategies, therapy 
procedures, anticipated symptoms, the meaning of symptoms, the wound healing process, strategies to 
handle symptoms, or the right time to contact a health care professional. Before discharge, Kathrin 
reported:  
When I’m here [at the hospital], someone can always look at it. But when you get 
home, you are never able to evaluate it. Should I go to the doctor now or not?  
Affected women described a lack of information as very distressing, especially in the first days after 
discharge.  
All women highlighted ineffective and effective ways to get the required information and strategies to 
handle their situations. They stated that the most effective factors were optimism, supportive social 
contacts and confidence to cope with difficult and sometimes overwhelming situations. Sophia found a 
way to get information:  
I had many conversations with my daughter, she has a little idea; she is working in a 
cancer clinic and talking to her helped me a lot.  
4.3.12 The socio-cultural context and the health care system   
Social values and norms affected women’s concerns with regard to the above interrelated themes. 
Women for example felt embarrassed to talk about their sexual organs to others, especially to men. 
Sandra searched for an appropriate term to name her vulva and her disease:  
To speak with another woman is easier anyway. But if there is a man, he has no idea 
what a uterus is. He is thinking, woman stuff. But, when I should have explained 
something more. What do I say? It is abnormal cells in the vagina? And afterwards, 
what will he have in his mind? … it is something that can be hard to imagine because 
you have not seen it. … You are simply ashamed.  
The diagnosis and treatment pushed women to break society’s secrecy about vulvar diseases.  
In addition healthcare values, norms, and power relations shaped concerns with regard to the above 
interrelated themes. For example, several women’s wound assessments were discordant with health 
care professional’s assessments. Kathrin was not educated to look at her vulva with a hand mirror. She 
recognized 2 weeks after vulvar surgery symptoms of infection, bad odor and pain, but her concerns 
were dismissed by nurses:  
I feel quite misunderstood. ... So I thought it was very painful. It has now improved. So 
last Friday they began to treat these wounds. Before that, nothing had actually been 
done. ... If they checked it, they said: ‘It really is not that bad and it will be all right’.  
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Due to the disease it became necessary for women and health care professionals to look at this hidden 
part of the female body and to assess symptoms appropriately so that timely medical treatment was 
initiated. 
4.4 Discussion 
This multicenter study is the first to report knowledge about symptom experience of women with 
vulvar neoplasia focusing on the post-surgical phase while employing a critical hermeneutic approach 
and embedding the experiences of women within their socio-cultural context. The major issues that 
women faced after surgery were stigmatization related to the location of their disease, how to care for 
the vulva, and dealing with multiple symptoms. Assessment, communication and treatment of 
symptoms were hampered by social taboos which left vulvar symptoms in the realm of the 
unspeakable. The society and the health care system have the tendency to overlook these symptoms.  
These findings are in line with Scholz’s description that speaking about the vulva is taboo and evoked 
feelings of guilt.34 The vulva is a neglected area of the skin, hidden away by ignorance, with the result 
that women with vulvar diseases, are desperate for help, suffer needlessly and waste money on 
inadequate treatment.35 The visible parts of the female genitals have been described as linguistically 
invisible with no independent meaning.36 The lack of common vocabulary among health care 
professionals and patients may make it more difficult for women to talk about the vulva, vulvar 
disease and care. Many of the medical terms used by clinicians may not be understood by women. For 
many women it is socially unacceptable to talk about problems ‘down there’. In our society the social 
stigma of vulvar neoplasia threatens the identity of affected women and they fear discrimination. The 
control of information and techniques of deception are perceived as necessary to prevent 
discrimination. To protect one's identity, stigmatized people often use 1 of 2 techniques either hiding 
the problem or pointing it out.37 Pamela for example pointed her problem out by using the metaphor of 
a ‘bloody pig’.  
Consistent with findings in previous studies,19, 20, 38, 39 themes identified in this study included changes 
in self-image and concerns about sexuality. To improve care for affected women, health care 
professionals should explore these issues with them and give information on sexual activity or refer 
patients for counseling. Management of psychosexual effects of treatment should inform women on 
how the disease and treatment can affect their sexual self-concept, relationships, and functioning, as 
well as long-term consequences and how to overcome these alterations.11, 40 
Patients need 3 fundamental resources to manage their symptoms and to avoid complications.41 They 
need to be (1) informed about expected symptoms and effective strategies to prevent complications, 
(2) motivated to change and maintain daily health behaviors to self-manage their symptoms, and (3) 
prepared with behavioral skills to manage their symptoms at home.  
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Consistent with a recent published article,28 many women in this study reported an information gap 
about what to expect and how to care for their vulva and to manage their surgical wound. This gap 
evoked negative emotional responses, affected relationships and caused potentially preventable 
distress. Jefferies and Clifford28 described women’s experiences as ‘searching to control emotions’ and 
emphasized their personal informational needs as well as a need to raise awareness of vulvar cancer 
through publicity for women in general and increased availability of relevant information. In this study 
affected women reported evoked emotions such as embarrassment throughout the course of their 
illness. This is probably due to the fact that VIN and vulvar cancer are rare diseases42, 43 and 
knowledge about the disease in our society and in our health care system needs to be developed 
further.26, 28, 44 
To enable patients to self-manage post-surgical care, health care professionals should encourage them 
to look at the vulva prior to discharge because this allows explanation of the changes that have 
occurred with surgery.11 Self-assessment is necessary to evaluate symptoms and to prevent 
complications.45-47 Systematic information is essential for patients48, 49 to know which symptoms are 
part of a normal wound healing process, and which may indicate complications or may indicate 
reoccurrence of their cancer and the information should include guidelines for when the health care 
professional should be contacted. Without a clear understanding of wound healing-related symptoms, 
women may worry that many ‘normal’ or ‘expected’ postoperative symptoms mean that their cancer 
has reoccurred. Differentiated VIN diagnosis has been frequently missed and is associated with rapid 
progression to squamous cell carcinoma.50 To date no standard screening programs exist to detect 
precursor lesions and, therefore, health care providers should be aware of the clinical features of 
vulvar neoplasia.51, 52  
To date the consequences of delayed consultation in case of complications remain unknown, but it can 
be estimated that a delay in recognition of early symptoms of complications or complicated wound 
healing leads to a delay in seeking treatment and therefore results in complications that are more 
advanced, difficult and costly to treat. For example, Langbecker et al.53 emphasized that the 
assessment, treatment and advice about lower limb lymphedema in cancer patients are important for 
early detection of lymphedema.  
The study investigating the symptom experience of women with vulvar neoplasia and embedding 
these experiences in a wider socio-cultural context was subject to a number of limitations. Recruiting a 
small and purposeful sample of women at different tumor stages and undergoing radically different 
surgical treatments in university clinics limits the transferability of the findings to a larger population 
of patients and other settings.54 As some women, who were considered as being too ill to participate in 
the study were excluded, selection bias might have affected the findings. Another limitation of the 
study is related to the formulation of the study goal and the method of data transcription and analysis 
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undertaken by qualitative researchers. The researchers, born and raised in Switzerland or Germany and 
the third author an American, have a background understanding as nurses and were trained in 
advanced practice nursing. Our background certainly influenced the formulation of the study goal and 
the data analysis. The experience of an interview is changed when translated to the written text. 
Furthermore language translation from German to English which is a form of interpretation could have 
influenced the data analysis process.  
4.5 Conclusions  
Despite the mentioned limitations, the experiences of the 20 women interviewed in this study are 
indicative of a need for action and change especially in postsurgical care. Women with VIN and vulvar 
cancer at different tumor stages and undergoing different surgical treatments experienced similar pre- 
and post-surgical symptoms, even after minimal invasive surgery. They handled diverse tasks and 
gained skills to deal with symptoms throughout the course of their illness. Health care professionals 
and the socio-cultural context enabled or complicated the handling of symptoms. Physical and 
psychosocial symptoms as well as informational needs seem to be apparent over months. In line with 
Jefferies and Clifford’s findings,28 even if diagnosis and appropriate treatment is found, it seems to be 
a lonely journey for women diagnosed with VIN or vulvar cancer. 
This study is a first step in developing a conceptual framework of symptom experience of women with 
vulvar neoplasia. The data provide a foundation to develop a self-report measure to help women with 
vulvar neoplasia recognize, assess, and evaluate the seriousness of symptoms so that medical 
treatment is sought in a timely manner. This measure could be employed to monitor symptom 
experience in clinical studies and in the routine clinical follow-up of patients. Furthermore health care 
professionals should facilitate patients' ability to communicate tabooed symptoms by providing 
structured information on expected symptoms.  
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Abstract 
Background 
The vulvar intraepithelial neoplasia (VIN) is a rare chronic skin condition that may progress to an 
invasive carcinoma of the vulva. Major issues affecting women’s health were occurring symptoms, 
negative influences on sexuality, uncertainty concerning the illness progression and changes in the 
body image. Despite this, little is known about women’s experiences throughout their course of 
illness. Therefore the aim of this study was to describe the experiences of women with VIN during 
their illness trajectory.  
Methods 
In a secondary data analysis of the foregoing qualitative study we analyzed eight narrative interviews 
with women with VIN. We used thematic analysis in combination with critical hermeneutics.  
Results 
Central for these women during their course of illness was a sense of ‘Hope and Fear’. This 
constitutive pattern reflects the fear of recurrence but also the trust in healing. The narratives showed 
women’s experiences during their illness occurred in five phases: (1) There is something unknown; (2) 
One knows, what it is; (3) It is treated and should heal; (4) It has effects on daily life; (5) Meanwhile it 
works. These phases showed many women (1) had a late or incorrect diagnosis; (2) despite having a 
diagnosis women did not know what they suffered from; (3) experienced a high uncertainty in 
decision-making during treatment, (4) VIN had an impact on their physical and psychosocial level; 
and (5) that the women learned over time to deal with their illness. Women’s experiences were 
influenced twofold, by their feelings of ‘embarrassment’ and in ‘dealing with health care 
professionals’. 
Conclusions  
Current care seems to lack adequate support for women with VIN to manage these phases. We suggest 
based on our study and the international literature that new models of counseling and providing 
information need to be developed and evaluated.  
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Zusammenfassung 
Hintergrund 
Die vulväre intraepitheliale Neoplasie (VIN) ist eine seltene chronische Krankheit, die zu einem 
invasiven Karzinom der Vulva fortschreiten kann. Symptome von VIN, negative Auswirkungen auf 
die Sexualität, die Ungewissheit der Krankheitsentwicklung und Körperbildveränderungen wurden 
von betroffenen Frauen als die schlimmsten Begleiterscheinungen benannt. Zum Erleben des 
Krankheitsverlaufes bei VIN ist jedoch wenig bekannt. Ziel dieser qualitativen Studie ist es, das 
Erleben von Frauen mit VIN während dem Krankheitsverlauf darzustellen.  
Methoden 
In einer Sekundäranalyse der qualitativen Daten der WOMAN-PRO Studie wurden acht Interviews 
mit Frauen nach chirurgischen Eingriffen bei VIN mittels thematischer Analyse und in Kombination 
mit kritisch hermeneutischer Reflexion ausgewertet.  
Resultate 
‚Bangen und Hoffen‘ stellt ein grundlegendes Muster dar und beinhaltet die stets vorhandene Angst 
vor Rezidiven sowie die Hoffnung, dass die Therapie wirkt. Es zeigte sich aufgrund der Analyse eine 
Darstellung des Krankheitsverlaufs in fünf Phasen: ‚Da ist etwas Unbekanntes‘, ‚Man weiss, was ES 
ist‘, ‚ES wird behandelt und soll heilen‘, ‚ES hat Auswirkungen‘ und ‚Mittlerweile geht es‘. Diese 
Phasen beschreiben, dass viele Frauen (1) eine späte oder inkorrekte Diagnose erhielten, (2) trotz 
Diagnosestellung nicht wussten woran sie litten, (3) die Behandlung beschwerlich war, (4) VIN 
Auswirkungen auf der körperlichen und psychosozialen Ebene hatte und (5) die Frauen mit der Zeit 
lernten, mit ihrer Krankheit umzugehen. Der Krankheitsverlauf wurde durch das Gefühl der Frauen 
‚Sich dafür schämen‘ beeinflusst, auch das Thema ‚Mit Fachpersonen umgehen‘ spielte eine 
massgebende Rolle. 
Schlussfolgerungen 
Die gegenwärtige Behandlung und Pflege scheint Frauen mit VIN nicht ausreichend zu unterstützen, 
um diese Phasen adäquat zu bewältigen. Wir empfehlen basierend auf Ergebnissen unserer Studie und 
der internationalen Literatur neue Modelle der Beratung und Information zu entwickeln und zu 
evaluieren.  
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5.1 Einleitung 
Die vulväre intraepitheliale Neoplasie (VIN) ist eine seltene chronische Hautveränderung,1 die zu 
einem invasiven Karzinom fortschreiten kann.2 Die VIN stellt für die betroffenen Frauen ein 
einschneidendes Erlebnis dar und geht mit negativen Auswirkungen auf Lebensqualität und Sexualität 
sowie mit Schmerzen und Einschränkungen im Alltag einher.2 Die Inzidenzrate von VIN hat seit den 
1970er Jahren zugenommen und liegt derzeit bei 5 pro 100’000 Frauen.3 VIN (ehemals VIN 2/3 
genannt) wird in zwei Typen, die klassische und die differenzierte VIN, unterteilt.3 Die klassische VIN 
ist mit 90-98% die häufigere Form und betrifft Frauen die durchschnittlich 30 Jahre alt sind. Zudem ist 
das Auftreten einer klassischen VIN mit dem Humanen Papilloma Virus (HPV) assoziiert, welches 
primär über Geschlechtsverkehr übertragen wird.4 Die differenzierte VIN ist mit 2 bis 10% die 
seltenere Form. Ihr Auftreten ist nicht mit HPV assoziiert, betrifft mehrheitlich ältere Frauen und geht 
häufig aus einer vulvären Dystrophie (z. B. Lichen Sklerosus) hervor.4, 5 Symptome, die auf einen der 
beiden VIN-Typen deuten, können Juckreiz, Schmerzen, Brennen, Pigmentstörungen und palpable 
Veränderungen sein. Rund 40% der Patientinnen sind jedoch beschwerdefrei.4  
Die am meisten verbreiteten chirurgischen Behandlungen bei VIN sind die CO2-Laserevaporisation, 
die Skinning Vulvektomie und die lokale Exzision.6 Pepas et al.7 beschrieben in ihrer Meta-Analyse 
Hinweise, dass die Anwendung der Imiquimod-Crème (ein lokaler Immunmodulator) für die Heilung 
von VIN wirksam ist. Jedoch treten bei deren Anwendung Nebenwirkungen wie Schmerzen, Brennen, 
Juckreiz und Hautrötungen auf.4 Innerhalb von 36 Monaten erleiden 30% der Frauen, nach einer 
Therapie bei der klassischen VIN einen Rückfall.8 Die Kosten für einen einfachen chirurgischen 
Eingriff bei VIN in Deutschland betragen durchschnittlich 1560€.9   
Herkunft, Übertragungsweise und mögliche Auswirkungen von HPV scheinen HPV-positiven Frauen 
nicht immer klar zu sein.10 HPV-Infektionen lösen bei betroffenen Frauen Angst vor Krebs und vor 
Verlust der Fruchtbarkeit aus.11 Die Art und Weise der Information durch Fachpersonen spielen bei 
der Entwicklung dieser Ängste eine massgebende Rolle.12, 13 HPV-induzierte Krankheiten können 
einen bedeutenden Einfluss auf die Sexualität der Frauen haben, sind mit Stigmatisierung, Scham und 
Unreinheit konnotiert und können in der Partnerschaft Fragen nach Treue und Ehrlichkeit auslösen.14 
Nach chirurgischen Eingriffen an der Vulva haben die Frauen ein erhöhtes Risiko für eine 
Verminderung der Lebensqualität und der partnerschaftlichen Zufriedenheit. Sie leiden häufiger unter 
Depressionen und ihr Körperbild kann gestört sein.13, 15-17  
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Unter Einfluss christlicher Werte wurde die Sexualität lange Zeit nur innerhalb der Ehe und zur 
Zeugung eines Kindes gutgeheissen und ansonsten als Sünde bewertet.18 Obwohl das 20. Jahrhundert 
eine Liberalisierung der Sexualethik in Europa mit sich brachte, sind die christlich geprägten 
Überzeugungen weiterhin wirksam.19 Diese prägen die Bedeutungszuschreibungen der Vulva, die aus 
biologischen, emotionalen und symbolischen Gründen als Schlüsselorgan der Erotik und Sexualität 
gilt.14 Im Rahmen religiöser Überzeugungen wurde und wird die Vulva als heiliger und heilender, aber 
auch als Ort der Sünde und des Bösen bezeichnet. Trotz diesen gewichtigen Bedeutungen ist die Vulva 
ein besonders stigmatisierter Bereich des weiblichen Körpers. Vielen Frauen ist die korrekte 
Bezeichnung ihrer Vulva unbekannt. In einer Schweizer Studie zur Prävention von sexuellem 
Missbrauch bei Kindern im Kindergartenalter im Jahre 1997 wurde festgestellt, dass die meisten 
Mädchen keine Bezeichnung für ihre Vulva kannten.20  
Bisher wurde das Erleben einer VIN und deren Auswirkungen auf Lebensbereiche wie Arbeit, 
Freizeitaktivitäten oder Familie in drei qualitativen Studien beschrieben. Senn et al.21 beschrieben das 
Erleben von Symptomen nach chirurgischen Eingriffen bei Frauen mit vulvären Neoplasien in der 
Schweiz und in Deutschland. Betroffene Frauen waren erstaunt über die Lokalisation der Krankheit 
und wussten nicht, wie sie Symptome handhaben und die Wunde pflegen sollten. Die Autoren 
schlussfolgerten, dass soziale Tabus die Kommunikation, die Diagnose und die Behandlung der 
vulvären Beschwerden erschwerten.21 In einer US-amerikanischen Studie beschrieben Likes et al.,13 
dass betroffene Frauen die Diagnosestellung einer VIN als schockierend erlebten. Die Patientinnen 
erwähnten das Gefühl von Kontrollverlust, da sie weder den Virus, noch die (wiederkehrenden) 
Zellveränderungen beeinflussen konnten. Rückfälle und wiederholte Biopsien waren für die Frauen 
belastend.13 Auftretende Symptome, negative Auswirkungen auf die Sexualität, die Ungewissheit der 
Krankheitsentwicklung und die Körperbildveränderungen wurden von betroffenen Frauen als die 
schlimmsten Begleiterscheinungen von VIN benannt.2 
Weitere qualitative Studien, welche die Erfahrungen von Frauen mit VIN im zeitlichen Verlauf des 
Therapieprozesses darstellen, sind notwendig, um Betroffenen eine ganzheitliche, systematische und 
prozessorientierte Betreuung anzubieten. Eine solche Betreuung ermöglicht es, Frauen mit VIN 
während dem Krankheitsverlauf ihren Bedürfnissen entsprechend zu unterstützen. Ziel dieser Studie 
ist es, das Erleben von Frauen mit VIN in deren Krankheitsverlauf zu erforschen und darzustellen. Die 
Forschungsfrage lautet: Wie erleben Frauen mit chirurgischen Eingriffen bei VIN den Verlauf ihrer 
Erkrankung? 
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5.2 Methoden 
5.2.1 Studiendesign 
Bei dieser Studie handelt es sich um eine Sekundäranalyse der qualitativen Daten der WOMAN-PRO 
Studie (Klinische Studiennummer: NCT01300663). Die WOMAN-PRO Studie, welche einem 
sequentiell explorativen Mixed-Methods Design folgte, diente der Entwicklung eines konzeptuellen 
Modells zur Beschreibung von Symptom-Erfahrungen. In 20 narrativen Interviews wurden Frauen mit 
VIN oder Vulva Karzinom nach ihrem persönlichen Erleben der Krankheit und ihrer Behandlung 
befragt.21 Die Analyse der Symptomerfahrungen machte deutlich, dass sich diese in Abhängigkeit des 
zeitlichen Verlaufs veränderten. Daher wurde entschieden, diesen Aspekt in einer Sekundäranalyse 
genauer zu analysieren. Acht der 20 interviewten Frauen hatten VIN. Deren Interviews wurden in die 
Sekundäranalyse einbezogen.  
In dieser qualitativen Studie, wurden Interviews mittels thematischer Analyse in Kombination mit 
kritisch hermeneutischer Reflexion analysiert. Die thematische Analyse ist eine Methode zur 
Identifizierung, Analyse und Beschreibung von Themen und Mustern.22 Die kritische Hermeneutik 
behält die Patientin im Fokus des Geschehens und reflektiert das gesprochene Wort sowie die daraus 
resultierenden Handlungen innerhalb des institutionellen und gesellschaftlichen Rahmens.23, 24 Die 
kritisch hermeneutische Reflexion und Textanalyse lehnt sich an den hermeneutischen Zirkel an, 
einem methodologischen Prozess, bei dem zum Erreichen eines vertieften Verständnisses einzelne 
Textpassagen immer wieder mit dem gesamten Text verglichen werden.24 Laut Berman et al.25 wird 
mit dieser Methode Wissen mit Potential zu Veränderungen in der Praxis generiert. Die Kombination 
der thematischen Analyse mit der kritisch hermeneutischen Textanalyse nach Diekelmann et al.23 
ermöglicht es, die Analyseresultate systematisch darzustellen und die Daten in einem Forschungsteam 
kritisch hermeneutisch zu reflektieren. 
5.2.2 Untersuchungsgruppe und -ort 
Für die WOMAN-PRO Studie wurde eine zielgerichtete Untersuchungsgruppe von Frauen mit einem 
breiten Erfahrungshintergrund (verschiedene Altersgruppen, Diagnosen, operative Eingriffe und 
unterschiedliche Zeitpunkte nach dem chirurgischen Eingriff) bei vulvären Neoplasien gewählt. Die 
Rekrutierung fand in den ambulanten oder stationären Abteilungen eines Schweizer und eines 
Deutschen Universitätsspitals zwischen dem 1. September 2009 und dem 31. März 2010 statt. Ein- 
und Ausschlusskriterien für diese Sekundäranalyse sind in Tabelle 1 aufgelistet.  
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Tabelle 1. Ein- und Ausschlusskriterien für Teilnehmende der Folgestudie 
Einschlusskriterien Ausschlusskriterien 
• Alter > 18 Jahre  • Kognitive Einschränkungen, die ein Interview 
verunmöglichen 
• Deutsch mündlich und schriftlich 
beherrschen 
• Aktuelle psychiatrische Behandlung 
• Diagnose einer VIN • Terminale Krankheitsphase 
• Chirurgische Behandlungen einer VIN  
VIN, Vulväre intraepitheliale Neoplasie 
5.2.3 Rekrutierung der Studienteilnehmerinnen 
Pflegende und Ärzte der gynäkologischen Abteilungen beider Kliniken informierten die Patientinnen 
über die WOMAN-PRO Studie. Die Erst- und Letztautorin kontaktierten interessierte Patientinnen, 
instruierten diese über den Ablauf der Studie und die informierte Einwilligung. Anschliessend wurde 
ein Interviewtermin vereinbart.  
5.2.4 Datensammlung 
Insgesamt 8 Interviews der WOMAN-PRO Studie wurden für die Sekundäranalyse genutzt. Sechs 
führte die Erstautorin in der Schweiz durch. Zwei weitere Interviews führte die Letztautorin in 
Deutschland durch. Beide Interviewerinnen sind ausgebildet in qualitativer Forschung und diskutierten 
die Interviewtechniken mit erfahrenen Forschenden. Die Interviewerinnen hatten Erfahrung mit 
gynäkologischer Pflege, waren aber nicht in die Pflege der Interviewteilnehmerinnen involviert. Die 
Interviews fanden je nach Wunsch der Patientinnen bei ihnen zu Hause oder im Spital unter 
Beachtung der Intimsphäre statt. Der Interviewleitfaden wurde von der Letztautorin entwickelt, dessen 
Inhalt und Verständlichkeit von zwei Forschenden im Gebiet der gynäkologischen Onkologie beurteilt 
und wo nötig überarbeitet. Die Interviews umfassten Fragen zum aktuellen Befinden der Frauen sowie 
zu ihren Erfahrungen mit der Diagnose und der Behandlung. Eine Frage zum Krankheitsverlauf war 
nicht Bestandteil des Leitfadens. Bei inhaltlichen Unklarheiten wurde nachgefragt. Die Interviews 
wurden auf Tonband aufgenommen, Wort für Wort transkribiert und mit Hilfe von ATLAS.ti 6.2.26 
(ATLAS.ti GmbH, Berlin) strukturiert. Alle Interviews dauerten 40 bis 80 Minuten. Anhand eines 
Fragebogens wurden soziodemographische Daten zu Alter, Zivilstand, Nationalität, Ausbildung und 
Berufstätigkeit erfragt. Aus den Patientenakten wurden Angaben zu Diagnose und Therapie erfasst.  
5.2.5 Datenanalyse 
Die acht Interviewtexte wurden thematisch analysiert22 und kritisch hermeneutisch reflektiert.23 Ziel 
der thematischen Analyse in Anlehnung an die kritisch hermeneutische Reflexion war, Kategorien, 
wiederkehrende Themen und grundlegende Muster zur Identifikation subjektiver Sichtweisen des 
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Krankheitsverlaufes sowie von Verhaltensweisen von Frauen mit VIN zu erkunden.22, 23 Die 
Analyseschritte sind in Tabelle 2 dargestellt.  
Die WOMAN-PRO-Studie und die Sekundäranalyse wurden von der Kantonalen Ethikkommission 
Bern und der Ethikkommission der Universitätsklinik in Freiburg im Breisgau (Nr. 385-09) 
gutgeheissen. Die Teilnehmerinnen wurden vor dem Interview über ihre Rechte aufgeklärt und 
unterzeichneten eine Einverständniserklärung. Personennamen und Ortsangaben wurden beim 
Transkribieren anonymisiert.  
Tabelle 2. Die Analyseschritte nach Braun & Clarke (2006) in Anlehnung an das Vorgehen  
nach Diekelmann et al. (1989) 
Phase Prozessbeschreibung a 
1. Bekanntmachung mit den 
Interviews 
Die Erst- und Letztautorin lasen alle transkribierten Interviews mehrmals 
durch, um einen Überblick über die Interviewinhalte zu gewinnen. 
2. Erarbeiten erster 
Kategorien 
Die Erstautorin fasste besonders aussagekräftige Passagen aus den Interviews 
zusammen und identifizierte erste inhaltliche Kategorien. Das 
Forschungsteam, bestehend aus der Erst-, Dritt- und  Letztautorin, diskutierte 
die Inhalte sowie die Bedeutungen dieser Kategorien und suchte im Dialog 
nach einem Konsens.  
3. Suchen nach 
wiederkehrenden Themen 
Die Erstautorin identifizierte, basierend auf den Kategorien, wiederkehrende 
Themen, die in allen Interviews auftraten. Die Mitglieder des 
Forschungsteams diskutierten Ähnlichkeiten und Widersprüche in den 
gefundenen Themen. Um soziokulturelle Hintergründe besser zu verstehen, 
wurde zusätzliche Literatur recherchiert. 
4. Wiederkehrende Themen 
und grundlegende Muster 
identifizieren 
Die Mitglieder des Forschungsteams ordneten und verglichen die 
wiederkehrenden Themen. Sie suchten nach Zusammenhängen zwischen den 
wiederkehrenden Themen und nach grundlegenden Mustern. Anschliessend 
überprüften sie die grundlegenden Muster wiederum durch Beiziehung der 
Interviewtranskripte. 
5. Themen und grundlegende 
Muster definieren und 
benennen 
Die Erstautorin benannte und definierte Themen und grundlegende Muster. 
Die Zweitautorin (Externe Expertin) prüfte die Analyseergebnisse und 
beurteilte das Verhältnis zwischen den wiederkehrenden Themen und 
grundlegenden Muster. 
6. Verfassen des Manuskripts Die Erstautorin verfasste einen Entwurf des Manuskripts mit Zitaten. Diesen 
sandte sie zur Begutachtung an die anderen Autorinnen. Kritische 
Kommentare wurden diskutiert und Ergebnisse daraus im Manuskript 
angepasst.  
a
 Der Analyseprozess wurde in sechs Analysetreffen mit den Mitgliedern des Forschungsteams und in fünf Treffen mit fünf 
weiteren qualitativ Forschenden diskutiert. Letztere verglichen bei den Treffen jeweils ihre Analyseergebnisse mit 
derjenigen der Erstautorin und suchten dabei nach Ähnlichkeiten und Unterschieden.  
5.3 Resultate 
5.3.1 Demographische und medizinische Daten 
Alle 8 Teilnehmerinnen wurden auf Grund einer VIN chirurgisch behandelt. Sechs Teilnehmerinnen 
stammten aus der Schweiz, zwei aus Deutschland. Die Frauen waren durchschnittlich 49 Jahre alt. Aus 
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den Interviews ging hervor, dass die Frauen zum Zeitpunkt des Interviews zwischen 3 Monaten und 9 
Jahren an VIN litten. Weitere demographische und medizinische Daten sind in Tabelle 3 aufgelistet. 
Tabelle 3. Demographische und medizinische Daten 
Variablen Häufigkeit 
Alter (zwischen 25-80)  
In Jahren 49.25 (Median) 
Zivilstand  
Ledig 1 
Verheiratet 4 
Geschieden 3 
Leben in einer Partnerschaft  
Ja 7 
Nein 1 
Ausbildung  
Weniger als 10 Schuljahre 1 
Mehr als 10 Schuljahre 7 
Berufstätigkeit   
Ja  6 
Pensioniert 2 
Diagnose  
Klassische VIN 7 
Differenzierte VIN 1 
Rezidive von VIN  
Erstdiagnose 1 
Rezidiv 7 
Operation   
Laserevaporisation 6 
Skinning Vulvektomie 2 
Art der Hospitalisation  
Ambulant (< 24h) 2 
Stationär ( 24h) 6 
Hospitalisationsdauer stationär   
Tage (zwischen 1-3 Tage) 2 (Median) 
5.3.2 Ergebnisse der Interviews  
Basierend auf den Interviewtexten stellte sich heraus, dass das Gefühl ‚Bangen und Hoffen‘ für viele 
Frauen mit VIN immerwährend war, zumal sie stets mit der Angst lebten, ein Rezidiv zu erleiden, aber 
auch hofften, dass die Therapie wirke. ‚Bangen und Hoffen‘ als fortwährendes Gefühl ist ein 
grundlegendes Muster des Modells des Krankheitsverlaufs von Frauen mit VIN (Abbildung 1). Weiter 
zeigte sich aufgrund der Analyse eine Darstellung des Krankheitsverlaufs in fünf 
aufeinanderfolgenden, sich teilweise überlappenden Phasen: ‚Da ist etwas Unbekanntes‘, ‚Man weiss, 
ILLNESS TRAJECTORY OF WOMEN WITH VULVAR INTRAEPITHELIAL NEOPLASIA 
- 82 - 
was ES ist‘, ‚ES wird behandelt und soll heilen‘, ‚ES hat Auswirkungen‘ und ‚Mittlerweile geht es‘. In 
diesen Phasen zeigt sich, dass Frauen mit VIN eine lange Krankheitsgeschichte beschreiben, bevor sie 
eine Diagnose erhielten. Trotz Diagnosestellung äusserten Frauen nicht gewusst zu haben, woran sie 
litten. Betroffene Frauen erlebten die Behandlung als beschwerlich und sie beschrieben, VIN hatte 
Auswirkungen auf der körperlichen und psychosozialen Ebene. In den Interviews kam auch zum 
Ausdruck, dass die Frauen mit der Zeit lernten, mit ihrer Krankheit umzugehen. Während des 
Krankheitsverlaufs wurden die Frauen vom Gefühl ‚Sich dafür schämen‘ begleitet und Fachpersonen 
beeinflussten den Krankheitsverlauf massgeblich. Die fünf Phasen des Krankheitserlebens stellen 
zusammen mit ‚Sich dafür schämen‘ und ‘Mit Fachpersonen umgehen‘ die wiederkehrenden Themen 
dar. Kategorien bilden die in Abbildung 1 dargestellten Subthemen der fünf Phasen.  
 
 
Abbildung 1. Erfahrungen von Frauen mit vulvären Neoplasien während des Krankheitsverlaufs. a 
a
 Das grundlegende Muster ‚Bangen und Hoffen‘ beinhaltet die stets vorhandene Angst vor Rezidiven sowie die 
Hoffnung, dass die Therapie wirkt. Die fünf Phasen des Krankheitsverlaufes: ‚Da ist etwas Unbekanntes‘, ‚Man 
weiss, was ES ist‘, ‚ES wird behandelt und soll heilen‘, ‚ES hat Auswirkungen‘ und ‚Mittlerweile geht es‘ und die 
Themen ‚Sich dafür schämen‘ sowie ‚mit Fachpersonen umgehen‘ beschreiben die wiederkehrenden Themen. 
Kategorien bilden die Subthemen der fünf Phasen. 
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5.3.3 Bangen und Hoffen 
‚Bangen und Hoffen‘ beschreibt ein zwiespältiges Gefühl, das den Krankheitsverlauf besonders prägt 
und während allen Krankheitsphasen immer vorhanden ist. ‚Bangen‘ beinhaltet die Angst vor 
Rezidiven, vor weiteren schmerzhaften Behandlungen, dass die VIN nicht heilt und zum Krebs 
fortschreitet, dass man stigmatisiert oder vom Partner verlassen wird. ‚Hoffen‘ beschreibt die 
Zuversicht, dass die angewandte Therapie nützt, dass die Krankheit mit der nächsten Behandlung 
bekämpft werden kann und dass keine weiteren Rezidive auftreten. Für Frau Jaun1 lagen Bangen und 
Hoffen nahe beieinander. Aktuell hoffte sie, ihren guten Zustand möglichst beibehalten zu können und 
dass die Krankheit nicht fortschreitet. Sie bangte jedoch, dass Rezidive wieder auftreten können: 
Jetzt geht es mir eigentlich gut, da ich weiss, dass soweit alles in Ordnung ist. [Aber] 
das kann immer wieder kommen. Das ist der Mist daran. … Bis jetzt habe ich schon 
gehofft, oder ein bisschen gebangt, dass es nichts Schlimmes ist.  
5.3.4 Die fünf Phasen des Krankheitserlebens  
Die Phase ‚Da ist etwas Unbekanntes‘ beschreibt, wie die Frauen die Hautveränderungen feststellen, 
sich in ärztliche Behandlung begeben und wie die Ärzte darauf reagieren. Frau Jaun entdeckte eine 
Wucherung, die brannte, schmerzte und die ihrer Meinung nach „hässlich“ und nach „Hautkrebs“ 
aussah. Sie wandte sich mit ihrem Leiden an den Hausarzt. Dieser verwies sie an den Hautarzt, 
welcher sie wiederum ins gynäkologische Ambulatorium weiterwies. Frau Jaun erhielt relativ schnell 
eine Diagnose. Frau Beer, Frau Egger und Frau Sieber beschreiben hingegen eine lange Phase der 
Behandlung ohne dass die VIN erkannt worden wäre. Frau Beer wurde über mehrere Monate mit 
Antibiotika-Crèmes und Frau Egger zwei Jahre lang mit Antimykotika behandelt. Frau Sieber hatte 
vier Jahre lang eine wunde Stelle an der Vulva und wurde von ihrem Gynäkologen immer wieder mit 
verschiedenen Cremes vertröstet, die ihr nicht halfen. Frau Sieber sagte über ihren Gynäkologen:  
Der wusste nicht, was das ist!  
Die Phase ‚Man weiss, was ES ist‘ beinhaltet den Zeitraum, in dem die Frauen die Diagnose erhalten 
und über ihre Krankheit informiert werden. Es kann sein, dass betroffene Frauen bis zu diesem 
Zeitpunkt bereits eine mehrjährige Leidensgeschichte hinter sich haben, die Diagnose bei Symptomen 
auf Anhieb korrekt gestellt wurde oder es sich um eine Zufallsdiagnose handelt. Trotz der Information 
über die Krankheit benutzten die Frauen die genaue Bezeichnung ihrer Krankheit VIN nicht. Frau Jaun 
sprach von ‚Zeug‘, ‚Veränderung der Haut‘ oder ‚Hautkrebs‘. Frau Giger erläuterte, es seien ‚nicht 
gute Zellen mit verschiedenen Vorstufen‘ und dass sie an ‚der letzten Vorstufe‘ erkrankt sei. Die 
Bezeichnung ‚ES‘ in der Abbildung stellt diese Namenlosigkeit der Krankheit dar.   
                                                     
1
 Bei sämtlichen Patientinnennamen handelt es sich um Pseudonyme 
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Die meisten Frauen bemängelten, dass sie weder zur Krankheitsentstehung noch zum weiteren Verlauf 
genügend Informationen erhielten. Frau Giger hätte gerne gewusst, ‚was auf mich hätte zukommen 
können‘. Frau Jaun ergänzte, dass die erhaltenen Informationen widersprüchlich und verwirrend 
waren: 
Jedesmal wird irgendetwas anderes erzählt. Einmal ist die Ursache das, einmal das… 
Ich weiss gar nicht mehr, was richtig oder falsch ist. 
Die Phase ‚ES wird behandelt und soll heilen‘ erläutert Erfahrungen mit den operativen Behandlungen 
und der Therapie mit der Imiquimod-Crème. Symptome während der Heilungsphase nach operativen 
Behandlungen waren Schmerzen, Brennen, Wundsekrete, Blutungen, Entzündungen, offene 
Wundränder, Beschwerden während der Ausscheidung und ein Spannungsgefühl beim Sitzen. Einige 
Frauen fühlten sich psychisch geschwächt. Die Symptome wurden als sehr beschwerlich bezeichnet. 
Als eines der unangenehmsten Symptome, nannten mehrere Frauen das Brennen beim Wasserlösen. 
Frau Sieber bezeichnete diese Schmerzen als die schlimmsten ihres Lebens:  
Wasser lösen, das war wirklich ganz, ganz schlimm. Solche Schmerzen hatte ich in 
meinem Leben noch nie!  
Frau Egger beschrieb Erfahrungen mit der Imiquimod-Crème und erzählte, dass sie nicht schlafen 
konnte und bei der Arbeit ‚böse und aggressiv‘ wurde. Die Crème brannte und juckte so stark, dass sie 
das Gefühl hatte, ‚die Hände auf den Rücken binden‘ zu müssen, um nicht alles wegzukratzen. Frau 
Jaun erläuterte, dass sie wegen der Crème an ‚Wahrnehmungsstörungen‘ in Form von 
Hypersensibilitäten litt. Kaltes Wasser fühlte sich eisig kalt an und Geräusche in normaler Lautstärke, 
nahm sie unangenehm laut wahr.  
Die Phase ‚ES hat Auswirkungen‘ beschreibt die verschiedenen Auswirkungen der Erkrankung auf 
den Alltag von Frauen mit VIN. Die Krankheit hat Auswirkungen während der Behandlung, während 
der Heilungsphase und nach abgeschlossener Therapie. Nebst den Auswirkungen auf körperlicher 
Ebene (z.B. Schmerzen, Narben) gibt es auch Auswirkungen auf soziokultureller Ebene. Letztere 
treten im Bereich der Arbeit, der Hobbies, der Partnerschaft und der Lebensplanung auf. 
Auswirkungen auf die Arbeit äusserten sich beispielsweise durch lange Absenzen. Frau Egger störte 
bezüglich Hobbies, dass sie keinen Sport treiben konnte und dadurch ihre Kondition verlor:  
Sport kannst du keinen [machen]. Du kannst nicht joggen gehen, nicht Fahrrad 
fahren, nicht Ski fahren. Du kannst nichts! … Man verliert in zwei Monaten die 
Kondition! 
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Zu den Auswirkungen auf die Partnerschaft erzählte Frau Xantia, dass sich bei ihr die ‚sexuelle Lust 
ziemlich zurückgebildet‘ hatte. Wegen den Schmerzen beim Geschlechtsverkehr habe sie sich davon 
‚distanziert‘. Frau Egger berichtete, dass eine Partnerschaft an der Krankheit ‚zerbrochen ist‘. VIN 
hatte für Frau Egger auch Auswirkungen auf ihre Lebensplanung. So waren die Krankheit und die 
Behandlungen für sie nicht mit der Gründung einer Familie vereinbar.  
Ich finde, um ein Kind zu bekommen solltest du gesund sein.… Ich hatte immer das 
Gefühl, irgendwie in Behandlung zu sein … Ich hätte gar keine Zeit gehabt, mich auf 
eine Familie einzustellen. 
Die Phase ‚Mittlerweile geht es‘ stellt dar, wie Frauen mit VIN lernen, mit ihrer Krankheit 
umzugehen. Sie beschreiben gelernt zu haben, Symptome nach chirurgischen Eingriffen und bei 
Behandlungen mit Imiquimod zu handhaben und für sich eine Strategie im Umgang mit VIN gefunden 
zu haben. Frau Giger berichtete, wie sie feststellte, dass sie das Brennen reduzieren konnte, wenn sie 
im Stehen Wasser löste. Dank dem konnte sie das Symptom kontrollieren, was sie erleichterte: 
Ich habe bemerkt, dass mir [beim Wasser lösen im Stehen] wohler ist. Wenn ich mich 
[dabei] nach vorne beuge, fliesst das Wasser nicht über die Wunde herab. … Jetzt 
kann ich wenigstens wieder Wasser lösen. 
Frau Hirt hatte lange Erfahrung mit VIN und wusste, dass ‚wenn es jucke oder brenne, dann soll ich es 
zeigen kommen‘. Dieses Wissen erlaubte ihr ein weitgehend normales Leben zu führen, jedoch bei 
auftretenden Symptomen schnell und korrekt zu handeln. Trotz der immer bestehenden Ungewissheit 
sagte Frau Jaun, dass sie mit der VIN einigermassen zurechtkomme. Ihre Strategie im Umgang mit der 
Krankheit war die Ablenkung und die Hoffnung, dass sie wieder gesund wird: 
Man weiss nicht, was jetzt noch alles kommt. … Aber mittlerweile ist es eigentlich 
gegangen. … Man lenkt sich ab, man macht etwas anderes [und] hofft auf das Beste. 
5.3.5 ‚Sich dafür schämen’ und ‘mit Fachpersonen umgehen’ 
Die zwei Themen begleiten die Phasen des Krankheitserlebens und können während dem gesamten 
Krankheitsverlauf immer wieder auftreten. Bezeichnend für die beiden Themen ist, dass sie mit 
zunehmender Erfahrung der Frauen mit VIN tendenziell an Bedeutung verlieren. ‚Sich dafür schämen‘ 
beinhaltet das von den Frauen geäusserte Schamgefühl. Es wird einerseits durch die Lokalisation, 
andererseits durch die Art der Übertragung der Krankheit hervorgerufen. Mehrere Frauen erwähnten, 
dass die Lokalisation der Krankheit ein ungutes Gefühl förderte, weil sie beim Erläutern der Krankheit 
gegenüber Mitmenschen über ihre Schamlippen sprechen mussten. Frau Beer schämte sich so, dass sie 
sich nicht wagte, zum Gynäkologen zu gehen. Erst als die Schmerzen unerträglich wurden, sagte sie 
sich ‚jetzt musst du dich nicht schämen, jetzt muss etwas gehen!‘ und vereinbarte einen Termin. 
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Die Tatsache, dass VIN durch HPV verursacht und somit durch Geschlechtsverkehr übertragen 
werden kann, löste Schamgefühle aus. Für Frau Egger war die Diagnose einer Geschlechtskrankheit 
etwas Schmutziges und Verrufenes. Sie befürchtete, dass andere sie deswegen verurteilen könnten und 
schämte sich, an VIN erkrankt zu sein: 
Für mich ist das [die Geschlechtskrankheit] etwas Dreckiges, etwas Verrufenes. … 
Was denken die anderen? Am liebsten niemandem sagen, dass es eine 
Geschlechtskrankheit ist … Ich schäme mich, dass ich diese Krankheit habe. 
‚Mit Fachpersonen umgehen‘ beschreibt ein Kontinuum, nach welchem Frauen mit VIN die Qualität 
der Begegnungen mit Fachpersonen zwischen sehr schwierig und unterstützend erlebten. Viele Frauen 
sehnten sich nach einer Vertrauensperson. Jedoch gelang es ihnen durch die wechselnden 
Assistenzärzte und die kurz bemessene Zeit der Sprechstunden oft nicht, eine vertrauensvolle 
Beziehung mit dem Arzt aufzubauen und ihre Anliegen zu besprechen. Dazu erzählte Frau Giger:  
Man hat jedes Mal einen anderen Ansprechpartner. Man kann kein Vertrauen zu 
einem Arzt aufbauen, weil jedes Mal jemand anderes da ist. Also das ist für mich 
eigentlich das Schlimmste gewesen… Ja, man fühlt sich nicht aufgehoben. 
Mehrere Frauen mit VIN fühlten sich durch pauschale Aussagen der Ärzte mit ihren Anliegen und 
Beschwerden nicht ernst genommen. Frau Egger vermisste das Einfühlungsvermögen in ihre Situation 
bei einer Verlaufskontrolle während der Therapie mit Imiquimod. Wegen starken Nebenwirkungen 
konnte sie die Crème nicht so lange wie vorgeschrieben auftragen und wurde deswegen von einer 
Ärztin getadelt. Das war für Frau Egger entmutigend, verletzend und löste Wutgefühle gegenüber der 
Ärztin aus:  
Zeitweise haben sie mir gesagt: ‚Frau Egger, Sie müssen es [die Crème] mindestens 
sechs Stunden drauf haben.‘ Dann hätte ich am liebsten gesagt: ‚Haben Sie es auch 
schon mal drauf gehabt? Wissen Sie denn, wie das ist?‘  
Im Gegensatz dazu erlebte Frau Sieber die Auskunft der Fachpersonen als sehr hilfreich. Sie wandte 
sich mit ihren Beschwerden telefonisch an die ambulante Gynäkologie, wo sie Auskunft darüber 
erhielt, wie sie das Brennen beim Wasser lösen reduzieren konnte: 
Sie [das Personal im Spital] haben gesagt, man könne während dem Sitzbad Wasser 
lösen. … Das hat wirklich geholfen. 
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5.4 Diskussion 
Diese Studie beschreibt anhand einer thematischen Analyse unter Beachtung der soziokulturellen 
Hintergründe das Gefühl ‚Bangen und Hoffen‘ und welche Phasen Frauen während des Verlaufs einer 
VIN erlebten. Die Themen ‚Sich dafür schämen‘ und ‚Mit Fachpersonen umgehen‘ begleiteten das 
Erleben der Krankheitsphasen und spielten eine wichtige Rolle.  
‚Bangen und Hoffen‘ und ‚Sich dafür schämen‘ vereinen drei psychosoziale Hürden von VIN. Erstens 
handelt es sich um eine Krankheit im Bereich der Vulva. Die Vulva ist für betroffene Frauen und für 
Fachpersonen nach wie vor ein Tabubereich und den Frauen fehlt eine umgangssprachliche 
Bezeichnung.20, 21 Zweitens wird VIN zu einem grossen Teil durch Geschlechtsverkehr übertragen und 
ist dadurch bei den betroffenen Frauen mit Unreinheit und Scham konnotiert.14 Drittens ist VIN eine 
Vorstufe invasiver Karzinome. Diese Information kann bei betroffenen Frauen Angst vor Krebs 
auslösen. ‚Krebs‘ geht für viele Menschen mit der Vorstellung von beschwerlichen Chemo- und 
Radiotherapien, einem langandauernden Leiden mit Metastasen und Schmerzen und schlussendlich 
einem qualvollen Tod einher.12 Persönliche Überzeugungen, wie eine Krankheit zu Stande kommt und 
wie damit umgegangen wird, spielen dabei eine massgebende Rolle.26 Durch die hohe 
Wahrscheinlichkeit eines Rezidivs kann die Angst vor Krebs immer wieder aufflammen.  
Das Erleben der verschiedenen Krankheitsphasen von VIN sowie der Umgang mit Fachpersonen 
zeigen deutlich, dass VIN eine übersehene und unbekannte Krankheit ist, dass Frauen mit VIN ein 
Informationsdefizit haben und sie während dem Krankheitsverlauf eine konstante Ansprechperson 
benötigen. Die Hauptschwierigkeit in der Phase ‚Da ist etwas Unbekanntes‘, besteht darin, dass Ärzte 
die von den Frauen angegebenen Symptome nicht erkennen oder nicht ernst nehmen und Frauen diese 
aufgrund einer wahrgenommenen Stigmatisierung nicht ausreichend äussern. Mögliche Gründe dafür 
sind das ungenaue Hinschauen und das Übersehen der Vulva1 oder, wie einige Frauen erläuterten, die 
Unkenntnis der Ärzte bezüglich der VIN Symptome. Das Informationsdefizit von Frauen mit VIN 
bezüglich ihrer Krankheit wird in der Phase ‚Man weiss, was ES ist‘ beschrieben. Laut der 
Association of Reproductive Health Professionals (ARHP) beträgt die Wahrscheinlichkeit einer HPV-
Infektion während dem gesamten Leben 75-90%. HPV-Infektionen verlaufen meist ohne Symptome, 
heilen in rund 92% der Fälle innerhalb von zwei bis fünf Jahren spontan ab und werden meist nicht als 
Krankheit erfahren.4, 27 Dieses Wissen kann die negative Bedeutung der Geschlechtskrankheit und die 
Angst vor der Weiterentwicklung zum Karzinom reduzieren.14 Frauen mit VIN sollten demnach bei 
der Diagnosestellung über Herkunft und Bedeutung der Krankheit informiert werden, um Gefühle wie 
Scham und Angst vor Krebs oder Stigmatisierung gering zu halten. Braun und Gavey28 beschrieben, 
dass das ‚Konzept‘ der Krankheitsentstehung für Frauen mit zervikalen intraepithelialen Neoplasien 
anhand angepasster Information normalisiert werden kann. Das ‚sich normalisieren‘ scheint ein 
wichtiger Schritt im Verlauf der Krankheit zu sein. Ziel ist es, dass diese Normalisierung möglichst 
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schnell nach der Diagnosestellung eintritt, um betroffene Frauen im Umgang mit ihrer Krankheit zu 
bestärken und sie zur Phase ‚mittlerweile geht es‘ zu führen. Nebst dem Informationsdefizit 
bezeichneten es einige Frauen als etwas vom Schlimmsten, keine vertrauensvolle Beziehung zu den 
Fachpersonen zu haben. Sie wünschten sich, dass Fachpersonen Bezugspersonen darstellten, die sich 
mit der Krankheit auskennen und mit welchen offen gesprochen werden kann. Wie auch in der Studie 
von Likes et al.‚13 waren sich Fachpersonen dieser Rolle oft nicht bewusst und bagatellisierten 
beispielsweise Symptome. An dieser Stelle wäre ein Beratungskonzept mit einer Advanced Practice 
Nurse (APN) nach Hamric et al.29 denkbar, die sich in ihrem Arbeitsbereich auf HPV und VIN 
spezialisiert hat und wissenschaftlich ausgebildet ist. Eicher et al.30 beschrieben in einer 
systematischen Review, dass das Konzept einer Breast Care Nurse positive Auswirkungen auf das 
physische und psychosoziale Wohlbefinden von Frauen mit Brustkrebs haben kann. Dies könnte auch 
bei einer APN spezialisiert auf HPV und VIN der Fall sein. Jedoch muss der wissenschaftliche 
Hintergrund dazu erst erarbeitet und die Informationsbedürfnisse von Frauen mit VIN, um sie in all 
ihren Krankheitsphasen angepasst unterstützen zu können, anhand weiterer Studien in Erfahrung 
gebracht werden.  
Im Rahmen dieser Studie entstanden zahlreiche Fragen, die nicht beantwortet werden konnten. So 
stellt sich aus historischer Sicht die Frage, inwiefern die Stigmatisierung weiblicher 
Geschlechtsmerkmale, insbesondere der Vulva beim Nicht-Erkennen, Übersehen oder Bagatellisieren 
von Symptomen von VIN durch Fachpersonen eine Rolle spielt. Aus gesundheitspolitischer 
Perspektive wäre interessant zu untersuchen, in wie weit ein föderalistisches und dezentrales 
Gesundheitssystem, wie jenes der Schweiz, die Erkennung und korrekte Behandlung von seltenen 
Krankheiten wie VIN beeinflusst. Auch wäre es interessant, den Einfluss des in den letzten Jahren 
vermehrt aufgekommenen Diskurses bezüglich der HPV-Impfungen auf die Wahrnehmung des HPV 
als Geschlechtskrankheit näher zu betrachten. Diese Fragen stellen Inhalte für weitere Studien dar.  
Limitationen dieser Studie sind die kleine Untersuchungsgruppe und die Tatsache, dass es sich um 
eine Sekundäranalyse von bereits bestehenden Interviews handelt. Die Sekundäranalyse bringt mit 
sich, dass einseitige Aussagen und Verzerrungen nicht ausgeschlossen und nicht weiter elaboriert 
werden können. Zudem enthielt der Interviewleitfaden keine spezifischen Fragen zum Erleben des 
Krankheitsverlaufes. Weiter wurden Frauen mit VIN ohne chirurgischen Eingriff, ausgeschlossen. 
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5.5 Schlussfolgerungen 
Trotz den genannten Limitationen zeigen die Erfahrungen von Frauen mit VIN während dem 
Krankheitsverlauf einen Verbesserungsbedarf in der Versorgung. Das Erleben von VIN basiert auf 
dem Grundgefühl ‚Bangen und Hoffen‘. Wesentliche Aspekte zum Krankheitsverlauf wurden in fünf 
Phasen zusammengefasst, welche von den Themen ‚Sich dafür schämen‘ und ‚Mit Fachpersonen 
umgehen‘ begleitet werden. Die gegenwärtige Behandlung und Pflege scheint Frauen mit VIN nicht 
ausreichend zu unterstützen, um diese Phasen adäquat zu bewältigen. Daher empfehlen wir basierend 
auf der internationalen Literatur und unseren Studienergebnissen neue Modelle der Beratung und 
Information zu entwickeln und zu evaluieren. Weitere Studien können dazu beitragen, die Bedeutung 
von VIN innerhalb des soziokulturellen, gesundheitspolitischen und historischen Kontextes 
detaillierter zu beschreiben.  
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Abstract 
Objectives 
The aims of this study were to (1) develop a WOMen with vulvAr Neoplasia – Patient-Reported 
Outcome (WOMAN-PRO) instrument to measure women’s post-vulvar-surgery symptom experience 
and informational needs, (2) examine the content validity of the newly developed WOMAN-PRO 
instrument, (3) describe modifications based on pilot-testing, and (4) examine the content validity of 
the revised instrument. 
Methods 
In a mixed-methods research project (Clinical Trial ID: NCT01300663) a new instrument was 
developed according to the PRO guidelines, as no self-report instrument assessing women’s symptom 
experience and informational needs after surgical treatment of vulvar neoplasia (vulvar intraepithelial 
neoplasia and vulvar cancer) is available. Participants were recruited from 1 Swiss and 2 German 
University Hospitals. The instrument was developed based on literature searches, expert feedback 
(n=9) and patient interviews (n=20). Thirty-seven items were first pilot-tested by patients (n=6) and 
experts (n=6). The revised 36 items were pilot-tested by patients (n=4). The content validity index 
(CVI) for each item and for the entire instrument was calculated. Content validity for the WOMAN-
PRO instrument is defined as the extent to which items on the scale represent the symptom experience 
and informational needs of patients with vulvar neoplasia.  
Results 
The initial pilot test showed an excellent scale CVI based on patient (CVI = .98) and expert feedback 
(CVI =.92). After revising 6 items based on low individual item CVI’s and participant comments, the 
revised WOMAN-PRO showed excellent item and scale content validity (CVI=1.0). 
Conclusions 
The newly developed patient reported outcome instrument has the potential to guide patients and 
clinicians in assessing symptoms, informational needs and related distress. Use of the WOMAN-PRO 
instrument in clinical practice can offer patients guidance in self-assessment and early recognition of 
symptoms. This can decrease women’s uncertainty about symptoms and reassure their decision-
making about when to seek health care provider evaluation. It can provide clinical experts with 
systematic information about key symptoms from a patient perspective, and women’s unmet 
informational needs. If the results of further psychometric testing are promising, the WOMAN-PRO 
will provide an outcome measure for clinical trials. 
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6.1 Introduction 
The term vulvar neoplasia includes vulvar intraepithelial neoplasia (VIN)1 and vulvar cancer.2 Vulvar 
neoplasia is an uncommon disease with increasing incidence rates in Europe and in the United  
States.3, 4 In Germany the incidence rate of VIN was estimated to be 7 per 100’000 women per year 
and vulvar cancer occurs at a rate of 2.5 per 100’000 women per year.3 VIN can affect women at any 
age, however it is more common under the age of 50.5, 6 High grade VIN is associated with human 
papilloma virus (HPV) infection and may progress to invasive disease.6 The mean age of vulvar cancer  
diagnosis is 72 years.7 Women with VIN and vulvar cancer have a high recurrence rate of 30-40%.3, 8 
Although vulvar neoplasia includes different diseases, surgical treatment is the standard therapy for 
women with VIN and vulvar cancer.9, 10 Different surgical treatment methods are used for the 
treatment of vulvar neoplasia such as local excision, skinning vulvectomy, laser vaporization, partial 
or radical vulvectomy and inguinofemoral lymph node dissection depending on disease stage and the 
lymph node involvement. Based on tumor staging, medical interventions, (neo-) adjuvant 
chemotherapy and radiation therapy may be indicated.6, 9  
Studies investigating clinician-reported outcomes in vulvar neoplasia showed that recent surgical 
modifications have reduced postoperative morbidity in women with vulvar cancer,11 but the rates of 
the post-surgery complications such as lower extremity lymph edema (30-70%),12-14 wound dehiscence 
(10-30%), infections (5-40%)15-17, and psychosexual effects18-20 remain high.  
Even minor surgical interventions for VIN caused physical and psychosexual morbidity and impacted 
women’s quality of life.21, 22 One randomized clinical trial included 30 women with VIN and reported 
no statistically significant differences in disease recurrence and adverse events in women treated with 
carbon dioxide laser (CO2 laser) versus ultrasonic surgical aspiration (selective removal of diseased 
tissue) after 1 year follow-up. Eleven of 30 women had disease recurrence after 1 year. Several 
adverse events were reported: (1) pain (all participant), (2) scars (n=5), (3) dysuria or burning (n=7), 
(4) an adhesion (n=1), (5) infections (n=4), and eschars (n=4).21 A 2-year prospective study included 7 
women after surgical treatment for VIN. Women scored poorly on quality of life and sexual 
functioning scores.22 
Despite these complication rates, to date little is known about patients’ complication-related symptom 
experience (e.g. odor as a symptom of a possible wound infection) and their informational needs. 
Symptoms are defined as patients’ perceived indications of disease or changes in their biopsychosocial 
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functioning, sensation or cognition.23 Symptom experience includes 2 common dimensions with 
symptom occurrence (frequency and severity) as the cognitive dimension, and symptom distress as the 
emotional dimension.24  
The main challenge in understanding the symptom experience of women with vulvar neoplasia is the 
absence of a conceptual and psychometrically sound post-vulvar-surgery instrument specifically 
designed to assess the full range of key symptoms, informational needs and related distress. Patient 
reported outcome (PRO) data on post-surgical symptoms are important since patients may use 
different criteria than clinical experts25 to assess the surgical wound healing process and the treatment 
efficacy with respect to improvements in co-morbidities and, therefore, may disregard potentially 
serious symptoms. An inadequate assessment of symptoms and informational needs may impair 
patient self-management and influence health care decisions and the use of health care services.26 
Consequently, the assessment of symptom experience and informational needs is crucial to identify 
patients’ immediate health care needs in the provision of high-quality care.27, 28 The aims of this study 
were (1) to develop a Patient Reported Outcome instrument for WOMen with vulvAr Neoplasia 
(WOMAN-PRO), (2) to examine the content validity of the newly developed WOMAN-PRO, (3) to 
describe modifications based on pilot-testing, and (4) to examine the content validity of the revised 
instrument.  
6.2 Methods 
6.2.1 Study design 
This study is part of a larger mixed-methods research project (Clinical Trial ID: NCT01300663). The 
development of the WOMAN-PRO closely followed the PRO guidelines with 4 phases: A-D.29 A 
qualitative study describing symptom experience and needs considered important by patients with 
vulvar neoplasia, based on interviews with 20 patients, informed the instrument development.30 This 
article will focus on the development processes of phases A and B, while phases C and D including 
psychometric testing are ongoing.  
6.2.2 Development of the WOMAN-PRO  
The development process (Figure 1) followed the predefined phases, process steps and procedures 
recommended in the PRO guidelines. During the project updated guidelines were published.31 We 
adopted our project to this new version where possible, e.g. defining a primary endpoint for the 
research application and documentation of the preliminary instrument development. 
6.2.2.1 Phase A: Identify concepts & develop a conceptual framework 
Process step 1: Determine intended population & research applications. The reason for developing a 
WOMAN-PRO assessing symptom experience of women after vulvar surgical treatment was two-fold. 
On one hand, the instrument was developed to be used in clinical practice. The goal is to use it to inform 
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patients about expected symptoms following vulvar surgery, to improve patient-health care provider 
communication about women’s symptom experience, informational needs and to prevent surgery-
related complications (e.g. wound infections) during clinical follow-up by supporting self-management 
and by influencing health care decisions and the use of health care services. On the other hand, the 
WOMAN-PRO - if the psychometric properties prove to be acceptable - can be used in clinical trials 
that chose the post-surgical symptom experience in women with vulvar neoplasia as a primary endpoint.  
Process step 2: Identify concepts and domains that are important to patients (literature review, patient 
interviews). Relevant symptoms and assessment instruments for these patients were identified by 
literature searches undertaken by 2 authors (B.S., M.E.) from January 2009 to April 2009 in the 
Medline and CINAHL databases, Cochrane library and the Web of Science with the search terms 
combined and formulated as appropriate for each data base: ‘vulvar neoplasia’ OR ‘genital neoplasia, 
female’ OR ‘ovarial neoplasia’ OR ‘cervix neoplasia’ AND ‘needs’ OR ‘assessment’ OR  
‘gynecologic surgical procedures’ OR ‘signs and symptoms’ OR ‘quality of life’ OR ‘wounds and 
injuries’ OR ‘nursing evaluation research’ OR ‘experience’. An additional hand search was performed 
within references of identified studies. The literature search returned 957 citations which were 
screened for eligibility by title. Thirty-one were assessed by full text based on inclusion criteria (peer 
reviewed German and English publications from 2000 to 2009). A total of 9 studies were included in 
this review: two qualitative studies addressing experiences of women with vulvar neoplasia32, 33 and 7 
describing instruments assessing quality of life for gynecological cancer patients,34-36 adverse events,37 
and general symptoms.38-40 Since no instrument focusing on the symptom experience and needs of 
women with vulvar neoplasia and surgical treatment was identified, a qualitative study was undertaken 
to provide a basis for generating items for a new post-vulvar-surgery specific PRO instrument. We 
used information from retrieved studies to develop an interview guide for use in interviews with 
patients following vulvar surgery.30 
Process step 3: Hypothesize expected relationships among concepts. Based on twenty open-ended 
patient interviews conducted 1 to 6 month after surgical treatment, 46 categories, 8 themes, and 3 
patterns were identified and presented in a conceptual model. Narratives showed 8 key themes 
composing the essence of women’s symptom experience: delayed diagnosis, disclosed disease, 
disturbed woman’s self-image, changed vulva care, experienced wound-related symptoms, evoked 
emotions, affected interpersonal interactions, and feared illness progression. The identified themes 
were consistent across different surgical procedures. The pattern present in all narratives was that 
women experienced a lack of information with regard to the above interrelated themes and that all of 
them used strategies to handle their situation, which affected their distress level.30 
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Figure 1. Development Process of the WOMAN-PRO 
CH refers to Switzerland; D refers to Germany; US refers to the United States 
 
6.2.2.2 Phase B: Create the instrument 
Process step 4: Generate items. Based on this qualitative data, a preliminary conceptual framework 
with items (based on categories) and domains (based on themes and patterns) was developed. Direct 
patient input into PRO item generation was assured by validating the items with patients who 
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participated in the qualitative part of the study. Item wording and completeness was confirmed by 
going back to the coded transcriptions and was performed with ATLAS.ti 5.6.3 (ATLAS.ti GmbH, 
Berlin, D). 
Process step 5: Choose administration method, recall period, and response scales. A paper-based data 
collection method and a self-administered approach were selected to include all age groups (20-80) of 
the target patient population. As participants in the qualitative study described a lack of information as 
very distressing in the first days after discharge and symptoms occurring during the first weeks 
following discharge are central in preventing complications related to wound healing, the WOMAN-
PRO instrument should be completed for the first time 7 days after discharge. To consider patient 
burden, minimize recall bias and give patients the opportunity to react in a timely manner when 
symptoms occurred, a 7-day recall period was selected. Likert scale scoring options were developed. 
Process step 6: Draft instructions. Patients’ instructions for self-administration as well as instructions 
for health care provider-supervising self-administration were drafted in written form. 
Process step 7: Format instrument. The new provisional post-vulvar-surgery specific PRO instrument 
was formatted, based on the final item selection criteria (see ‘Data analysis’) by the first author. 
Process step 8: Draft procedures for scoring and administration procedures. Draft procedures for 
scoring and administration were defined. This provisional instrument was shown to 9 experts in April 
2010: four Swiss gynecologic cancer nurses, 1 Swiss gynecologic surgeon, 2 US and 1 Swiss nursing 
scientists and 1 US statistician. A total of 32 face-to-face meeting with one or more of these experts 
took place. Expert feedback was utilized to ensure that the questionnaire captured clinically relevant 
items and was usable in clinical practice. The provisional instrument (April 2010) covered 6 
dimensions of women’s experiences following surgery for vulvar neoplasia with 40 items. Based on 
experts’ face-to-face feedback 3 dimensions (emotions, female genitalia and social contacts) were 
collapsed to 1 domain (psychosocial aspects) and 3 items were deleted to minimize redundancies in 
the instrument. 
Process step 9 and 10: Pilot test the draft instrument and refine instrument. The provisional 
instrument was pilot-tested in 2 phases. The quality of the provisional instrument was assessed in June 
2010 by patient and clinical experts. The instrument was revised based on the first pilot test and was 
pilot-tested again in August 2010 by patient experts as they were the target group for the instrument 
(see ‘Pilot-testing of provisional instrument’). The provisional self-report instrument (June 2010) 
included: 
• General information (explanations about: terms such as symptom experience, vulva, 
anatomical components of the female genital, medical diagnoses, normal wound healing 
process; and how this instrument and a hand mirror can help assess symptoms) 
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• Personal information to support decision making (space to list the contact person and 
his/her telephone number, individual information about normal expected symptoms, 
warning symptoms, and recommendations concerning  behavior after surgical treatment) 
• Instructions on how to fill out the symptom list (e.g. when and how to mark the appropriate box) 
• Symptom list (items with answer categories for the occurrence of each item and its related 
distress) 
• Need list (items with answer categories for the occurrence of each item and its related 
distress) 
• Individual symptom list (space for 3 other items with answer categories covering the 
occurrence of each item and its related distress) 
• Individual prioritization of 3 to 5 experienced symptoms (issues which women wanted to 
discuss at the next appointment with their health care provider) 
• Invitation to note 3 individual strategies (which could help during this time of changes) 
The provisional instrument (June 2010) covered 37 items representing symptom experience and 
informational needs following surgery for vulvar neoplasia within the following 4 dimensions: (1) 
sixteen items asked about wound-related symptoms; (2) five items addressed difficulties in daily life; 
(3) twelve items focused on psychosocial feelings, thoughts or activities; and (4) the informational 
needs list covered 4 items.  
• For the symptom list the occurrence of each item was measured on a 5-point Likert scale 
[0-4]. For the wound-related symptoms and difficulties in daily life, women were asked to 
rate how frequent they experienced the symptom during the first 7 days after discharge 
(answer categories: never [0], 1-2 days [1], 3-4 days [2], 5-6 days [3], or daily [4]). 
Women were asked to assess the severity of psychosocial symptoms (answer categories: 
not at all [0], a little bit [1], somewhat [2], quite a bit [3], very much [4]). 
• Four response options assessed the degree of informational needs (answer categories: not 
existing [0], a little [1], moderate [2], large [3]).  
• The distress associated with each item was measured on a 5-point Likert scale (answer 
categories: not at all [0], a little bit [1], somewhat [2], quite a bit [3], and very much [4]).  
6.2.3 Pilot testing of provisional instrument 
6.2.3.1 Sample and setting 
This study was approved by the ethical committees of Berne, Switzerland; Freiburg (no. 385-09) and 
Munich (no.412-09), Germany. All participants (n=20) from a previously conducted qualitative study 
were invited to participate in pilot-testing.30 They were originally recruited from gynecological wards 
or ambulatory facilities at 1 Swiss (Berne) and 2 German University Hospitals (Munich, Freiburg). 
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Eligible patients were (a) older than 18 years, (b) able to read and write German, (c) diagnosed with 
vulvar neoplasia, and (d) treated with vulvar surgery during the prior 6 months. Excluded patients 
were (a) cognitively impaired (b) concurrently under psychiatric treatment or (c) terminally ill. The 
purposeful sample represented a variety of vulvar neoplasia-related diagnoses, age groups, time points 
after surgery, and surgical techniques. All 20 women consented after the qualitative interviews to 
participate in pilot-testing of the content validity of the instrument. Ten were invited to participate in 
the first pilot test and the other 10 to participate in the evaluation of the revised instrument. 
Participants were purposefully allocated to each group to represent a comparable variety of the above 
mentioned sampling criteria. In addition, 16 clinical experts were invited to participate to ensure that 
the WOMAN-PRO would be useful to clinicians and that all clinically relevant aspects of each domain 
were captured in the instrument. Eligible clinical experts were (1) graduated nurses and physicians 
working in the participating units/facilities, (2) working directly with patients with vulvar neoplasia, 
and (3) working for at least 1 year in the gynecology setting with a work load of at least 50%.  
6.2.3.2 Content Validity Instrument 
The patients and clinical experts were asked to rate the relevance of each item on the provisional 
instrument on a content validity index (CVI) rating form.41 The question to patients was: ‘Please rate 
the relevance of this item to your experiences following vulvar surgery’. The question to clinical 
experts was: ‘Please rate the extent to which this item is relevant to symptoms / needs that you see in 
women who have had vulvar surgery’. The instrument contained 37 items rated on a 4-point Likert 
scale (1 = not relevant, 2 = somewhat relevant, 3 = quite relevant, 4 = highly relevant). After rating the 
items, patients and clinical experts were asked whether all significant aspects of symptoms / needs had 
been included and to identify any important aspects of women’s experiences that were missing. They 
were asked, ‘From your perspective, are there other symptoms / needs that should be added or any that 
should be removed from the symptom diary? If so, please write your suggestions below’.  
All participants were also asked if they had any concerns about the following aspects (yes / no) and if 
so, how they would revise the issue of concern: (1) layout, (2) introduction, (3) instructions for self-
administration, (4) clarity and correctness of item wording, and (5) response-options for the scales. 
The last question asked if study participants had further comments / suggestions to improve the 
provisional instrument. 
6.2.3.3 Data collection 
Questionnaires were sent out between June and September 2010 by the first author. Paper and pencil 
questionnaires for CVI-rating were sent out to patients to be completed at home. All patients 
completed the CVI-rating once between 3 and 12 months following their surgery. Clinical experts 
were provided with an online version of the questionnaire for CVI-rating. Data collection procedures 
were identical for patients in both rounds of pilot-testing. All patient participants received a cover 
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letter, an information letter, an informed consent, a provisional instrument, a content validity form, 
and a socio-demographic data form. This paper based survey packet included 2 pre-addressed stamped 
envelopes, 1 for the signed consent and 1 for the questionnaires. Telephone reminders were carried out 
by the first author 1 to 5 weeks after sending the questionnaires to the patients, depending on their 
availability. Upon return of the questionnaires, they were checked for completeness and if there was 
any missing data, patients were telephoned. Clinical experts received an e-mail reminder 5 weeks after 
receiving the online questionnaire. If they did not respond following the reminder, they were 
considered non-responders. Informed consent of clinical experts was implied by completion of 
questionnaires. 
6.2.3.4 Data analysis 
Data analysis procedures were identical for both rounds of pilot-testing. The CVI for each item was 
calculated by summarizing the number of patients/clinical experts giving a 3 (quite relevant) or 4 
(highly relevant) rating divided by the total number of patients/clinical experts who completed the 
item. The CVI for the entire instrument was calculated by summing all items rated as 3 or 4 and 
dividing the total score by the number of items. We followed the guidelines recommended by Polit 
and Beck when evaluating the content validity of individual items41 and the entire questionnaire.42 
They recommend that at least 3 experts complete the CVI instrument and that individual items be 
considered as having good content validity if their mean CVI score is at least .78, while a mean CVI 
score of .90 on the total questionnaire represents excellent content validity. The item and total 
questionnaire CVIs were calculated separately for the patient and clinical experts. Additional written 
text was summarized and all results were discussed and evaluated by the research group (co-authors 
M.M., M.E., S.E., R.S.) to determine which questions met the criteria for final selection. The 
following 3 predefined criteria were considered for selection of the final items:  
(1) Symptoms / needs that were most distressing for patients  
(2) Symptoms / needs that are clinically meaningful in predicting complications  
(3) The length of the instrument. 
6.3 Results 
6.3.1 Participants 
Eight of 10 patient experts (Table 1) and 6 of 16 clinical experts (Table 2) completed the first pilot 
test. Two content validity forms of the patients were excluded because of invalid data (contradictory 
answers). Four of 10 patient experts completed the second pilot test (Table 1). Reasons for not 
replying to the survey were being too busy or too ill. Table 1 summarizes the characteristics of the 
patients and Table 2 presents those of the clinicians.  
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Table 1. Patients’ Socio-demographic and Medical Characteristics of the Pilot Test. 
Characteristics  Pilot 1 N=6 
Pilot 2 
N=4 
Age (in years); median (IQR) 52 (43.75;64.75) 75 (65.25;80.25) 
Marital status (n, %)     
 Single 2 (33.3%) 1 (25%) 
 Married 3 (50%) 0  
 Widowed 1 (16.7%) 2 (50%) 
 Divorced 0  1 (25%) 
Nationality (n, %)     
 German 3 (50%) 2 (50%) 
 Swiss 3 (50%) 2 (50%) 
Educational level (n, %)     
 10 or less school years 6 (100%) 3 (75%) 
 More than 10 years 0  1 (25%) 
Current employment status (n, %)     
 Working 4 (66.7%) 1 (25%) 
 Not working 2 (33.3%) 3 (75%) 
Living arrangement (n, %)     
 Alone 1 (16.7%) 3 (75%) 
 With the partner and/or children 5 (83.3%) 1 (25%) 
Wound management (n, %)     
 Without help 5 (83.3%) 2 (50%) 
 Help of health care professionals 1 (16.7%) 1 (25%) 
 Help by non-health care professionals 0  1 (25%) 
Type of vulvar disease (n, %)     
 Condyloma accuminatum 1 (16.7%) 0  
 VIN, pagetoid type 1 (16.7%) 0  
 Melanoma 0  1 (25%) 
 VIN (II & III) 1 (16.7%) 0  
 Vulvar squamous cell carcinoma 3 (50%) 3 (75%) 
Stage of disease - AJCC Groupings (n, %) 
    
 0 3 (50%) 0  
 Ia and Ib 2 (33.3%) 3 (75%) 
 II 1 (16.7%) 0  
 III  0  1 (25%) 
 IV  0  0  
Recurrent diagnosis (n, %) 5 (83.3%) 0  
Surgical therapy a (n, %) 
    
 Local excision 1 (16.7%) 0  
 Laser-vaporization 3 (50%) 0  
 Partial vulvectomy b  0  2 (50%) 
 Radical wide excision/vulvectomy c 2 (33.3%) 2 (50%) 
Lymph node dissection (n, %) 
    
 Sentinel 2 (33.3%) 3 (75%) 
 Inguinofemoral 1 (16.7%) 1 (25%) 
 Removed lymph nodes; median (IQR) 0 (0;3.75) 1 (0.75;3.5) 
Adjuvant postoperative therapy d 0  0  
Length of hospitalization (in days); median (IQR)  3.5 (1.25;8.75)  9,5 (8;11.25) 
IQR, interquartile range; VIN, vulvar intraepithelial neoplasia; AJCC stage groupings, American Joint Committee on 
Cancer’s 
a
 Surgeries were performed at all three hospitals according to the guidelines of the German Society for Gynecology and Obstetrics. 
b
 Partial vulvectomy means an ant-, posterior or unilateral surgical treatment; c Radical wide excision/vulvectomy 
incorporates a bilateral surgical treatment; d Adjuvant postoperative therapy means chemo- or radiotherapy. 
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Table 2. Clinical Experts’ Socio-demographic Characteristics of the first Pilot Test. 
Characteristic  Pilot 1 N = 6 
Age; median (IQR)   
 In years 47.5 (35.75; 49.5) 
Marital status (n, %)   
 Single/divorced 3 (50%) 
 Married/cohabiting 3 (50%) 
Nationality (n, %)   
 German 2 (33.3%) 
 Swiss 4 (66.7%) 
Profession (n, %)   
 Nurse 4 (66.7%) 
 Physician 2 (33.3%) 
Working place (n, %)   
 Ward 2 (33.3%) 
 Ambulatory 3 (50%) 
 Not documented 1 (16.7%) 
Working status (n, %)   
 60% 1 (16.7%) 
 80% 2 (33.3%) 
 100% 3 (50%) 
Working experience a (n, %)   
 1-2 years 1 (16.7%) 
 3-4 years 1 (16.7%) 
 > 10 years 4 (66.7%) 
IQR, interquartile range (1.quartile; 3.quartile) 
a
 Working experience means years after finishing professional training. 
6.3.2 Content validity of the provisional WOMAN-PRO 
Content validity of the WOMAN-PRO instrument is the extent to which items on the scale represent the 
symptom experience and informational needs of patients with vulvar neoplasia. The provisional 
instrument (June 2010) had a scale CVI of .98 based on 6 patients’ ratings and a scale CVI of .92 based 
on 6 clinical experts’ assessments. Clinical experts’ assessments of 34 items showed excellent CVI 
ranging from .83 (15 items) to 1.0 (19 items). The remaining 3 items (‘release clear fluid’, ‘warmth’ and 
‘burning’) had a lower CVI of .66. Patients’ assessment of 36 items showed excellent item CVIs of .83 
(3 items) to 1.0 (33 items). The remaining item, ‘release clear fluid’, had a lower CVI of .66. 
6.3.3 Modifications based on pilot-testing 
Based on the CVI and the comments from the initial piloting of the provisional instrument, a decision 
was made to delete 2 items, revise 3 items, add 1 item (Table 3) and reduce the response options from 
5 to 4 categories. Two of the symptom frequency response options (‘5 to 6 days’ and ‘daily’) were 
collapsed into ‘5 to 7 days’. The ‘somewhat’ response option for the psychosocial items and distress 
items was deleted.  
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Table 3. Items revised on the provisional instrument based on the first pilot test. 
Items Revision Reason  
‘Release clear fluid’ Deleted CVI patient experts .66 
CVI clinical experts .66 
‘Release clear fluid’& 
‘Release cloudy fluid’ 
Renamed as ‘drainage’  
(e.g. clear, cloudy) 
One patient suggested to reword the items to 
‘drainage’ 
‘Warmth’ No revision Item CVI clinical experts .66, but the patient item 
CVI was  1.0 and warmth is a cardinal symptom of 
infection 
‘Burning’ No revision Item CVI clinical experts =.66, but the item CVI of 
patients was 1.0 and it was a very distressing and an 
often mentioned symptom in patient interviews 
‘Scar’ Renamed as ‘scarred skin’ One clinical expert mentioned ‘irritated word for a 
symptom’ 
‘Dissolving urine’ (Swiss 
expression) 
Renamed as ‘passing urine’ One clinical expert mentioned ‘an understandable 
expression for Swiss and German speaking patients is 
needed’ 
‘Difficulties talking about 
the disease’ 
Deleted 
 
One patient mentioned ‘redundant or obsolete 
question’ by filling out the instrument 
‘Need for more information 
about daily activities (e.g. 
wearing underwear, 
hobbies, sexuality)’ 
New  One clinical expert mentioned the question on the 
need for more information about ‘sex, swimming, 
wearing underwear’ is missing 
6.3.4 Content validity of the revised WOMAN-PRO  
The revised instrument (August 2010) had a scale CVI of 1.0 based on 4 patients rating. Patients’ 
assessment of 36 items showed excellent CVI of 1.0. There were no suggested changes to the content 
of this version. Patients completed the revised instrument within 20 minutes (Figure 2). Figure 2 
presents the hypothesized conceptual framework and items included in the final version of the 
instrument (Appendix). 
6.4 Discussion  
The WOMAN-PRO is the first instrument to focus on post-vulvar-surgery symptoms, informational 
needs and related distress during the first week after hospital discharge in women at different tumor 
stages and undergoing different surgical treatments. The content of the measure was determined by 
reviewing international literature; involving US, German and Swiss physicians and nurses; and most 
importantly, by interviewing patients from 2 European Countries.  
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Figure 2. Hypothesized Conceptual Framework of the WOMAN-PRO (September 2010). 
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If subsequent studies support the reliability and validity of this instrument, it has the potential to be of 
value in research and clinical practice. It may be useful in evaluating the benefits of new and existing 
treatments for vulvar neoplasia as well as other aspects of patient care. Such data would support health 
outcomes research,43 and evidence-based practice.44 Furthermore, collection of PRO data during 
routine clinical follow-up may help patients and experts to identify problems, facilitate 
communication, and direct appropriate treatment of underappreciated symptoms.44 Using a PRO can 
help inform the patients’ decision-making process about when to seek health care provider 
evaluation,45 and may also play an important role in creating realistic expectations about post-surgical 
symptoms.44 Using the WOMAN-PRO, patients may recognize symptoms of complicated wound 
healing early enough to prevent complications. Clinical experts e.g. may be able to reliably measure 
informational needs concerning daily behaviors such as condom use after treatment.  
This study has several limitations. Recruiting a small and purposeful sample of patients without 
adjuvant chemo-radiation and a convenience sample of clinical experts in University clinics limits the 
generalization of the findings. The experiences of women who declined to participate in the qualitative 
interviews may have been different than those of the women who consented to participate. As a result, 
the findings may not be generalizable to this patient population. Despite efforts to allocated 
participants to the 2 groups to represent a comparable variety of the sampling criteria, the patient 
expert group in pilot 1 and pilot 2 differed in relation to demographic variables. The women in pilot 
test 2 were older, had a longer hospital stay, were more likely to be single and living alone, thereby 
needed more help. This could have had an impact on the reported CVI.  
6.5 Conclusions 
In conclusion, content validity of the WOMAN-PRO is strong, making it a promising instrument to 
assess the occurrence of symptoms, informational needs and the self-reported distress experienced by 
women with vulvar neoplasia. Further examination of psychometric properties of the WOMAN-PRO 
is still needed and the instrument should be also tested in future studies to assess late effects in patients 
after vulvar surgery. 
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Abstract 
Objectives 
To describe the (1) symptom experience of women with vulvar neoplasia (vulvar intraepithelial 
neoplasia and vulvar cancer) during the first week after hospital discharge, and (2) associations 
between age, type of disease, stage of disease, the extent of surgical treatment and symptom 
occurrence. 
Methods 
This cross-sectional study was conducted in eight Hospitals in Germany and Switzerland. Symptom 
experience after surgical treatment in women with vulvar neoplasia was measured with our newly 
developed WOMAN-PRO instrument. Outpatients (n=54) rated the frequency / severity of 31 
symptoms and the degree to which the symptoms distressed them. We used descriptive statistics and 
regression analysis. 
Results  
The average number of symptoms reported per patient was 20 (SD 5.02) with a range of 10 to 31 
symptoms. The three most prevalent wound-related symptoms were ‘swelling’ (n=46), ‘drainage’ 
(n=46) and ‘pain’ (n=43). The three most prevalent difficulties in daily life were ‘sitting’ (n=52), 
‘wearing clothes’ (n=48) and ‘carrying out my daily activities’ (n=43). ‘Tiredness’ (n=51), ‘insecurity’ 
(n=44) and ‘feeling that my body has changed’ (n=42) were the 3 most prevalent psychosocial 
symptoms. The most distress symptoms were ‘sitting’ (Mean 1.98, SD 0.90), ‘carrying out my daily 
activities’ (Mean 1.79, SD 0.89), and ‘open spot (e.g. opening of skin or suture)’ (Mean 1.79, SD 
0.92), which were on average reported to be ‘quite a bit’ distressing. No associations were found 
between symptom occurrence and age, type of vulvar disease, stage of disease and the extent of 
surgical procedures. 
Conclusions  
WOMAN-PRO data showed a high symptom prevalence and distress, call for a comprehensive 
symptom assessment, and may allow identification of areas in symptom management. 
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7.1 Introduction 
Even minor surgical interventions for women with vulvar neoplasia cause physical and psychosocial 
morbidity and impact women’s quality of life.1, 2 However, little is known about women’s symptom 
experience after surgical treatment for vulvar neoplasia. Vulvar neoplasia includes vulvar 
intraepithelial neoplasia (VIN)3 and vulvar cancer.4 Vulvar neoplasia has an incidence of 2 to 7 per 
100,000 women per year,5, 6 with increasing incidence rates especially in young women and high 
recurrence rates.7, 8 
Surgical removal of visible lesions is the standard therapy for women with VIN and vulvar cancer.9, 10 
High grade VIN lesions are usually managed by surgical excision or laser-vaporization.1, 2, 11 Vulvar 
cancer is normally treated by local excision, partial or radical vulvectomy and inguinofemoral lymph 
node dissection depending on disease stage and lymph node involvement. Depending on tumor 
staging, medical interventions, (neo-) adjuvant chemotherapy and radiation therapy may be 
indicated.10, 12  
Although treatment for vulvar neoplasia has become more individualized and less radical in recent 
years,13 women still experience symptoms related to wound complications and other adverse events.14 
The symptoms include bleeding, pain, odor, itching, burning, as well as problems with sexual 
dysfunction, loss of urine control and constipation.15-17 Despite the fact that investigators have 
identified the occurrence of multiple symptoms in women with vulvar neoplasia, little is known about 
their self-reported symptom experience after surgical treatment.  
According to Dodd et al. (2001), symptoms are defined as patients’ perceived changes in the 
biopsychosocial functioning, sensations, or cognition.18 There are two interrelated components of the 
symptom experience: symptom occurrence (frequency or severity) and symptom distress, the 
subjectively perceived burden of a symptom.19 The newly developed WOMAN-PRO instrument 
measures symptom experience in this patient population includes wound-related symptoms, 
difficulties in daily life, psychosocial symptoms, and related distress. Understand the individual’s 
symptom experience is crucial for effective symptom management.20 
As clinicians often underestimate symptom severity or even miss side effects associated with 
preventable adverse events during clinical assessment, patient self-report is the gold standard for 
measuring symptoms and tends to lead to earlier recognition and reporting.18, 21 Basch (2010) 
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emphasized the necessity of regularly including the patient’s voice by collecting Patient-Reported 
Outcome (PRO) data as part of general screening for adverse symptom events. A PRO is any report of 
the status of a patient‘s health condition - such as symptoms - that comes directly from the patient.22 
Symptom assessment is essential for effective symptom control.23 In oncology, application of PRO 
measures in clinical practice improved professional-patient communication and patient well-being.24 
PRO data can help to identify cancer patients’ most bothersome symptoms.25 Furthermore, PRO 
instrument can add important information for assessing consequences of treatment and for decision 
making.26 To have more valid and patient-oriented information for clinical decision-making and for 
setting research priorities, PRO data on patients’ post-vulvar-surgery symptom experience are needed. 
Therefore the aim of this study was to determine the prevalence of wound-related symptoms, 
difficulties in daily life, psychosocial symptoms and related distress experienced during the first 7-
days after discharge in a German-speaking sample of women with surgically treated vulvar neoplasia. 
Research questions were:  
(1) How prevalent are symptoms during the first 7-days following hospital discharge 
following the surgical treatment of vulvar neoplasia? 
(2) What is the mean number of symptoms and their distress level perceived by women with 
vulvar neoplasia? 
(3) Which are the most prevalent and distressing symptoms?  
(4) Are there associations between age, type of vulvar disease, stage of disease, and/or the 
extent of surgical treatment and symptom occurrence? 
7.2 Methods 
7.2.1 Study design 
This cross-sectional study is the quantitative part of an international multicenter mixed-methods study 
(Clinical Trial ID: NCT01300663). This article focuses on women’s symptom experience during the 
first 7 days following hospital discharge after the surgical treatment of vulvar neoplasia. 
7.2.2 Sample and setting  
Consecutive eligible women were recruited from gynecological wards or ambulatory facilities at four 
Swiss Hospitals (University Hospitals Basel, Berne, Zurich & Cantonal Hospital St. Gallen) and four 
German University Hospitals (Berlin, Dusseldorf, Freiburg, Munich). Women were eligible to 
participate in the study if they were older than 18 years, able to read and write German, diagnosed 
with vulvar neoplasia, and treated with vulvar surgery. Women who were cognitively impaired, had 
co-morbid severe psychiatric illnesses or were terminally ill were excluded from the study.  
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7.2.3 Variables and measures 
We measured socio-demographic and medical variables, as well as symptom experience. Socio-
demographic variables included age, marital status, nationality, educational level, current employment 
status, and living arrangement. Medical data included type of vulvar disease, stage of disease and 
therapy (Table 1 and 2). 
Women’s symptom experience after surgical treatment of vulvar neoplasia was measured with our 
newly developed WOMAN-PRO. This self-report instrument covers 31 symptoms occurring 
following surgery for vulvar neoplasia. The physical component assessed 15 wound-related symptoms 
and 5 difficulties in daily life. The psychosocial component has 11 items that inquire about 
psychosocial feelings, thoughts or activities. The response option for each item is a 4-point Likert 
scale [0-3]. For the wound-related symptoms and difficulties in daily life women were asked to rate 
how frequent they experienced the symptom / difficulty during the first 7 days after discharge (never, 
for 1 to 2 days, 3 to 4 days, or 5 to 7 days). For the psychosocial symptoms, women were asked to 
assess the severity of symptoms (not at all, a little bit, quite a bit, very much). For each reported 
symptom, associated distress was scored on a 4-point Likert scale [0-3] ranging from ‘not at all’ to 
‘very much distressing’. We developed the WOMAN-PRO instrument, according to the PRO 
guidelines, based on literature searches, expert feedback (n=9) patient interviews (n=20), and 2 pilot 
tests of the newly developed instrument with patients (n=10) and experts (n=6). The revised 
WOMAN-PRO showed an excellent item and scale content validity index (CVI=1.0). In this study we 
also examined the reliability of the instrument using a Cronbach’s alpha coefficient. For the items 
representing wound-related symptoms and difficulties in daily life alpha was 0.70, and it was 0.87 for 
items representing psychosocial symptoms. An alpha of 0.70 or above reflects adequate reliability.27 
Prior to calculating Cronbach’s alpha, we examined its appropriateness using inter-item and item-to-
total correlations.  
7.2.4 Data collection 
Data collection occurred between October 1, 2010 and August 31, 2011. Trained nurses and 
physicians informed all eligible patients about the study. Hospitalized women who were interested in 
participating received a study package (containing study information, the informed consent and two 
questionnaires: WOMAN-PRO and the socio-demographic form) to complete at home. To ensure 
subject confidentiality, women were asked to return the signed consent form and completed 
questionnaires in separate pre-addressed stamped envelopes. The first author called up all women once 
one week following discharge to remind them filling out the questionnaires and return them to the 
center. Women who did not return the questionnaire were considered as non-responders. Returned 
questionnaires were checked for completeness and women were called to obtain missing responses. 
Clinical information was collected from patients’ medical files by the first author. 
SYMPTOM PREVALENCE IN WOMEN WITH VULVAR NEOPLASIA 
- 116 - 
7.2.5 Data analysis 
We randomly selected and double entered 30% of the questionnaires to ensure data quality. The data 
entry error rate was less than 1%. Socio-demographic, medical, and WOMAN-PRO data were 
analyzed descriptively using means, frequencies and proportions. Missing responses are declared in 
the Tables and Figures. In the Scatterplot we used mean symptom frequency / severity scores (y-axis) 
and mean symptom distress scores (x-axis). Mean scores were calculated per item over all patients. 
We also examined to what extent the physical and psychosocial dimensions of symptom frequency / 
severity could be explained by the variables age and type of vulvar disease, stage of vulvar disease, 
and the extent of vulvar surgery using two different multiple linear regression analyses. The first 
regression model was with physical and the second with psychological mean frequency / severity 
symptom scores across all items as the outcome variable. The distress domain was not taken into 
account. Predictors were entered in the regression analysis simultaneously as continuous variables. 
Analyses were performed in SAS 9.1.3. (SAS Institute, Inc., Cary, NC). 
7.2.6 Ethical considerations 
This study was approved by the ethics committees of Berne, Basel (no.17/11), St. Gallen (no. 
10/123/1B), and Zurich (no. 2010-0467/0) in Switzerland and Berlin, Dusseldorf (no. 3505), Freiburg 
(no. 385-09) and Munich (no.412-09), Germany. The master list linking the study ID number to the 
women was stored in a locked cabinet separate from the study data to guarantee confidentiality.  
7.3 Results 
7.3.1 Sample characteristics 
Across the setting, 117 women had vulvar surgery during the study period; 15 declined to be assessed 
for eligibility and 35 did not meet eligibility criteria (Figure 1). Of the 67 eligible patients, 13 women 
(19.4%) refused to participate. Tables 1 and 2 summarize the sample’s socio-demographic and 
medical characteristics (N = 54).  
 
 
 
 
 
 
Figure 1. Flowchart of Sample (80,6% participant rate). 
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Table 1. Sample’s Socio-demographic Characteristics (N=54). 
Characteristics  No. (%) 
No of patients per country (n, %) 
  
 Germany 28 (51.9%) 
 Switzerland 26 (48.1%) 
Age; median (IQR) 
  
 In years 54 (44; 66) 
Marital status (n, %) 
  
 Married 20 (37.0%) 
 Single / widowed / Divorced 33 (61.1%) 
 Missing 1 (1.9%) 
Nationality (n, %) 
  
 German 31 (57.4%) 
 Swiss 19 (35.2%) 
 Others 3 (5.6%) 
 Missing 1 (1.9%) 
Educational level (n, %) 
  
 10 or less school years 18 (33.4%) 
 More than 10 years 34 (63.0%) 
 Missing 2 (3.7%) 
Current employment status (n, %) 
  
 Working 35 (64.8%) 
 Not working 19 (35.2%) 
Health insurance (n, %) 
  
 General 43 (79.6%) 
 Half private / private 10 (18.5%) 
 Missing 1 (1.9%) 
Living arrangement (n, %) 
  
 Alone 24 (44.4%) 
 With the partner or others 28 (51.9%) 
 Missing 2 (3.7%) 
Wound management (n, %) 
  
 Without help 35 (64.8%) 
 Help of a health care professionals 13 (24.1%) 
 Help by a non-health care professionals 4 (7.4%) 
 Missing 2 (3.7%) 
IQR, interquartile range (1.quartile; 3.quartile) 
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Table 2. Sample’s Medical Characteristics (N=54). 
Characteristics No. (%) 
Type of vulvar disease (n, %) 
  
 Condyloma accuminatum 5 (9.3%) 
 VIN (II & III) 12 (22.2%) 
 Vulvar squamous cell carcinoma 31 (57.4%) 
 Melanoma 2 (3.7%) 
 Other vulvar carcinoma 2 (3.7%) 
 Missing 2 (3.7%) 
Stage of disease (AJCC Groupings) (n, %) 
  
 0 17 (31.5%) 
 Ia and Ib 28 (51.9%) 
 II 1 (1.9%) 
 III  1 (1.9%) 
 IV  5 (9.3%) 
 Missing 2 (3.7%) 
Previous diagnosis with VIN or VC (n, %)   
 Yes 11 (20.3%) 
 Missing 2 (3.7%) 
Surgical therapy a (n, %) 
  
 Local excision 6 (11.1%) 
 Laser-vaporization or skinning vulvectomy 14 (25.9%) 
 Partial vulvectomy b  26 (48.2%) 
 Radical wide excision/vulvectomy c 6 (11.1%) 
 Missing 2 (3.7%) 
Lymph node dissection (n, %) 
  
 Sentinel 21 (38.9%) 
 Inguinofemoral 14 (25.9%) 
 Removed lymph nodes; median (IQR) 2 (0; 7) 
 Missing 2 (3.7%) 
Adjuvant postoperative therapy (n, %)   
 Chemo- or radiotherapy during hospitalization 2 (3.7%) 
Length of hospitalization (days); median (IQR) 9 (3.5; 12.5) 
 Missing 2 (3.7%) 
Filling out the diary; median (IQR)   
 Days after discharge  7 (7; 8) 
IQR, interquartile range (1.quartile; 3.quartile); VIN, vulvar intraepithelial neoplasia; VC, vulvar cancer;  
AJCC stage groupings, American Joint Committee on Cancer’s 
a
 Surgeries were performed at all hospitals according to the guidelines of the German Society for Gynecology and Obstetrics. 
b
 Partial vulvectomy means an ant-, posterior or unilateral surgical treatment. 
c
 Radical wide excision/vulvectomy incorporates a bilateral surgical treatment. 
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7.3.2 Symptom prevalence and distress  
The mean number of symptoms per woman was 20 (SD 5.02) with a range of 10 to 31 symptoms. 
Table 3 presents the number and proportion of women reporting each symptom along with the mean 
frequency / severity and distress scores for individual items. The three most prevalent wound-related 
symptoms were ‘swelling’ (n=46), ‘drainage’ (n=46) and ‘pain’ (n=43). The three most prevalent 
difficulties in daily life were ‘sitting’ (n=52), ‘wearing clothes’ (n=48) and ‘carrying out my daily 
activities’ (n=43). ‘Tiredness’ (n=51), ‘insecurity’ (n=44) and ‘feeling that my body has changed’ 
(n=42) were three most prevalent psychosocial symptoms. Based on mean scores of all 31 assessed 
items, ‘sitting’ (2.67), ‘wearing clothes’ (2.33) and ‘swelling’ (2.20) were the most frequent 
symptoms. On average, women reported that they occurred for 3 to 4 days. The most distress 
symptoms were ‘sitting’ (1.98), ‘carrying out my daily activities’ (1.79),  and ‘open spot (e.g. opening 
of skin or suture)’ (1.79) which were on average reported to be ‘quite a bit’ distressing. Figure 2 shows 
the classification of items into four categories: (1) frequent / severe and distressing (n=5), (2) 
infrequent / not severe but distressing (n=14), (3) frequent / severe but not distressing (n=6), and (4) 
not frequent / severe and not distressing (n=6). ‘Sitting’, ‘wearing clothes’ and ‘carrying out my daily 
activities’ were the three most distressing and most common difficulties. The two least severe but still 
distressing psychosocial symptoms were ‘embarrassment’ and ‘sadness’. 
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Table 3. Symptom Prevalence in descending Order with Number and Percentages of Women experiencing a 
Symptom, mean Symptom Frequency/Severity and Distress Scoresa (N=54). 
 
 
a
  Symptom frequency/severity mean scores refers to: (1) symptom frequency for the wound-related symptoms  and 
difficulties in daily life (0 = never; 1 = 1-2 days; 2 = 3-4 days; 3 = 5-7 days), as well as to (2) symptom severity for 
psychosocial symptoms (0 = not at all; 1 = a little bit; 2 = quite a bit; 3= very much). Symptom distress mean scores ranged 
from 0 = not at all, 1 = a little bit, and 3 = quite a bit, to 4 = very much distressing. 
b  For the symptom ‘scarred skin’, data from 53 patients were available due to missing values.  
Symptom No. (%) of patients 
with a symptom 
Symptom 
frequency/ 
severity Mean 
(SD)a 
Symptom 
distress 
Mean  
(SD) 
Wound-related symptoms    
 Swelling 46 (85.2%)  2.20 (1.14)  1.39 (0.95) 
 Drainage (e.g. clear, cloudy) 46 (85.2%)  2.13 (1.13)  1.26 (0.80) 
 Pain 43 (79.7%)  1.78 (1.19)  1.42 (0.91) 
 Bleeding 41 (75.9%)  1.70 (1.25)  1.27 (0.90) 
 Altered sensation (e.g. numbness) 36 (66.7%)  1.81 (1.39)  1.53 (0.97) 
 Redness 35 (64.8%)  1.59 (1.34)  0.94 (0.94) 
 Burning 32 (59.3%)  1.39 (1.34)  1.52 (0.85) 
 Unusual odor 31 (57.4%)  1.43 (1.37)  1.50 (0.98) 
 Hardness  30 (55.6%)  1.41 (1.39)  1.47 (0.97) 
 Pressure 30 (55.6%)  1.28 (1.29)  1.30 (0.79) 
 Open spot (e.g. opening of skin or suture) 28 (51.9%)  1.20 (1.28)  1.79 (0.92) 
 Changed skin color 26 (48.2%)  1.13 (1.32)  0.85 (0.88) 
 Itching 24 (44.4%)  0.94 (1.22)  1.38 (0.88) 
 Warmth 23 (42.6%)  0.76 (1.04)  0.61 (0.78) 
 Scarred skin b 19 (35.9%)   0.87 (1.29)  1.35 (0.93) 
Difficulties in daily life       
 During sitting   52 (96.3%)  2.67 (0.73)  1.98 (0.90) 
 Wearing clothes (e.g. underwear, trousers) 48 (88.9%)  2.33 (1.08)  1.69 (0.90) 
 Carrying out my daily activities  
 (e.g. climbing stairs, cooking, working) 43 (79.6%) 
 
2.07 (1.24)  1.79 (0.89) 
 During bowel movements 32 (59.3%)  1.13 (1.17)  1.63 (0.94) 
 Passing urine 29 (53.7%)  1.06 (1.19)  1.69 (0.81) 
Psychosocial symptoms       
 Tiredness   51 (94.4%)  1.54 (0.82)  1.04 (0.92) 
 Insecurity 44 (81.4%)  1.31 (0.91)  1.50 (0.82) 
 Feeling that my body has changed 42 (77.8%)  1.46 (1.09)  1.57 (0.97) 
 Feel that I reached my limit  
 (e.g. be exhausted) 39 (72.2%)  1.30 (1.00)  1.61 (0.82) 
 Concerns related to sexuality 37 (68.5%)  1.30 (1.08)  1.66 (0.91) 
 Anxiety 36 (66.7%)  1.04 (0.95)  1.67 (0.83) 
 Changed social activities (e.g. meeting 
 friends, excursions) 34 (63.0%)  1.04 (0.97)  1.50 (0.71) 
 Sadness 34 (63.0%)  0.94 (0.88)  1.45 (0.79) 
 Changed feeling about myself as a woman 
 (e.g. concerning self-confidence) 30 (55.6%) 
 
1.04 (1.12)  1.73 (0.91) 
 Embarrassment  23 (42.6%)  0.69 (0.93)  1.50 (0.93) 
 Difficulties in my partnership 18 (33.3%)  0.54 (0.91)  1.25 (1.07) 
  
 
 
 
 
 
 
 
 
 
Figure 2.  Scatterplot: Ranking of Average Symptom
 (mean scores per item over all patients, N=54).
 
  
a
 Legend:  
Wound-related symptoms 
1  = Bleeding 
2  = Drainage (e.g. clear, cloudy) 
3  = Warmth 
4  = Swelling 
5  = Redness 
6  = Pain 
7  = Itching 
8  = Unusual odor 
9  = Burning 
10 =Altered sensation (e.g.  
        numbness) 
11 = Pressure 
12 = Hardness 
13 = Open spot (e.g. opening of skin 
  or suture) 
14 = Changed skin color 
15 = Scarred skin b  
  b For the symptom 15 ‘scarred skin’, data from 53 patients were available due to missing values.
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a
 Frequency / Severity and Distress Scores
 
Difficulties in daily life Psychosocial symptoms
 
16 = Difficulties passing urine  
17 = Difficulties during bowel  
  movements 
18 = Difficulty during sitting 
19 = Problems wearing clothes (e.g.  
  underwear, trousers) 
20 = Difficulty carrying out daily  
  activities (e.g. climbing stairs, 
  cooking, working) 
21 = Insecurity
22 = Anxiety 
23 = Sadness 
24 = Tiredness  
25 = Feel that I
  be exhausted)
26 = Feeling that my body has 
  changed
27 = Changed feeling about myself as
  a woman (e.g. concerning self
  confidence)
28 = Embarrassment
29 = Concerns related to sexuality
30 = Difficulties in my partnership
31 = Changed social activities 
  (e.g. meeting friends, 
   excursions)
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7.3.3 Relationship between variables and symptom occurrence 
In our linear regression analysis the average frequency / severity of physical (wound-related and daily 
life) and psychosocial symptoms were not significantly related to the subjects' ages or to the disease- 
and treatment-related factors examined (i.e. type of vulvar disease, stage of disease and the extent of 
surgical procedures, Table 4).  
Table 4. Symptom Occurrence and its Relationship to Age and Disease- and Treatment-related Variables (N=52).  
Outcome variable: Mean frequency/severity score 
over all wound-related and daily life symptoms 
(Model 1) 
df Wald (95%CI) Chi-Square p value 
Age  
   
 Years (1-) 1 0.00 (-0.01 - 0.01) 0.29 0.5873 
Type of vulvar disease     
 VIN (incl. condylomata), Vulvar cancer (1,2) 1 0.04 (-0.36 - 0.44) 0.04 0.8452 
Stage of vulvar disease     
 AJCC Groupings (0-IV) 1 0.03 (-0.12 - 0.17) 0.16 0. 6892 
Surgical therapy     
 Excision, laser-vaporization or skinning vulvectomy, 
 partial vulvectomy, radical wide excision (1-4) 1 0.09 (-0.83 - 0.27) 1.05 0.3065 
Outcome variable: Mean frequency/severity score 
for all psychosocial symptoms  
(Model 2) 
df Wald (95%CI) Chi-Square p value 
Age     
 Years (1-) 1 -0.01 (0.01- -0.02) 1.42 0.2328 
Type of vulvar disease     
 VIN (incl. condylomata), Vulvar cancer (1,2) 1 0.34 (0.19 - 0.87) 1.56 0.2115 
Stage of vulvar disease     
 AJCC Groupings (0-IV) 1 -0.06 (-0.26 - 0.13) 0.41 0.5225  
Surgical therapy     
 Excision, laser-vaporization or skinning vulvectomy,  
 partial vulvectomy a, radical wide excision b (1-4) 1 0.03 (-0.20 - 0.27) 0.08 0.7736 
CI=confidence interval; df=degree of freedom; AJCC stage groupings, American Joint Committee on Cancer’s 
a
 Partial vulvectomy means an ant-, posterior or unilateral surgical treatment. 
b
 Radical wide excision/vulvectomy incorporates a bilateral surgical treatment. 
7.4 Discussion 
To our knowledge this is the first study exploring self-reported symptom frequency / severity and 
distress during the first week after hospital discharge in women with vulvar neoplasia and surgical 
treatment. In addition to objective measures such as wound complications, this PRO data allow 
evaluation of symptoms and symptom-related distress from women‘s perspective, which provide 
relevant additional information for researchers and clinical practitioners. The high participation rate 
among women invited to participate in the study (80.6%) suggests that symptom assessment with the 
self-report WOMAN-PRO instrument is feasible. 
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Women in this study experienced a high number of symptoms (mean 20, SD 5.02, range 10-31). This 
number is larger than previously reported in studies with surgical or advanced cancer samples where 
the mean or median number of symptoms per patient ranged from 2 to 13.28, 29 Differences may be 
related to the different sample characteristics, use of different measures, or assessing a variable 
number of symptoms, as well as different data collection time points.  
In this study, 80% or more of the women experienced the wound-related symptoms ‘swelling’, 
‘drainage’, and ‘pain’. We were unable to identify other studies that examined the prevalence of 
swelling and drainage in this patient population in the last ten years. Other studies have examined the 
prevalence of pain and consistent with our findings, reported that it was the most prevalent adverse 
event associated with the treatment of vulvar neoplasia.1, 30 Kaushik et al.1 described the prevalence of 
adverse events in a randomized clinical trial comparing carbon dioxide laser (CO2 laser) and 
ultrasound surgical aspiration (selective removal of diseased tissue) in 30 women with VIN. One week 
after surgery, patients completed a postoperative pain assessment by using a visual analog pain scale 
and all experienced pain. Other adverse events were evaluated once 2 to 4 weeks after surgery and 
included scars (n = 5, 16.6%), dysuria or burning (n = 7, 23.3%) 1. Comparable prevalence data was 
not found for other assessed symptoms. 
In the current study, the three most prevalent psychosocial symptoms were ‘tiredness’ (94.4%), 
‘insecurity’ (81.4%) and ‘feeling that my body has changed’ (77.8%). This is consistent with previous 
studies which reported that tiredness31 and changed body image32 were reported by women with vulvar 
neoplasia during the course of their therapy.  
Surprisingly, we found that ‘sitting’, ‘wearing clothes’ and ‘carrying out my daily activities’ were the 
3 most common and most distressing problems identified by the women in this study. In fact, these 
items were, on average, rated considerably higher in both their occurrence and distress dimensions 
than most wound-related and psychosocial symptoms. Three previous qualitative studies reported that 
they were distressing for women with vulvar neoplasia.16, 20, 33  
The evaluation of distress provides relevant additional information on patients’ symptom experience. 
We found that ‘embarrassment’ was a less common (42.6%) and less severe (0.69) symptom in our 
sample, but still distressing for the women who experienced it (distress score 1.50). This is similar to 
previous qualitative studies that found that embarrassment was a distressing problem for women with 
vulvar neoplasia.15, 34 Attention should be given to symptoms associated with high distress because 
such symptoms are linked to poor quality of life.35 Women with vulvar neoplasia should, therefore, be 
asked about both common and distressing symptoms. 
The Scatterplot (Figure 2) allows clinicians to identify the relationship between frequency / severity 
and distress of all symptoms. Whereas physical symptoms may occur more frequent, in this sample 
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they were less distressing than psychosocial symptoms and difficulties in daily life. Symptoms that 
were neither frequently occurring nor distressing such as ‘warmth’ could be left out of the instrument 
to diminish the burden of completing a long questionnaire. The findings of this and future studies can 
provide more balanced information for affected women and their families about what to expect most 
frequently as well as the symptoms that may be most distressing after discharge.  
We studied a heterogeneous study sample of women that included two types of vulvar diseases and 
different tumor stages, ages36 and surgical treatments37 which are known to effect the risk for short-
term complications (e.g. wound breakdown) after vulvar surgery. In our study we did not find a 
significant relationship between the average symptom severity / frequency and the above mentioned 
variables. As the small sample limited the power to detect relationships that may have been evident 
with a larger sample, these relationships should be examined in future studies. 
In summary, women with vulvar neoplasia (33-96%) seem to experience significant number of 
symptoms and many of those symptoms are distressing.  However, it is still unclear if and which type 
of intervention may benefit these women. The findings of this study support the necessity to monitor 
short-term symptoms carefully in all women with vulvar neoplasia after surgical treatment and to 
investigate treatment and supportive care options. An assessment of symptom experience from the 
individual’s perspective can support the goal to avert negative outcomes. It should be followed by 
identifying appropriate intervention strategies.18  
The findings of this trial need to be interpreted in light of potential limitations: The sample size was 
small, which limited the power of detecting relationships between variables. To reduce patients burden 
for a new measure, women were asked to complete the WOMAN-PRO instrument only once after 
discharge. We were unable to measure differences between responders and non-responders. Further 
examination of psychometric properties of the WOMAN-PRO is still needed and the instrument 
should be also tested to demonstrate its ability to detect outcome changes over time. To address some 
of these limitations, in further trials we would include a larger sample, compare responders and non-
responders, evaluate addition psychometric properties of the WOMAN-PRO and / or examine its 
ability to detect changes in women’s symptom experience over time following surgery.   
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7.5 Conclusions 
This trial provides preliminary evidence that the WOMAN-PRO instrument for women with vulvar 
neoplasia and surgical treatment who attend cancer centers offers a feasible, targeted screening 
measure to support systematic symptom assessment. WOMAN-PRO data focusing on patients’ post-
vulvar-surgery symptom experience (1) showed high symptom prevalence and distress, (2) calls for a 
comprehensive symptom assessment, (3) may allow identification of areas for symptom management. 
Where difficulties with symptom control exist, WOMAN-PRO data may allow clinicians to identify 
symptoms that need to be the focus of care because they are distressing, and to evaluate the impact of 
patient-centered care on the occurrence of symptoms and their associated distress. 
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DISCUSSION 
In this final chapter the key findings of the research project’s studies are summarized and discussed 
(8.1) and the limitations and strengths of research methods are described (8.2). Further, implications 
for research (8.3) and practice (8.4) are suggested while also outlining further perspectives. This 
chapter ends with conclusions (8.5).  
Our research project added to the existing knowledge on complications, symptoms and associated 
distress of women with surgically treated vulvar neoplasia. Using quantitative and qualitative research 
methods made it possible to focus on both the clinician and the patient perspective. Therefore both 
perspectives will be discussed in this chapter.  
8.1 Discussion of key findings 
This discussion will focus on the following three key findings across the research project: post-vulvar-
surgery complications identified by clinicians (8.1.1), post-vulvar-surgery experiences reported by 
women with vulvar neoplasia (8.1.2), and the new WOMAN-PRO instrument for patients and 
clinicians (8.1.3). 
8.1.1 Post-vulvar-surgery complications identified by clinicians 
The results of the first cross-sectional study of this thesis showed a high prevalence of short-term 
wound complications of 45.4% (49/108), indicating a need for systematic wound assessment. Wound 
assessment is necessary especially for women at high risk for wound-related complications after hemi- 
and radical vulvectomy (OR, 2.6; 95% confidence interval [CI], 1.34-5.14) and inguinofemoral 
lymphadenectomy (OR, 3.0; 95% CI, 1.03-8.76).1 This research study generated knowledge about 
post-vulvar surgery wound complications utilizing two approaches, a literature search and a cross-
sectional study. The literature search, as described in the introduction section of the cross-sectional 
article (Chapter 3), revealed that previous research focused on a limited selection of wound 
complications such as wound dehiscence and infections. The full range of wound complications was 
not fully summarized.2 The findings of the literature search guided us in the development of a data 
collection tool utilized to collect medical record information about eight short-term wound 
complications. This retrospective study showed that women, particularly after hemivulvectomy, 
radical vulvectomy, and inguinal lymphadenectomy, are at higher risk of developing complications. 
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Better risk management including systematic wound assessment and early risk management may 
contribute to lowering these risks.1 Although other studies described several risk factors for wound 
complications,3-6 this study with a small sample of 108 patients found only two significant predictors, 
hemi- and radical vulvectomy and inguinofemoral lymphadenectomy. Addition research is needed to 
clarify the risk factors for wound complications following the surgical treatment of vulvar cancer. 
Secondary to the rarity of vulvar cancer, international multicenter studies will be necessary to provide 
an adequate sample to identify these risk factors. 
Despite study limitations, our and other studies confirm that the wound complications are a frequent 
problem in patients who have had surgical treatment of vulvar neoplasia.3-5 Furthermore, these 
complications lead to substantial patient morbidity,7-9 prolonged hospital stay and cause considerable 
costs.10-12 The results of these studies have provided the evidence-base for a multidisciplinary team of 
the Department of Obstetrics and Gynecology, University Hospital Berne, Switzerland to develop and 
implement an evidence-based guideline for wound management for patients after hemivulvectomy, 
radical vulvectomy, and inguinal lymphadenectomy. The guideline describes a clinical pathway for 
care which should contribute to prevention, recognition and treatment of wound complications.13  
Current evidence on complication rates and our experience in clinical practice show that further 
research and practice development are needed. The evaluation of implemented guidelines and the 
development of effective wound management interventions remain a central issue that nurses have to 
focus on in the future.14, 15 In addition, interventions are needed to address the assessment and 
management of other common post-surgical complications such as lymphedema,6 depression,16 sexual 
dysfunction,17 and the negative impact of  this intimate condition on women’s lives.18   
8.1.2 Post-vulvar-surgery experiences reported by women with vulvar neoplasia  
The results of our qualitative study provided a conceptual model to inform nurses and physicians 
about the perceptions that women with vulvar neoplasia have about their post-surgical symptom 
experiences and management. Narratives showed that vulvar neoplasia is considered an unspoken 
disease. Women experienced a lack of information from different health professionals that might be 
related to the stigmatization of the vulva. They expressed many difficulties in communicating about 
their disease, caring for their vulva and dealing with symptoms. This information gap and the 
difficulties evoked negative emotional responses, affected interpersonal interactions and caused 
potentially preventable distress.19 These findings are consistent with other qualitative research 
findings.15, 18, 20, 21  
Our qualitative findings revealed, that women experience similar symptoms ‘prior to their diagnosis’ 
and ‘during their postoperative wound healing process’. They seemed not to have a clear 
understanding of wound healing-related symptoms. Some women worried that many ‘normal’ or 
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‘expected’ postoperative symptoms were a sign that their cancer has reoccurred. These issues appear 
to increase women’s uncertainty and their distress level. Further aspects discussed in the literature call 
for action in clinical practice: (1) early and differentiated VIN diagnosis is frequently missed by 
physicians and such a delayed diagnosis can be associated with rapid progression to squamous cell 
carcinoma,22 and (2) the lack of a standard screening program to detect precursor lesions.23 
Additionally, recent qualitative research has illustrated that most women were unfamiliar with vulvar 
cancers symptoms.24, 25 Therefore, we recommend that health care providers educate women about 
symptoms that may indicate vulvar neoplasia.  
Another two questions arose out of the qualitative portion of this dissertation that need investigated in 
the future, the clinician-patient collaboration and socio-cultural aspects. Clinicians’ recommendations 
were perceived as either enablers or barriers to managing of vulva care and the symptoms that 
occurred. Clear advice concerning symptom management was given to some patients. Other clinicians, 
however, did not even assess symptoms during the hospital stay. Women described several issues 
related to obtaining professional support during the follow-up, e.g. changing physicians, not having a 
trusting physician-patient relationship and time pressure of nurses and physicians. Further, socio-
cultural factors added to women’s experience of distress,19, 26 e.g. communication about an unspoken 
disease and the non-recognition of symptoms by patients and clinicians. The current debate about 
Human Papilloma Virus (HPV) vaccine and its related discourse that links HPV with sexually 
transmitted diseases27-29 may enhance the stigmatization of this rare disease. The in-depth analysis of 
women’s experiences showed a gap in the level of information concerning the above mentioned 
aspects. Further detailed insights into the care needs of women with vulvar neoplasia are necessary. 
For example, which information can be provided in written form and which information needs to be 
shared during personal appointments with nurses.15, 20, 21  
In summary, women’s experiences, clinician’s evaluation and socio-cultural aspects all play a key role 
in decision-making regarding communication, symptom assessment and its management during vulvar 
neoplasia treatment. Consequently, including patient self-reporting as a major element in follow-up 
care has the potential to enhance the quality of supportive care. 
8.1.3 The new WOMAN-PRO instrument for patients and clinicians  
We developed a WOMen with vulvAr Neoplasia–Patient Reported Outcome (WOMAN-PRO) 
instrument to fill the void between complications identified by clinicians and symptoms reported by 
patients with vuvlar neoplasia (Appendix). The WOMAN-PRO content is described in detail in 
chapter 6. The self-report WOMAN-PRO showed excellent item and scale content validity (CVI=1.0) 
and adequate reliability (Cronbach’s alpha≥0.70). In a prospective cross-sectional survey in eight 
Hospitals in Switzerland and Germany, outpatients (n=54) rated the occurrence of each of 31 
symptoms, and the degree to which the symptoms distressed them during the first 7 days after 
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discharge following surgical treatment for their vulvar neoplasia (Chapter 7). WOMAN-PRO data 
showed high symptom prevalence and distress. The average number of symptoms reported per patient 
was 20 (SD 5.02, range 10-31 symptoms). In addition, the survey provided preliminary evidence that 
the WOMAN-PRO instrument offers a feasible, targeted screening instrument to support systematic 
symptom assessment. The new WOMAN-PRO provides (1) women with written information and (2) a 
list to assess the symptom experience, informational needs and associated distress of women with 
surgically treated vuvlar neoplasia. The symptom list in the new PRO measure supports systematic 
symptom assessment which has the potential to be used as an outcome measure in future research. 
According to Dodd et al.,30, 31 symptom assessment leads to the identification of the symptoms that 
need to be the focus for symptom management. Given that women in our qualitative study reported 
using a number of self-management strategies to manage their symptoms after vulvar surgery, we also 
included space for women to record these strategies in the WOMAN-PRO symptom diary.  Clinicians 
can also use the Diary to provide individualized information for women about which symptoms are 
expected and which should prompt contact with the clinician based on the type of surgical procedure 
or other pertinent clinical information. For instance, after vulvar excision expected symptoms during 
the first four days after discharge include swelling, warmth and redness. This information should 
increase the capacity of women to perceive such symptoms as part of normal wound healing. 
Therefore, we consider the WOMAN-PRO instrument not only as a clinical instrument for health 
professionals but as guide for women to enhance their self-assessment, early recognition and 
evaluation of symptoms and their related distress. Our assumption is that such an approach may 
decrease women’s uncertainty about symptoms and reassure their decision-making about when to seek 
health care provider evaluation. It can also provide clinicians with systematic information about key 
symptoms from a patient perspective, the impact of those symptoms on women’s daily lives, and their 
unmet informational needs. In addition, women are given an opportunity to prioritize the three most 
important issues that they would like to address during their next appointment with their clinician. 
This personal preparation should facilitate communication and self-tailored action plans to manage 
symptoms. 
However, the WOMAN-PRO instrument was not designed to address all of the complexity associated 
with effective self-management skills as proposed by Lorig (2002).32 Self-management involves 
people taking responsibility for their own health and wellbeing, as well as learning to behave in a 
manner that promotes health and manages their illnesses.32, 33 Lorig et al. (2002) described six self-
management skills (1) problem solving, (2) decision making, (3) resource utilization, (4) the formation 
of a patient-provider partnership, (5) action planning, and (6) self-tailoring.32 Evidence from clinical 
trials in patients with diverse chronic conditions suggests that supporting patient self-management 
positively impacts clinical outcomes, reduces health care costs and lowers the use of health care 
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services over the course of illness.34-40 Given the WOMAN-PRO instrument content discussed above, 
we believe that this instrument has the potential to improve self-management following surgical 
treatment of vulvar neoplasia by assisting patients with problem solving, decision making, action 
planning, and individualized reporting of symptoms and needs during the immediate post-discharge 
period.  Additional research is needed to determine the usefulness of the WOMAN-PRO beyond the 
initial post-discharge period. In addition, there is a gap in the evidence base concerning (1) the 
comprehensive self-management support needs of women with vulvar neoplasia with and without 
surgical treatment, and (2) the health care providers’ implementation of evidence based and 
individualized intervention strategies to improve health outcomes. Both aspects will be further 
elaborated below (see ‘implications for future research and practice’)  
8.2 Limitations and strengths of research methods 
Study 1 of this research project was a cross-sectional study exploring the period prevalence and risk 
factors for postoperative short-term wound complications in vulvar cancer which also summarized the 
literature from a clinical perspective. Studies 2 to 5 were guided by an sequential exploratory two-
phase mixed-methods approach with equal weighting of qualitative and quantitative data.41 Our intent 
in the first phase was to conduct an interview study to explore the symptom experience in women with 
surgically treated vulvar neoplasia from a patient perspective. In the second phase, findings from this 
qualitative interview study were used to develop the WOMAN-PRO instrument for quantitative 
studies and for clinical purposes.  
The research project has three main methodical limitations. First, not all aspects of the updated 
patient-reported outcome guidelines published during our ongoing project could be addressed. For 
example we did not select, translate and test items from the Common Terminology Criteria for 
Adverse Events (CTCAE) - PRO item bank, which contains symptoms related to adverse events of 
cancer treatment.42 Second, a limitation in the prospective cross-sectional survey was that we only 
assessed one measurement time point. As a result, we were not able to capture changes in symptoms 
over time. Third, the limited timeframe for data collection in the survey restricted the sample size and 
only permitted us to partly test the psychometric properties of the WOMAN-PRO instrument. 
Utilization of a mixed-methods approach in this research project had several methodical strengths. The 
interview data broadened understanding of experienced symptoms and their related distress, as well as 
providing insights into problems that women experienced during the course of their illness. Second, 
the new conceptual model developed from the qualitative study enabled us to formulate items for the 
new WOMAN-PRO instrument. Therefore, we believe that the sequential exploratory mixed-method 
design was vital to the development of knowledge from a patient perspective, and that this 
comprehensive and differentiated information would not have been arisen from an approach that was 
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purely quantitative. Third, based on the qualitative and quantitative study results we were able to 
develop a new PRO measure and collect initial evidence about symptom prevalence and related 
distress in two European countries.  
8.3 Implications and perspectives for future research 
Based on our findings, further studies need to include a larger sample so that addition psychometric 
properties of the WOMAN-PRO can be examined. We only examined women’s symptom experiences 
and distress during the first 7 days after discharge following vulvar surgery. Future studies should 
examine the ability of the WOMAN-PRO to detect changes in women’s symptom experience over 
time following surgery. 
In general, nursing research needs to progress from descriptive to intervention studies to be more useful 
to clinicians and patients.43-46 It is important for intervention studies to include PRO self-reporting 
measures to monitor subjective adverse events and assess specific treatment benefits from the patient 
perspective.47, 48 This may improve the quality and completeness of disease specific intervention 
outcome data, provide a more comprehensive picture of the patient experience, and improve the 
efficiency of clinical operations.49 Based on the evidence discussed above, we plan (1) to develop and 
test a patient self-management support intervention for women with vulvar neoplasia, and (2) continue 
to test the psychometric properties of the WOMAN-PRO instrument in future studies. Guided by the 
United Kingdom Medical Research Council’s Complex Intervention Framework,50 development and 
testing a patient self-management support intervention requires the following three steps:  
(1) First, a meta-synthesis of qualitative studies describing aspects of self-management in 
women with vulvar neoplasia needs to be conducted.51 This should result in a comprehensive 
understanding of informational and educational needs, self-management tasks and skills 
needed by affected women and their families. Then it is necessary to decide which needs 
could be translated into a self-management support intervention for women with different 
disease stages, therapies and co-morbidities.  
(2) Second, a systematic literature review needs to elaborate the most effective self-management 
support intervention in terms of improving patient outcomes in the field of gynecologic 
oncology since based on our knowledge; no such interventions exist in the vulvar neoplasia 
literature. In addition current evidence about the effective implementation of research 
interventions in clinical practice should be considered.52, 53  
(3) Third, the new developed self-management support intervention with a specified dose and 
duration should be tested in a pilot study to assess its effectiveness and feasibility as well as 
to understand the change process.50  
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To allow the simultaneous (1) examination of the newly developed self-management support 
intervention and (2) the psychometric testing of the WOMAN-PRO instrument, validated tools should 
be included in the planed pilot study to measure symptom occurrence and distress. In addition, to 
recruit a large enough sample size to ensure acceptable statistical power to perform analyses on 
subgroups, e.g. women with different disease stages, therapies and co-morbidities, a multicenter study 
will be required. 
8.4 Implications and perspectives for practice  
In addition to the implications for future research, we believe that this study also has implications for 
clinical practice. The high prevalence of symptoms and the finding that symptoms that are less 
common may, nonetheless, be distressing for the women who experience them, support the need for 
the systematic assessment of symptoms and their related distress in patients follow surgical treatment 
of vulvar cancer. Given this, we recommend that clinicians use and evaluate the new PRO self-report 
instrument as a major element of follow-up care in women with vulvar intraepithelial neoplasia (VIN) 
and vulvar cancer. 
The shift of care to outpatient settings, the short hospital stays after surgical treatment, and the 
treatment by different players present challenges for health care.54 The shorter hospital stays reduced 
the counseling time and inconsistent health care providers make the systematic assessment of 
symptoms and their related distress important.54, 55 While research supports the importance of 
including patient reports when assessing symptoms of adverse events,56-58 there is also some research 
to suggest that there is better agreement between nurse and patient-reported adverse event symptoms 
than between patient and physician reports. These findings suggest that nurses could play an important 
role in collecting symptom data related to adverse treatment events.59 In our German-speaking context, 
interdisciplinary follow-up visits may improve recognition of early signs of recurrence and adverse 
events. Nurses and physicians play a key role in symptom assessment and management in women with 
vulvar neoplasia and their families. Based on our research and that of others,56, 58, 60 we recommend the 
incorporation of PRO self-reports into the follow-up care in this patient population to facilitate 
communication, decision-making, symptom assessment and management. Clinicians should be 
educated in the delivery of individualized evidence-based care based on PRO data. The synthesis of 
PRO information with clinician’s objective observations will result in better care for women who have 
vulvar neoplasia and surgical treatment. We suggest nurse-led follow-up consultations complementary 
to physician appointments to allow adverse symptom event monitoring. Whether vulvar-specific 
instruments will improve the completeness or interpretability of adverse symptom event data will be 
evaluated and reported in the future.47  
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8.5 Conclusions  
We conclude that the results of this research project narrowed the gap in existing knowledge on 
women with vulvar neoplasia and post-surgical care. It added data to support nurses’ and physicians’ 
ability to identify patients at risk for post-surgical wound complications. Furthermore, it provided the 
first conceptual model of symptom experience in affected women. In addition, it added evidence on 
VIN patients’ experiences during their illness trajectory. Furthermore, the development of the 
WOMAN-PRO instrument with a good content validity and reliability has the potential to contribute 
to the valid assessment of symptoms, informational needs and related distress in women with vulvar 
neoplasia who have undergone surgical treatment. Moreover, WOMAN-PRO data showed a high 
symptom prevalence and distress, and provided preliminary evidence that the WOMAN-PRO 
instrument offers a feasible, targeted screening instrument to support systematic symptom assessment.  
The study results confirmed the need for further research on (1) implementation strategies for 
comprehensive symptom assessment and (2) identification of areas in symptom management. 
Clinicians should focus on the early recognition of symptoms and interventions to decrease symptom 
related distress in women with surgically treated vulvar neoplasia. 
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